Therapeutic,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Aug '23),Est. Status,Heavy Sequence,Light Sequence,Heavy Sequence (if bispec),Light Sequence (if bispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes
Abagovomab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS,DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK,na,na,None,None,None,2006,2007,MUC16/CA125,Menarini,na,na,Ovarian cancer;Pancreatic cancer ,,
Abciximab,Fab,G1,Kappa,Approved,NFD,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA,EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK,na,na,6v4p:CD,None,None,1993,1994,ITGA2B/CD41,Janssen Biologics BV;Eli Lilly,Coronary artery restenosis;Unstable angina pectoris,na,Arterial occlusive disorders;Myocardial infarction;Stroke,,Sequence sourced through DrugBank. Biosimilars available from ISU Abxis and Harvest Moon Pharmaceuticals
Abelacimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL,na,na,6r8x:CB,None,None,2018,2019,F11,Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group,na,Venous Thromboembolism; Stroke;Thrombosis,na,,Feb '22: Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3.
Abiprubart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQRLEWIGYINPSNDYTKYNQKFKDRATLTADKSANTAYMELSSLRSEDTAVYYCARQGFPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRRWIYDTSKLASGVPARFSGSGSGTDYTLTISSLEPEDFAVYYCHQLSSDPFTFGGGTKVEIK,na,na,None,None,None,2023,na,TNFRSF5/CD40,TBC,TBC,TBC,TBC,,
Abituzumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,na,na,None,None,None,2013,2014,ITGAV/CD51,Merck,na,Colorectal cancer;Systemic scleroderma ,Ovarian cancer;Prostate cancer;Solid tumours ,,"4o02 claims to be abituzumab (17E6), but is not"
Abrezekimab,Fab,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYRFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL13,UCB,na,na,Asthma,,Jun '22: Added missing FWH3 and CDRL3 residues
Abrilumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2014,2015,ITGA4B7,Amgen;AstraZeneca,na,na,Crohn's disease;Ulcerative colitis ,,
Acapatamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,FOLH1/GCPII/PSMA;CD3E,Amgen,na,Cancers;Prostrate cancer;Metastatic cancer,na,BiTE Technology. ,Genetics of Fv2: musmus/homosap
Acasunlimab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-I/II,Active,EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2020,2021,PDL1/CD274;TNFRSF9/CD137/4-1BB,Genmab;BioNTech,na,Solid tumours,na,,
Acimtamig,Bispecific (VH-VK-VH'-VL Homodimer),na;na,Lambda;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSAYYYDFADYWGQGTLVTVSS,SYVLTQPSSVSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVL,QVQLQQSGAELARPGASVKMSCKASGYTFTTYTIHWVRQRPGHDLEWIGYINPSSGYSKYNQNFKGKTTLTADKSSNTAYMQLNSLTSEDSAVYYCARRADYGNYEYTWFAYWGQGTTVTVSS,DIVMTQSPKFMSTSVGDRVTVTCKASQNVGTNVAWFQQKPGQSPKVLIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYHTYPLTFGGGTKLEIN,None;None,None;None,7seg:AB:HL;None,2023,na,FCGR3A/CD16/CD16A;TNFRSF8/CD30,Affimed Therapeutics,na,Hodgkin's disease;Peripheral T/NK cell lymphoma,na,,Genetics of both Fvs: musmus/homosap
Acrixolimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS,DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,Y-Biologics,na,Solid tumours,na,,
Actoxumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,Clostridium difficile Toxin A,Bristol-Myers Squibb;Merck;University of Massachussets Medical School,na,na,Clostridium difficile,Medarex HuMAb Mouse,
Adalimumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,na,na,6cr1:HL/4nyl:AB:CD:EF:HL,3wd5:HL,None,1999,2000,TNF/TNFA,Abbvie;MedImmune;180 Life Sciences,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma,Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis,Interstitial cystitis ,CAT Phage Display,Many biosimilars and related drugs.
Adebrelimab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDL1/CD274,Jiangsu Hengrui Medicine;Atridia,na,Small cell lung cancer;Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours,Haematological malignancies,,Genetics: musmus/homosap
Adecatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,EPCAM/CD326,Micromet Inc;Merck Sorono;Amgen,na,na,Breast cancer;Colorectal cancer;Prostate cancer,,Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299
Adintrevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL,na,na,None,7u2d:HL,7u2e:HL,2021,2022,SARS-CoV-2 Spike,Adagio Therapeutics,na,COVID-19,na,,
Aducanumab,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,6cnr:HL/6co3:HL,None,None,2013,2014,APP,Biogen;Neurimmune,Alzheimer's disease ,na,na,,
Afasevikumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,na,na,6ppg:HL:BA,None,None,2015,2016,IL17A,NovImmune;Genentech,na,na,Autoimmune disorders;Inflammation,,
Alacizumab,di-Fab,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK,na,na,None,None,None,2007,2008,KDR/CD309/VEGFR2,UCB,na,na,Non-small cell lung cancer ,,
Alemtuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,na,na,1bey:HL/1ce1:HL,None,None,2000,2001,CD52,Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge,Chronic lymphocytic leukaemia;Multiple sclerosis ,Lymphoma;T-cell prolymphocytic leukaemia ,Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma ,,
Alextatug,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGALVKPGGSLRLSCAASGFTFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL,na,na,None,None,None,2023,na,RNP complex containing PABPC1,TBC,TBC,TBC,TBC,,
Alirocumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital,Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias,Coronary artery disease,na,VelocImmune Mouse,
Alomfilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK,na,na,7joo:HL,None,None,2020,2021,ICOS/CD278,Kymab,na,Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma,na,,
Alnuctamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Celgene Corporation,na,Multiple myeloma,na,,Genetics of both Fvs: musmus/homosap
Alsevalimab,Whole mAb,G1,Kappa,Phase-I,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK,na,na,None,None,None,2019,2020,VTCN1/B7H4,Five Prime Therapeutics,na,Solid tumours,na,,
Amatuximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK,na,na,7ued:HL,4f33:BA:DC:FE:HG/4f3f:BA,None,2010,2011,MSLN,Eisai Co Ltd;Morphotek;National Cancer Institute (USA),na,Mesothelioma,Pancreatic cancer;Solid tumours ,,
Amivantamab,Bispecific mAb,G1;G1,Kappa;Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,None;6wvz:HL,None;None,None;None,2019,2020,EGFR/ERBB1/HER1;MET/HGFR,Genmab;Janssen Research & Development,Non-small cell lung cancer,Gastic cancer;Oesophageal cancer;Solid tumours,na,,
Amlitelimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK,na,na,None,None,None,2020,2021,TNFSF4/CD134/CD252/OX40L,Kymab,na,Atopic dermatitis,na,,
Amubarvimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK,na,na,7cdi:HL/7xnf:HL/8gx9:HF:IL/7x2k:HL,7e8m:HL,7swo:HL,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,COVID-19,na,,
Anbenitamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV),Alphamab,na,Breast cancer;Gastric cancer,na,,4llu is 94.7% identical to ERBB2 (domain II) Fv
Andecaliximab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK,na,na,5th9:HL:IM:JN,None,None,2016,2017,MMP9/GELB,Gilead Sciences,na,na,Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma,,
Anetumab,Whole mAb ADC,G1,Lambda,Phase-II,Active,QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL,na,na,8cz8:AA:CC,None,None,2013,2014,MSLN,Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) ,na,Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma,Fallopian tube cancer;Peritoneal cancer,MorphoSys HuCAL Phage Display,ADC with ravtansine
Anifrolumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,na,na,4qxg:HL,None,None,2013,2014,IFNAR1,Medarex;Medical University of Vienna;MedImmune,Systemic lupus erythematosus,Lupus nephritis,Rheumatoid arthritis;Scleroderma,Medarex UltiMAb Mouse,
Anivovetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA,DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK,na,na,None,None,3iy6:BA/3jcx:HL,2022,2022,Minor Capsid VP2 (Canine),Kindred Biosciences,na,Canine parvovirus,na,,Chimeric: Rat/Dog
Anrukinzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2007,2008,IL13,Pfizer;Wyeth,na,na,Asthma;Ulcerative colitis,,
Anselamimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK,na,na,None,None,None,2021,2022,Light Chain Amyloid Fibrils,Caelum Biosciences,na,AA amyloidosis,na,,Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7. Chimeric: Mouse/Human
Ansuvimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS,DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK,na,na,None,5fha:HL/5fhc:HL,None,2020,2021,Zaire Ebolavirus Glycoprotein,Ridgeback Biotherapeutics,Zaire ebolavirus infection,na,na,,
Anumigilimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,CSF3R/CD114,CSL Behring,na,Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis,na,,
Anvatabart,Whole mAb ADC,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2022,na,ERBB2/CD340/HER2,Fudan University,na,Solid cancers;Breast cancer,na,,"Anvatabart has an identical V domain to Coprelotamab, Cinrebafusp, Timigutuzumab, and Trastuzumab. ADC with opadotin and pactil"
Anzurstobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK,na,na,7st5:HL:hl,None,None,2022,na,SIRPA,Celgene Corporation,na,Acute myeloid leukaemia;Myelodysplastic syndromes,Non-Hodgkin's lymphoma;Solid tumours,,
Apamistamab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Active,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS,DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,PTPRC/CD45,Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Hodgkin's disease;Non-Hodgkin's lymphoma,,
Apitegromab,Whole mAb,G4,Lambda,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL,na,na,None,None,6umx:HL:hl,2020,2021,pro-MSTN/pro-GDF8,Scholar Rock,na,Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries,na,,
Aprutumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL,na,na,None,None,None,2016,2017,FGFR2/CD332,Bayer,na,na,Solid tumours,,ADC with ixadotin
Arcitumomab,Whole mAb,G1,Kappa,Approved (w),NFD,EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS,QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK,na,na,1clo:HL,None,None,1995,1996,CEA/CEACAM,Immunomedics;Giliad Sciences,Colorectal cancer,na,na,,
Ascrinvacumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,na,na,None,None,None,2015,2016,ACVRL1/SKR3,Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals,na,na,Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer,,
Aselizumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK,na,na,None,None,None,2003,2003,L-Selectin,PDL Biopharma,na,na,Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock,,
Astegolimab,Whole mAb,G2,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL1RL1/ST2,Amgen;Genentech;University of Leicester,na,Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease,Asthma;Rhinosinusitis,,
Atezolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,na,na,5x8l:FK:HM:GL:JO:SN,5xxy:HL,None,2014,2015,PDL1/CD274,Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University,Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer,Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma,Hodgkin's disease;Myelodysplastic syndromes,Human Phage Display,
Atibuclimab,Whole mAb,G4,Kappa,Phase-II,Active,DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,CD14,ICOS Corporation;Implicit Bioscience,na,Acute lung injury;COVID-19,Adult respiratory distress syndrome;Motor neuron disease;Septic shock,,
Atidortoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,Staphylococcus aureus Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,,
Atinumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK,na,na,None,None,None,2010,2011,RTN4/Nogo,Novartis,na,na,Spinal cord injuries,,
Atisnolerbart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,7mxl:JK/7n0v:HL,None,None,2022,na,Bet v 1,Regeneron,na,Allergic rhinitis;Birch pollen allergy,na,,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart.
Atoltivimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK,na,na,None,None,None,2018,2019,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,na,na,Ebola virus infections,,
Avdoralimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,C5AR1/CD88,Novo Nordisk;Innate Pharma,na,na,Rheumatoid arthritis;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours;Bullous pemphigoid,,
Avelumab,Whole mAb,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,PDL1/CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma,Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains
Avizakimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL21,MedImmune;Boston Pharmaceuticals,na,Systemic lupus erythematosus,Autoimmune disorders,,
Axatilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK,na,na,None,None,None,2019,2020,CSF1R/CD115/M-CSFR,Syndax Pharmaceuticals;AstraZeneca;UCB,na,Cholangiocarcinoma;Graft-versus-host disease;COVID-19,Solid tumours,,
Azintuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS,DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK,na,na,None,None,None,2016,2017,SLAMF7/CD319,AbbVie,na,na,Multiple myeloma,,ADC with vedotin
Bafisontamab,Bispecific Mixed mAb and Fab,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK,5sx4:HL:JI/5sx5:JK:HL;None,None;None,None;None,2021,2022,EGFR/ERBB1/HER1;MET/HGFR,EpimAb Biotherapeutics,na,Non-small cell lung cancer;Solid tumours,na,,Fv1 is Panitumumab
Balstilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Agenus;Ludwig Institute for Cancer Research,na,Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma,na,,
Bamlanivimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,na,na,7l3n:DE/7kmg:AB:DE,None,None,2020,2021,SARS-CoV-2 Spike,Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases,COVID-19,na,na,,
Bapineuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,na,na,None,None,4ojf:HL/4hix:HL,2005,2006,APP,JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation,na,na,Alzheimer's disease,,"Jain paper: ""Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL"""
Bapotulimab,Whole mAb,G2,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR,na,na,None,None,None,2020,2021,ILDR2,Bayer,na,Solid tumours,na,,
Barecetamab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL,na,na,7d85:BC:EF,None,None,2020,2021,ERBB3/HER3,ISU Abxis,na,na,Solid tumours;Head and neck cancer,Antibody Phage Display,
Barzolvolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK,na,na,None,None,None,2021,2022,KIT/CD117,Celldex Therapeutics,na,Chronic idiopathic urticaria,na,,Genetics: musmus/homosap
Basiliximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,na,na,1mim:HL/3iu3:AB:CD:HL,None,None,1996,1997,IL2RA/CD25,Cerimon Pharmaceuticals;Novartis,Renal transplant rejection;Transplant rejection,na,Ulcerative colitis;Uveitis,,
Batoclimab,Whole mAb,G1,Lambda,Preregistration,Active,QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS,SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,FCGRT/FcRn,Immunovant Sciences,na,Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura,na,,
Bavituximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,na,na,None,None,None,2006,2007,Phosphatidylserine,Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center,na,Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours,Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer,,
Bavunalimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS,DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2020,2021,LAG3/CD223;CTLA4/CD152,Xencor,na,na,Solid tumours,,Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A. Genetics of both Fvs: musmus/homosap
Bebtelovimab,Whole mAb,G1,Lambda,Approved,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL,na,na,7mmo:AB:DE,None,None,2022,na,SARS-CoV-2 Spike RBD,Eli Lilly;AbCellera,COVID-19,na,na,,
Becotatug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK,na,na,None,None,None,2022,na,EGFR/ERBB1/HER1,CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology,na,Cancers;Non-small cell lung cancer;Metastatic cancers,na,,
Bedinvetmab,Canine Whole mAb,G2,Lambda,Approved,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS,QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL,na,na,None,None,None,2018,2019,NGFB (Canine),na,na,Canine lupus familiaris,na,,June '22: Corrected FWL1 sequence
Befovacimab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL,na,na,None,None,None,2019,2020,TFPI,na,na,Haemophilia,na,,
Begelomab,Whole mAb,G2b,Kappa,Phase-II/III,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK,na,na,None,None,None,2014,2015,DPP4/ADCP2/CD26,ADIENNE,na,Graft-versus-host disease,na,,
Belantamab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK,na,na,None,None,None,2017,2018,TNFRSF17/CD269/BCMA/TNFRSF13A,GlaxoSmithKline,Multiple myeloma,na,na,,
Belimumab,Whole mAb,G1,Lambda,Approved,Active,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,na,na,5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE,None,6erx:HI:DE:QR:MN:FG:OP,2003,2004,TNFSF13B/CD257/BAFF,Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology,Systemic lupus erythematosus;Lupus nephritis,Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease,Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome,CAT Phage Display,
Belrestotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVIGPSGASTSYAQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARDHSDYWSGIMEVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFSPPWTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT/WUCAM/VSTM3,GlaxoSmithKline;iTeos Therapeutics,na,Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer,na,,
Beludavimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB;7tm0:JK:LM:NO/7tn0:BA:CD/7xck:AB/7x1m:AB/7xsw:AB:HL/7yad:AB:CD/7yr0:CB/7yqy:HF:IG:JE/7yqx:HF:IG/7yxz:IG:JH/8df5:AB:CD/8dw2:DC/8dw3:DC,None,2021,2022,SARS-CoV-2 Spike RBD,GlaxoSmithKline,na,COVID-19,na,,Beludavimab and Sotrovimab have identical Fvs
Bemarituzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK,na,na,None,None,7sob:GI:HJ:NO/7soc:HL,2017,2018,FGFR2/CD332,Five Prime Therapeutics;ZAI Lab,na,Gastric cancer,Oesophageal cancer;Solid tumours,POTELLIGENT Technology,
Bempikibart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHAMHWVRQAPGKGLEWVSGISWNSRGIGYADSVKGRFTIFRDNAKNSLYLQMNSLRAEDTALYYCAKDEYSRGYYVLDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLWITFGQGTRLEIK,na,na,None,None,None,2022,na,IL7R/CD127,Q32 Bio Inc.,na,Atopic dermatitis,na,,
Benmelstobart,Whole mAb,G1,Kappa,TBC,Active,QITLKESGPTLVKPTQTLTLTCTVSGFSLSTYGVHWIRQPPGKALEWLGVIWRGVTTDYNAAFMSRLTITKDNSKNQVVLTMNNMDPVDTATYYCARLGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKAPKLLIYYAANRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYFCQQDYTSPYTFGQGTKLEIK,na,na,None,None,None,2023,na,PDL1/CD274,TBC,TBC,TBC,TBC,,
Benralizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,na,na,None,None,None,2009,2010,IL5RA/CD125,AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa,Asthma,Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis,Skin disorders,POTELLIGENT Technology,
Bentracimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS,QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL,na,na,5alb:HL,None,5alc:HL,2020,2021,AR-C124910XX,MedImmune;AstraZeneca;PhaseBio,na,Haemorrhage (reversal of effects of ticagrelor),na,,
Benufutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK,na,na,6t3j:AB:FG,None,None,2019,2020,TNFRSF10B/CD262/DR5/TRAILR2,Genmab;VU University Medical Center;iDD Biotech,na,Solid tumours;Multiple myeloma,na,,Chimeric: Mouse/Human
Bepranemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,MAPT,UCB BioPharma,na,Progressive supranuclear palsy (PSP);Alzheimer's Disease,na,,June '22: Removed duplicate residue from FWL3
Berlimatoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK,na,na,5k59:HL:EF,None,None,2017,2018,Staphylococcus aureus Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,,
Bermekimab,Whole mAb,G1,Kappa,Preregistration (w),Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,na,na,None,None,None,2018,2019,IL1A,XBiotech Inc.,na,Systemic scleroderma,Haematological malignancies;Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer,,
Bersanlimab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL,na,na,None,None,None,2017,2018,ICAM1/CD54,BioInvent International,na,na,Multiple myeloma,n-CoDeR,
Betifisolimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYIFTTYWMHWVKQRPGQGLEWIGMIQPNSGGTKYNEKFKKKATLTVDKSISTAYMELSRLTSDDTAVYYCARGAGTVDYFDYWGQGSTLTVSS,DIVLTQSPASLAVSVGQRATITCRASESVDIYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEAQDTATYYCQQSTEDPYTFGGGTKLEIK,na,na,None,None,None,2022,na,PDL1/CD274,MabSpace Biosciences;Transcenta Holding,na,Solid tumours,Haematological malignancies,,Genetics: musmus/homosap
Bevacizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ/7v5n:BA:FE,None,6bft:AB:HL/1cz8:HL:YX,2000,2001,VEGFA,All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital,Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer,Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma,Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer,,Biosimilars available
Bexmarilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK,na,na,None,None,None,2019,2020,STAB1,Faron Pharmaceuticals,na,Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis,na,,
Bezetabart,Whole mAb ADC,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFNFSDYGMHWVRQAPGKGLEWVAVIWYDGSISYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGTVEHGAVYGTDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIGSWLAWYQQKPGKAPKLLIYAADRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHTYPLTFGGGTKVEIK,na,na,None,None,None,2023,na,CD74/HLA class II histocompatibility antigen gamma chain,TBC,TBC,TBC,TBC,Modified at two specific positions with reactive 4-(azidomethyl)-L-phenylalanine residues,
Bezlotoxumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK,na,na,4np4:HL:IM,None,None,2012,2013,Clostridium difficile Toxin A,Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme,Clostridium difficile,na,na,Medarex HuMAb Mouse,
Bifikafusp,Whole mAb Fusion,E,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours,Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer,,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Bimagrumab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,na,na,5nhr:HL:AB,5nhw:HL/5nh3:HL:IM/5ngv:HL,None,2012,2013,ACVR2B,MorphoSys;Novartis,na,Cachexia;Muscular atrophy;Type 2 diabetes mellitus,Inclusion body myositis,MorphoSys HuCAL Phage Display,
Bimekizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,IL17A,UCB,Plaque psoriasis,Ankylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis,Psoriasis;Rheumatoid arthritis,,Fv sequence identical to Galvokimig
Bintrafusp,Whole mAb Fusion,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,PDL1/CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer,Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains
Birtamimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,SAA1,Neotope Biosciences;Onclave Therapeutics;Prothena,na,na,Amyloid light-chain amyloidosis,,Genetics: musmus/homosap
Bleselumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK,na,na,None,None,None,2015,2016,TNFRSF5/CD40,Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin,na,na,Transplant rejection;Plaque psoriasis;Focal segmental glomerulosclerosis;Renal transplant rejection,,
Blinatumomab,Bispecific T-Cell Engager,na;na,Kappa;Kappa,Approved,Active,QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS,DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK,DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,None;None,None;None,None;None,2008,2009,CD19;CD3E,Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis,Precursor B-cell lymphoblastic leukaemia-lymphoma,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma,Chronic lymphocytic leukaemia,BiTE Technology,
Blontuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS,DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL,na,na,None,None,None,2015,2016,MS4A1/CD20,Aratana Pharmaceuticals,na,Canine B-cell lymphoma,na,,Chimeric:  Mouse/Dog
Blosozumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,Eli Lilly,na,Postmenopausal osteoporosis,na,,
Bococizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,3sqo:HL,None,None,2013,2014,PCSK9,Halozyme Therapeutics;Pfizer,na,na,Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia,,
Boserolimab,Whole mAb,G1,Kappa,Phase-II,Active,EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCAREGDAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYYCQQWNSYPFTFGQGTKLEIK,na,na,8ds5:CB,None,None,2022,na,TNFRSF7/CD27,Bionovion;Merck Sharp & Dohme,na,Non-small cell lung cancer;Small cell lung cancer,Solid tumours,,
Botensilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLFGPFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,CTLA4/CD152,Agenus,na,Solid tumours,na,,
Brazikumab,Whole mAb,G2,Lambda,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL,na,na,None,None,None,2016,2017,IL23A,Allergan;Amgen;AstraZeneca,na,na,Psoriasis;Crohn's disease;Ulcerative colitis,,
Bremzalerbart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCSVSGGSITNYFWTWIRQSPGKGLEWIGYIYYSGGTNYNPSLKSRVTISIDTSKNQFSLNMNSVTAADTAVYYCAGSYYYGVDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIKSFLAWYRQKPGQAPRLLIYDASNRPTGIPARFSGSGSGTDFTLTINSLESEDFAVYFCQQRNNWPFTFGPGTKVDIK,na,na,7mxl:AB/7n0u:HL,None,None,2022,na,Bet v 1,Regeneron Pharmaceutical,na,Allergic rhinitis;Birch pollen allergy,na,,Identical V region sequence to Atisnolerbart
Brenetafusp,Fusion Protein (scFv fused to TCR Fab),na,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2023,na,CD3,TBC,TBC,TBC,TBC,,6kr0:DD has an identical heavy chain. Identical sequence to Tebentafusp.
Brentuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2010,2011,TNFRSF8/CD30,Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine,Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma,Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma,Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus,,ADC with vedotin
Briakinumab,Whole mAb,G1,Lambda,Preregistration (w),Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,na,na,5n2k:LK:BA:PO:DC:NM:FE/5njd:RQ:TS:XW:VU:PO:NM,None,None,2009,2010,IL12B/CLMFp40,Cambridge Antibody Technology;Abbott GmbH & Co. KG,na,na,Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis,,
Briquilimab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,na,KIT/CD117,"Jasper Therapeutics;Amgen;National Heart,Lung and Blood Institute;Stanford University",na,Acute myeloid leukemia;Severe combined immunodeficiency,Inflammation,,Genetics: musmus/homosap
Brodalumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL17RA/CD217,Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis,Axial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis,Asthma;Crohn's disease;Rheumatoid arthritis,Abgenix XenoMouse,
Brolucizumab,scFv,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS,EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL,na,na,None,None,None,2014,2015,VEGFA,ESBATech;Alcon,Wet age-related macular degeneration,Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy,na,,
Brontictuzumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL,na,na,None,None,None,2014,2015,NOTCH1,OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center,na,na,Adenoid cystic carcinoma;Solid tumours;Haematological malignancies;Colorectal cancer,,
Budigalimab,Whole mAb,G1,Kappa,Phase-II,Active,EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,AbbVie,na,Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours;Endometrial cancer;Fallopian tube cancer;HIV-1 infections;Peritoneal cancer;Squamous cell cancer,na,,Genetics: musmus/homosap
Budoprutug,Whole mAb,G1,Kappa,TBC,Active,QVQLEQPGAEVVKPGASVKVSCKTSGYTFTSNWMHWVKQTPGKGLEWIGEIDPSDSYTNYNQKFDGKAKLTVDKSSSTAYMEVSDLTAEDSATYYCARGSNPYYYAMDYWGQGTSVTVSS,QIVLTQSPATLSASPGEKATMTCSASSGVNYMHWYQQKPGTSPKRWIYDTDKTASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,None,None,2023,na,CD19,TBC,TBC,TBC,TBC,,"B lymphocyte surface antigen B4, Leu-12. Genetics: musmus/homosap"
Burfiralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGKGLEWMGNIDPYYGSDTYAQKFQGRVTMTVDKSISTAYMELSRLRSDDTAVYYCARETGTRAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKPGKAPKLLIYVADNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHFYGSPRTFGGGTKVEIK,na,na,None,None,None,2022,na,VIM,ImmuneMed,na,COVID-19 Pneumonia;Pneumonia;Hepatitis B;Alcholic hepatitis;Non-alcoholic steatohepatitis;Psoriasis;Scleroderma,na,,
Burosumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK,na,na,7ven:BA,None,None,2016,2017,FGF23,Kyowa Hakko Kirin;Ultragenyx Pharmaceutical ,X-linked dominant hypophosphataemic rickets;Osteomalacia,Nevus,na,,
Cabiralizumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK,na,na,None,None,None,2015,2016,CSF1R/CD115/M-CSFR,Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University,na,Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours ,Rheumatoid arthritis,,
Cabotamig,Bispecific (VH-G1CH1h-G4CH2CH3-scFv),G1/G4;na,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQTPGKGLEWVAVIDSNGGSTYYPDTVKDRFTISRDNSKNTLYLQMNSLRAEDTAVYYCSSYTNLGAYWGQGTLVTVSA,DIQMTQSPSSLSASVGDRVTITCRASQDISGYLNWLQQKPGGAIKRLIYTTSTLDSGVPKRFSGSGSGTDFTLTISSLQSEDFATYYCLQYASSPFTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,None;None,None;None,None;None,2023,na,CDH17;CD3E,TBC,TBC,TBC,TBC,,6kr0:DD has an identical heavy chain to Fv2.
Cadonilimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Approved,Active,QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL,None;None,None;None,None;None,2020,2021,PDCD1/CD279/PD1;CTLA4/CD152,Akeso Biopharma,Cervical cancer,Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma,na,,June '22: Corrected FWH1 and FWL2 sequences. Genetics of Fv2: musmus/homosap
Calpurbatug,Whole mAb,G1,Kappa,TBC,Active,QSQVQLVESGPGLVKPSETLSLTCRVSGDSNRPSYWSWIRQAPGKAMEWIGYVYDSGVTIYNPSLKGRVTISLDTSKTRFSLKLTSVIAADTAVYYCARERFDRTSYKSWWGQGTQVTVSS,DIVLTQAPGTLSLSPGDRATLSCRASQRLGGTSLAWYQHRSGQAPRLILYGTSNRATDTPDRFSGSGSGTDFVLTISSLEPEDFAVYYCQQYGSPPYTFGQGTTLDIK,na,na,None,None,None,2022,na,Bacteria Proteins HU and IHF,TBc,TBC,TBC,TBC,,Conserved epitopes on HU (histone-like protein) and IHF (integrin host factor)
Camidanlumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL2RA/CD25,ADC Therapeutics;Genmab,na,Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma,,ADC with tesirine
Camoteskimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISADGYYWSWIRQPPGKGLEWIGSLYYSGSTYYNPSLKGRVTISGDTSKNQFSLKLSSVTAADTAVYYCARTPAYFGQDRTDFFDVWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSHHPPWTFGQGTKLEIK,na,na,None,None,None,2022,na,IL18,Avalo Therapeutics;MedImmune,na,Adult-onset Still's disease;Juvenile rheumatoid arthritis,Chronic obstructive pulmonary disease;Multiple myeloma,,
Camrelizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK,na,na,7cu5:BB,None,None,2016,2017,PDCD1/CD279/PD1,Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University,Hodgkin's disease,Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma,na,,
Canakinumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,na,na,None,4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL,None,2007,2008,IL1B,Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich,Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders,Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer;Pancreatic cancer;Renal cell carcinoma,Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Medarex UltiMAb Mouse,
Canrivitug,Whole mAb,G1,Lambda,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARHYDILTGFDWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGTHYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDNSLTAPYVFGTGTKVTVL,na,na,None,None,None,2023,na,SARS-CoV-2 RBD,TBC,TBC,TBC,TBC,,
Cantuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS,DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK,na,na,None,None,None,2003,2004,MUC1/PEM/EMA,ImmunoGen;GlaxoSmithKline,na,na,Gastric cancer;Solid tumours,,ADC with mertansine and ravtansine
Caplacizumab,Nanobody,na,na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS,na,na,na,7a6o:B/7eow:B,None,None,2011,2012,VWF,Ablynx,Thrombotic thrombocytopenic purpura,na,Thrombosis,Nanobody Technology,
Carlumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,na,na,None,4dn3:HL/4dn4:HL,None,2010,2011,CCL2/MCP1,MorphoSys;Janssen Biotech,na,na,Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours,Human Phage Display,
Carotuximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2015,2016,ENG/CD105,National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute,na,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration,,
Casdozokitug,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYGMNWVRQAPGKGLEWVSGISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGGRTSYTATAHNWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHASAPPTFGGGTKVEIK,na,na,7zxk:HL:JI,None,None,2022,na,IL27,Surface Oncology,na,Solid tumours;Hepatocellular carcinoma,na,Artificial human yeast display library,
Cemavafusp,Fusion Protein (Toxin fused to an scFv),na,Kappa,TBC,Active,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQRHGKSLEWIGGINPNNGGTWYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYFCARPYYYGSREDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLELK,na,na,None,None,None,2023,na,PDL1/CD274,TBC,TBC,TBC,TBC,,
Cemiplimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR,na,na,7wvm:AB:CD,None,None,2018,2019,PDCD1/CD279/PD1,Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center,Squamous cell cancer;Basal cell cancer;Non-small cell lung cancer,Cervical cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;Head and neck cancer;Malignant melanoma;Renal cell carcinoma,B-cell lymphoma,,
Cendakimab,Whole mAb,G1,Kappa,Phase-III,Active,EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL13,Abbott Laboratories;AbbVie;Receptos,na,Eosinophilic oesophagitis,Allergic asthma,,
Cepeprubart,Whole mAb,G2,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSASSTIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSYGYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSRSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQTTHVPLTFGQGTRLEIK,na,na,None,None,None,2023,na,SELPLG/CD162/PSGL1,TBC,TBC,TBC,TBC,,
Cergutuzumab,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,na,na,None,None,None,2015,2016,CEACAM5/CD66e,Roche,na,na,Solid tumours,,
Certolizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,na,na,5wuv:HL/5wux:HL:AB:CD,None,None,2004,2004,TNF/TNFA,UCB,Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis,Interstitial cystitis;Juvenile rheumatoid arthritis,Cognition disorders,,
Cetrelimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1/CD279/PD1,Janssen Research & Development ,na,Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer;Bladder cancer,na,,
Cetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC,5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,1999,2000,EGFR/ERBB1/HER1,Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center,Colorectal cancer;Head and neck cancer,Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer,Pancreatic cancer;Prostate cancer,,
Cevostamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,FCRL5/CD307;CD3,Genentech,na,Multiple myeloma,na,,Genetics of Fv1: musmus/homosap
Cibisatamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,CEACAM5/CD66e and CD3E;CD3E,Roche,na,Non-small cell lung cancer;Colorectal cancer,Solid tumours,,
Ciduvectamig,Bispecific mAb,G4;G4,Kappa;Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSVISGSGGFTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMPLNSPHDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPLTFGGGTKVEIK,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,None;None,None;None,None;None,2022,na,TMEFF2;CD3E,TBC,TBC,TBC,TBC,,
Cifurtilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,None,None,None,2022,2022,TNFRSF5/CD40,Merck;Seagen,na,Melanoma;Lymphoma,na,,
Cilgavimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIK,na,na,7l7e:CD:EF:MN:OP/8d8q:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,,
Cinpanemab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL,na,na,6ct7:HL:AB,None,None,2018,2019,SNCA,Neurimmune Therapeutics;Biogen,na,na,Parkinson's disease,,
Cinrebafusp,Fusion Protein,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2/CD340/HER2,Eli Lilly and Company;Pieris Pharmaceuticals;Seagen,na,Gastic cancer;Solid tumours,na,,"Identical Fv sequence to Anvatabart, Coprelotamab, Trastuzumab, Timigutuzumab"
Cirevetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFISSWMNWVRQAPGAGLDWMGQIYPGDGDTNYNGKFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARHYDGSTDYWGQGTLVTVSS,EIVMTQSPASLSLSQGEKVTITCRASENIYSNLAWYQQRPGQAPKLLIYAATNLADGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2022,na,TGFB1 (Canine),Zoetis,na,Chronic kidney disease,na,,
Citatuzumab,Fab Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM/CD326,Viventia Biotech;Sesen Bio,na,na,Solid tumours,,
Cixutumumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,na,na,None,None,None,2008,2009,IGF1R/CD221,Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) ,na,na,Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma,Dyax Human Phage Display,
Clazakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,na,na,None,None,None,2012,2013,IL6,Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris,na,Renal transplant rejection;COVID-19,Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis,,
Clervonafusp,di-Fab Fusion,G1,Kappa,Phase-I/II,Active,EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKAPKLLIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSREFPWTFGAGTKLELK,na,na,None,None,None,2018,2019,SLC29A2,Valerion Therapeutics,na,Glycogen storage disease type II,na,,June '22: Corrected FWL2 and CDRL3 sequences
Clesrovimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIK,na,na,6ous:MN:OP:QR:ST:UV:WX,None,None,2022,na,RSV gpF,Merck Sharp & Dohme,na,Respiratory syncytial virus infections,na,,
Clivatuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK,na,na,None,None,None,2009,2010,MUC1/PEM/EMA,Immunomedics,na,na,Pancreatic cancer,,ADC with tetraxetan
Cobolimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,HAVCR2/TIM3,AnaptysBio;GlaxoSmithKline;TESARO,na,Non-small cell lung cancer;Liver cancer;Malignant Melanoma,Solid tumours,,
Codrituzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,na,na,None,None,None,2013,2014,GPC3,Perseus Proteomics;Chugai Pharmaceutical;Roche,na,Liver cancer,na,,
Cofetuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2017,2018,PTK7,Stemcentrx;Indiana University;Pfizer;Stemcentrx,na,Non-small cell lung cancer;Solid tumours,Breast cancer,,
Coltuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,6ani:HL:IM,None,None,2013,2014,CD19,ImmunoGen,na,Diffuse large B cell lymphoma,Precursor cell lymphoblastic leukaemia-lymphoma,,ADC with ravtansine
Conatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK,na,na,4n90:DE:FG:HI,None,None,2008,2009,TNFRSF10B/CD262/DR5/TRAILR2,Amgen;Takeda,na,na,Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours,Abgenix XenoMouse,
Concizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK,na,na,4dtg:HL,None,None,2012,2013,TFPI,Novo Nordisk,Haemophilia B,Haemophilia A;Haemophilia,na,,
Coprelotamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2/CD340/HER2,Genor Biopharma,na,HER2 positive breast cancer,Breast cancer,,"Coprelotamab has an identical Variable region to Anvatabart, Cinrebafusp, Trastuzumab,  and Timigutuzumab. Jul '23: Corrected by removing biosimilar label."
Coramitug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLELVAEINNSGDTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHYYYGGGYGGWFFDVWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQLLIYRVSNLASGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPLTFGQGTKLEIK,na,na,None,None,None,2023,na,Misfolded TTR,TBC,TBC,TBC,TBC,,Chimeric: Mouse/Human
Cosfroviximab,Whole mAb,G1,Kappa,Phase-II,Active,DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS,DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR,na,na,None,5kel:CD:JN:MO/5kem:DE:IJ.5ken:GH:QP:CD:NO:JI,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,
Cosibelimab,Whole mAb,G1,Lambda,Preregistration,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc,na,Cancer;Lymphoma,na,,
Crefmirlimab,scFv Engineered Dimer,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHFVRQAPGKGLEWIGRIDPANDNTLYASKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCGRGYGYYVFDHWGQGTLVTVSS,DVQITQSPSSLSASVGDRVTITCRTSRSISQYLAWYQQKPGKVPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQHNENPLTFGGGTKVEIK,na,na,None,None,None,2022,na,CD8A,ImaginAb,na,Solid tumours;Cervical cancer;Gastic cancer,Graft-versus-host disease,,Uses G1 and CH3 region in the dimer. Genetics: musmus/homosap
Crenezumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,5vzx:HL:EI/5vzy:HL,5kmv:HL:EI,None,2011,2012,APP,AC Immune;Genentech;Universidad de Antioquia,na,Alzheimer's disease,na,,
Crexavibart,Whole mAb,G1,Lambda,Phase-II/III,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,None,7k90:HL:MN:OP/8dce:HH,None,2022,na,SARS-CoV-2 Spike RBD,NIAID,na,COVID-19,na,,
Crizanlizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,SELP/CD62,Selexys Pharmaceuticals;Novartis,Vaso-occlusive crisis,Priapism;Myelofibrosis;COVID-19,na,,
Crotedumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK,na,na,None,None,None,2015,2016,GCGR,Regeneron Pharmaceuticals;Sanofi,na,na,Type 2 diabetes mellitus,,
Crovalimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,na,na,5b71:DC:BA,None,None,2018,2019,C5,Chugai Pharmaceutical;Roche,na,Atypical Haemolytic Uraemic Syndrome;Paroxysmal nocturnal haemoglobinuria ,na,,
Cudarolimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Innovent Biologics,na,na,Solid tumours,,
Cusatuzumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL,na,na,None,None,None,2017,2018,CD70,arGEN-X,na,Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours,Nasopharyngeal cancer;Autoimmune disorders,POTELLIGENT Technology. SIMPLE Antibody Technology.,
Dacetuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,None,None,None,2007,2008,TNFRSF5/CD40,Seattle Genetics,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma,,
Daclizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,na,na,3nfs:HL/3nfp:HL:AB,None,None,1994,1998,IL2RA/CD25,AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma,Renal transplant rejection,Multiple sclerosis,Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis,GS Gene Expression System,Daclizumab is the new name for Dacliximab (PL78). Biosimilar available
Dafsolimab,Whole mAb,G2b,Kappa,Phase-III,Active,QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2020,2021,CD3E,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,,ADC with setaritox
Dalnicastobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2022,na,TNFRSF5/CD40,MD Anderson Cancer Center;Lyvgen Biopharma,na,Cancer;Gastric cancer;Head and neck cancer;Esophageal;Hepatocellular carcinoma;Metastatic cancer,na,,
Dalotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,na,na,None,None,None,2009,2010,IGF1R/CD221,Pierre Fabre;Merck & Co,na,na,Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours;Breast cancer;Colorectal cancer;Pancreatic cancer ,,"Jain paper: ""Entries in WHO-INN documents (PL102 and RL64) have errors"""
Dalutrafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKASGYAFSSSWINWVRQMPGKGLEWMGRIYPRAGDTNYAGKFKDQVTISADKSISTAYLQWSSLKASDTAMYYCASLLDYSMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPLTFGQGTKVEIK,na,na,None,None,None,2021,2022,TGFBR2,Gilead Sciences,na,na,Solid tumours,,
Danburstotug,Whole mAb Fusion,G1,Lambda,Phase-III,Active,QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYSWVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPIVATITPLDYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTATIACGGENIGRKTVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCLVWDSSSDHRIFGGGTKLTVL,na,na,None,None,None,2022,na,PDL1/CD274,Sorrento Therapeutics;Asan Medical Center;ImmuneOncia Therapeutics,na,Extranodal NK-T-cell lymphoma;Gastric cancer;Liver cancer;Oesophageal cancer;Solid tumours,na,,
Danvilostomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS,ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPGKVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL;None,None;None,7su0:HL:IM/7su1:HL;None,2022,na,CTLA4/CD152;PDCD1/CD279/PD1,TBC,TBC,TBC,TBC,,Fv1 is Ipilimumab
Dapirolizumab,Fab,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD40LG/CD154,Biogen;Biogen Idec;UCB,na,Systemic lupus erythematosus;Multiple sclerosis,Amyotrophic lateral sclerosis;Rheumatoid Arthritis,,
Daratumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,na,na,7dun:HL/7duo:HL/7dha:CB,None,None,2009,2010,ADPRC1/CD38,Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals,Multiple myeloma,Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours,Non-small cell lung cancer,Medarex HuMAb Mouse,
Dargistotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTSYPMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARVGGYSVDEYAFDVWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLSSYPTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT/WUCAM/VSTM3,Merck;Gilead;Nektar Therapeutics,na,na,Solid tumours;Carcinoma;Bladder cancers;Metastatic cancers;Urothelial cancers,,
Datopotamab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,TACSTD2/TROP2/EGP1,Daiichi Sankyo,na,Breast cancer;Non-small cell lung cancer,na,,ADC with deruxtecan
Davutamig,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGTSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGITWNSYNIDYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDDDYSNYVYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFIVTTNYMTWLRQAPGKGLEWVSLIYSSGHTYYADSVKGRFTISRHNSKNTLYLQMDSLRAEDTAVYYCASAFAADVFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2023,na,MET/HGFR;MET/HGFR,Regeneron Pharmaceuticals,na,"Cancers,Non-small cell lung cancer",na,,Biparatopic
Daxdilimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,na,na,None,None,None,2020,2021,LILRA4/CD85g,Viela Bio,na,Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury,na,,
Dazukibart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWMHWVRQAPGQGLEWMGHIDPSDSYTYYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWDYGNLLFEYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK,na,na,None,None,None,2023,na,IFNB1,Pfizer,na,Dermatomyositis,na,,
Dectrekumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL13,Novartis,na,na,Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis,,
Delpacibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIK,na,na,None,None,None,2022,na,TFRC/CD71,TBC,TBC,TBC,TBC,,
Demcizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Celgene Corporation;OncoMed Pharmaceuticals,na,na,Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours,,
Demupitamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,None,5sx4:HL:JI/5sx5:HL:JK,None,2019,2020,EGFR/ERBB1/HER1,Sinocelltech,na,Cancers,na,,Likely to be a Panitumumab biosimilar
Denecimig,Bispecific mAb,G4;G4,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQVPGKGLEWVSGISWRGDIGGYVKSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKSYGSGSFYNAFDSWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLERGTPSRFSGSGSGTEFSLTISSLQPDDFATYYCLEYSSYIRTFGQGTKVEIK,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIK,7ahu:BA:HL,7ahv:AB;Noe,None,2022,na,F9;F10,TBC,TBC,TBC,TBC,Human antibody phage display library. Transgenic mice.,Aug '23: Corrected name
Denintuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK,na,na,None,None,None,2014,2015,CD19,Seattle Genetics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,ADC with mafodotin,
Denosumab,Whole mAb,G2,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2005,2006,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network,Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis,Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma,Multiple myeloma ,Abgenix XenoMouse,Biosimilars available
Depatuxizumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,Ludwig Institute for Cancer Research;AbbVie,na,na,Solid tumours,,
Depemokimab,Whole mAb,G1,Kappa,Phase-III,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL5,GlaxoSmithKline,na,Asthma,na,,
Derlotuximab,Whole mAb Radiolabelled,G1,Kappa,Approved,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS,ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK,na,na,None,None,None,2015,2016,DNA/H1 Complex,Avid Bioservices;MediPharm Biotech,Lung cancer,Glioblastoma,na,,
Devextinetug,Whole mAb,G2,Kappa,Phase-II,Active,EIQLQQSGPELGKPGASVKVSCRASGFSFADYYIYWVKQSHGKSLELIGYIDPFNGGDTYNQIFKGKATLTVDKSSSTAFMYLNSLTSEDSAVYYCAAFRNPSFDFWGQGTTLTVSS,QIVLIQSPPIMSASPGEKVTLTCSASSSVSSRYLYWYQQKPGSSPKLWIYGTSNLASGVPARFSGSGSGTSFSLTISSMEAEDAASYFCHQWSSFPFTFGSGTKLEIK,na,na,None,None,None,2022,na,Metamphetamine,InterveXion Therapeutics;NIDA,na,Methamphetamine overdose,na,,
Dezamizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK,na,na,None,None,None,2016,2017,APCS/SAP,Pentraxin Therapeutics;GlaxoSmithKline,na,na,Amyloidosis,,
Dilpacimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,None;1bj1:HL:KJ/7v5n:BA:FE,None;None,None;6bft:HL:AB/1cz8:HL:YX,2018,2019,DLL4;VEGFA,AbbVie,na,Colorectal cancer;Solid tumours,na,,
Dinutuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL,2013,2014,Ganglioside GD2,National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation,Neuroblastoma,Small cell lung cancer,Malignant melanoma,,
Diridavumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL,na,na,3gbn:HL/3gbm:HL:IM/5c0s:HL/6uyn:HL/8dim:HI:BC:EF/8diu:EF:GC:HI,None,4evn:AB:CD:IJ:OP:KL:EF:GH:MN,2014,2015,Influenza A HA2,National Institute of Allergy and Infectious Diseases;Crucell,na,Influenza A virus (H1N1) infections,na,,
Disitamab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK,na,na,None,None,None,2018,2019,ERBB2/CD340/HER2,Yantai Rongchang Biological Engineering,Gastric cancer,Breast cancer;Urogenital cancer;Non-small cell lung cancer;Cholangiocarcinoma;Lung cancer,Solid tumours,,ADC with vedotin
Divozilimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS,QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,MS4A1/CD20,Biocad,na,Relapsing-remitting multiple sclerosis,na,,Genetics: musmus/homosap
Docaravimab,Whole mAb (Mouse),G2b,Kappa,Approved,Active,QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS,DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-III,Candila Healthcare,Rabies,na,na,,Mouse antibody
Domagrozumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK,na,na,None,5f3h:EF:GH:AB:CD,None,2015,2016,MSTN,Kennedy Krieger Institute;Pfizer,na,na,Duchenne muscular dystrophy;Limb girdle muscular dystrophies,,
Domvanalimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAFISSGSSSIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMRLDYYAMDYWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPWTFGGGTKVEIK,na,na,None,None,None,2020,2021,TIGIT/WUCAM/VSTM3,Arcus Biosciences,na,Solid tumours;Non-small cell lung cancer,na,,
Donanemab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK,na,na,None,None,None,2018,2019,APP,Eli Lilly,na,Alzheimer's disease,na,,
Donzakimig1,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv),G1;na,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYAMIWVRQAPGKGLEWIGIIDIEGSTYYASWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDRFVGVDIFDPWGQGTLVTVSS,AVQLTQSPSSLSASVGDRVTITCQASEDIYTNLAWYQQKPGKAPKLLIYWASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQASVYGNAADSRYTFGGGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK,None;None,None;5fuo:HL/5fuz:HL,None;None,2023,na,IL22;ALB,TBC,TBC,TBC,TBC,,VH-CH1-h-scFv_L-kappa segment. Fv2 identical to Galvokimig Fv2.
Donzakimig2,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv),na,Kappa,TBC,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYYIHWVRQAPGQCLEWMGRIGPGSGDINYNEKFKGRATFTVDKSTSTAYMELSSLRSEDTAVYYCARFHYDGADWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNINENLDWYQQKPGKAPKLLIYYTDILQTGIPSRFSGSGSGTDYTLTISSLQPEDFATYYCYQYYSGYTFGCGTKLEIK,na,na,None,None,None,2023,na,IL13,TBC,TBC,TBC,TBC,,Final scFv segment. Fv3 identical to Galvokimig Fv3
Dostarlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS,DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK,na,na,7wsl:HL,None,None,2018,2019,PDCD1/CD279/PD1,AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO,Endometrial cancer;Solid tumours,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer,na,,
Dovanvetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS,EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK,na,na,None,None,None,2019,2020,IL31 (Feline),na,na,na,na,,
Dresbuxelimab,Whole  mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS,DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,NT5E/CD73,Akeso Biopharma,na,COVID-19,na,,
Drozitumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,na,na,4od2:BA,None,None,2010,2011,TNFRSF10B/CD262/DR5/TRAILR2,Genentech,na,na,Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer,,
Duligotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,na,na,None,None,3p0v:HL:IM/3p0y:HL/3p11:HL,2012,2014,ERBB3/HER3,Genentech;Roche,na,na,Solid tumours;Colorectal cancer;Head and neck cancer,,Duligotuzumab is the new name for Duligotumab (PL110)
Dupilumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,na,na,6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB,None,None,2012,2013,IL4R/CD124,Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi,Asthma;Atopic dermatitis;Nasal polyps,Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria,Allergic asthma,VelocImmune Mouse,
Durvalumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,na,na,5xj4:HL/5x8m:BC,None,None,2014,2015,PDL1/CD274,Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine,Non-small cell lung cancer;Urogenital cancer;Small cell lung cancer,Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer,CNS cancer;Lymphoproliferative disorders;Thyroid cancer,,
Dusigitumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL,na,na,None,None,None,2012,2013,IGF1 and IGF2,MedImmune,na,na,Breast cancer;Liver cancer;Solid tumours,,
Duvakitug,Whole mAb,G1,Lambda,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWLNPNSGYTGYAQKFQGRVTMTADRSTSTAYMELSSLRSEDTAVYYCAREVPETAAFEYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTSSSSDIGAGLGVHWYQQLPGTAPKLLIEGYYNRPSGVPDRFSGSKSGTSASLTITGLLPEDEGDYYCQSWDGTLSALFGGGTKLTVL,na,na,None,None,None,2023,na,TNFSF15/TL1A/VEGI,TBC,TBC,TBC,TBC,,
Duvortuxizumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS,ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2016,2017,CD19;CD3E,Janssen Biotech;MacroGenics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,
Ebdarokimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCQSSGYTFTSYWIGWVRQMPGQGLEWIGIMSPVDSDIRYNPMFRGQVTMSVDKSSSTAYLQWSSLKASDTAMYYCARRRPGQGYFDFWGQGTMVTVSS,EIVLTQSPATLSASPGERATISCRASQSVGTWVAWYQQKPGQAPRSLIYAASNLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNIYPYTFGQGTRLEIK,na,na,None,None,None,2020,2021,IL12B/CLMFp40,Akeso Biopharma,na,Plaque Psoriasis;Ulcerative colitis;Systemic lupus erythematosus,Crohn's disease;Psoriatic arthritis,,
Eblasakimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARMPNWGSLDHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASFGQGTKVEIK,na,na,None,None,4hwe:HL/4hwb:HL,2021,2022,IL13RA1/CD213A1,ASLAN Pharmaceuticals,na,Atopic dermatitis,Asthma,,
Ebronucimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL,na,na,None,None,None,2020,2021,PCSK9,Akeso Biopharma,na,Heterozygous familial hypercholesterolemia,na,,
Eciskafusp,Fusion Protein,G1,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,TBC,TBC,TBC,TBC,,Fv identical in sequence to Tobemstomig and Lomvastomig Fv1.
Ecleralimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYWMHWVRQAPGKGLEWVGHIKSKTDAGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCAREIYYYAFDSWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDNIGSKYVHWYQQKPGQAPVLVIYGDNERPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQAADWVDFYVFGGGTKLTVL,na,na,None,None,None,2021,2022,TSLP,Novartis,na,Chronic obstructive pulmonary disease,Asthma,,
Ecromeximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVTLVESGGDFVKPGGSLKVSCAASGFAFSHYAMSWVRQTPAKRLEWVAYISSGGSGTYYSDSVKGRFTISRDNAKNTLYLQMRSLRSEDSAMYFCTRVKLGTYYFDSWGQGTTLTVSS,DIQMTQTASSLPASLGDRVTISCSASQDISNYLNWYQQKPDGTVKLLIFYSSNLHSGVPSRFSGGGSGTDYSLTISNLEPEDIATYFCHQYSKLPWTFGGGTKLEIK,na,na,None,None,None,2002,2003,GD3 ganglioside,Kyowa Hakko;Kyowa Kirin;Life Science Pharmaceuticals;Ludwig Institute for Cancer Research,na,na,Malignant melanoma,,
Eculizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,5i5k:HL:XY,None,None,2002,2003,C5,Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc,Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria,Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19,Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus,GS Gene Expression System,Biosimilars available
Edrecolomab,Whole mAb,G2a,Kappa,Approved (w),Discontinued,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,na,na,None,None,None,1995,1996,EPCAM/CD326,Ajinomoto;Centocor Inc,Colorectal cancer ,na,Adenocarcinoma;Pancreatic cancer,,
Efalizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,na,na,3eo9:HL/3eoa:HL:BA/3eob:HL:BA,None,None,2001,2002,ITGAL/CD11A/LFA1A,Genentech;Merck Serono;XOMA,Psoriasis,na,Psoriatic arthritis;Type 1 diabetes mellitus,,
Efungumab,scFv,na,Kappa,Phase-III,Discontinued,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,na,na,None,None,None,2006,2007,Heat Shock Protein 90 Homolog,NeuTec Pharma,na,na,Breast cancer;Candidiasis,,
Eglatoprutug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYAQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASESVDIYGQSFMHWYLQKPGQSPQLLIYLASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,na,KIT/CD117,TBC,TBC,TBC,TBC,,
Eldelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,na,na,None,None,None,2013,2014,CXCL10/IP10,Bristol-Myers Squibb;Medarex,na,na,Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries,Medarex UltiMAb Mouse,
Elezanumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL,na,na,None,None,None,2016,2017,RGMA,AbbVie,na,Multiple sclerosis;Spinal cord injuries;Stroke,na,,
Elgemtumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK,na,na,None,None,4p59:HL,2014,2015,ERBB3/HER3,MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology,na,na,Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours,Medarex HuMAb Mouse,
Elipovimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,na,na,None,None,4fq1:HL/4jy4:BA/4fqc:HL,2018,2019,HIV-1 gp120,Gilead Sciences,na,na,HIV infections,,
Elotuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,SLAMF7/CD319,AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma,Multiple myeloma,na,na,,
Elranatamab,Bispecific mAb,G2;G2,Kappa;Kappa,Preregistration,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGSGGSLPYADIVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLFNVRSRKNYLAWYQQKPGQPPKLLISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYDLFTFGSGTKLEIK,None;None,None;None,None;None,2021,2022,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Pfizer,na,Multiple myeloma,na,,
Eltrekibart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYEFTSYWIHWVRQAPGQGLEWMGNISPNSGSANYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGPYSYYPSREYYGSDLWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIYYTSRSVSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCGQNNEWPEVFGGGTKVEIK,na,na,6wzk:AB:CD/6wzl:AB:CD/6wzj:AB:CD/6wzm:AB:CD,None,None,2023,na,CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8,Eli Lilly,na,Hidradenitis suppurative,Skin disorders,,
Eluvixtamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,SIGLEC3/CD33/p67;CD3E,Amgen,na,na,Acute myeloid leukaemia,BiTE Technology,Genetics of Fv2: musmus/homosap
Emactuzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK,na,na,4liq:HL,None,None,2014,2015,CSF1R/CD115/M-CSFR,Roche;University of Texas M. D. Anderson Cancer Center,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours,Giant cell tumour of tendon sheath;Pigmented villonodular synovitis,,
Emapalumab,Whole mAb,G1,Lambda,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL,na,na,None,None,None,2016,2017,IFNG,NovImmune SA;Swedish Orphan Biovitrum,Haemophagocytic lymphohistiocytosis,na,na,,
Emerfetamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,SIGLEC3/CD33/p67;CD3E,Amgen,na,Acute myeloid leukemia,na,BiTE Technology,Genetics of Fv2: musmus/homosap
Emfizatamab1,"Tetraspecific (scFv-IgG-scFv-scFv, Bispecific entry 1)",na;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,EVQLVQSGAEVKKPGESLKISCKGSGYSFSSSWIGWVRQAPGKGLEWMGIIYPDDSDTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDTAMYYCARHVTMIWGVIIDFWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIK,None;None,None;None,None;None,2022,2022,CD3E;CD19,Sichuan Baili Pharmaceutical,na,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,scFv-IgG1 portion. Joint entry with Emfizatamab2 (tetraspecific)
Emfizatamab2,"Tetraspecific (scFv-IgG-scFv-scFv, Bispecific entry 2)",na;na,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK,SRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS,DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK,None;None,None;None,None;None,2022,2022,PDL1/CD274;TNFRSF9/CD137/4-1BB,Sichuan Baili Pharmaceutical,na,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,scFv-scFv portion. Joint entry with Emfizatamab1 (tetraspecific)
Emicizumab,Bispecific mAb,G4;G4,Kappa;Kappa,Approved,NFD,QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,F9;F10,Chugai Pharmaceutical;Roche,Haemophilia A,na,na,,
Emibetuzumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,MET/HGFR,Eli Lilly,na,Gastric cancer;Non-small cell lung cancer;Cancer,na,,
Emirodatamab,Bispecific scFv-scFv-scFc,na;na,Kappa;Lambda,Phase-I,Active,QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,FLT3/CD135/FLK2;CD3E,Amgen;BeiGene,na,Acute myeloid leukaemia,na,,Genetics of Fv2: musmus/homosap
Empasiprubart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSS,DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIK,na,na,None,None,None,2022,na,C2,arGEN-X;Broteio,na,Multifocal motor neuropathy;Dermatomyositis;Kidney disorders;Motor neuron disease,COVID-19,,
Enapotamab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,AXL/UFO,Genmab,na,na,Solid tumours,,ADC with vedotin
Enavatuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK,na,na,None,None,None,2010,2011,TNFRSF12A/CD266/TWEAKR,PDL BioPharma;Abbott Laboratories,na,na,Solid tumours,,
Encelimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Anaptys Bio;TESARO,na,Solid tumours,na,,
Enfortumab,Whole mAb ADC,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,PVRL4/Nectin-4,Agensys;Seattle Genetics,Urogenital cancer,Bladder cancer;Prostate cancer;Solid tumours,na,,ADC with vedotin
Englumafusp,Fusion Protein,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,CD19,Roche,na,B cell Lymphoma,na,,June '22: Corrected CDRH2 sequence. Aug '22: WHO changed name from ensomafusp to englumafusp in PL127.
Enibarcimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,ADM,Adrenomed,na,Septic shock;Cardiogenic shock;COVID-19,na,,Genetics: musmus/homosap
Enlonstobart,Whole mAb,G4,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLTCKASGLTFSSSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNNDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNWPRTFGQGTKVEIK,na,na,None,None,5ggr:HL:AB/5ggq:HL/5wt9:HL,2023,na,PDCD1/CD279/PD1,TBC,TBC,TBC,TBC,,
Enoblituzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,na,na,None,None,None,2015,2017,B7H3/CD276,MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Prostate cancer;Solid tumours;Head and neck cancer,Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer,,
Enokizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,IL9,Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune,na,na,Asthma,,
Enoticumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,VelocImmune Mouse,
Enristomig,Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer),G1;G1,na;na,TBC,Active,EVQLLESGGGEVQPGGSLRLSCAASGGIFAIKPISWYRQAPGKQREWVSTTTSSGATNYAESVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCNVFEYWGQGTLVTVKP,na,EVQLLESGGGEVQPGGSLRLSCAASGFSFSINAMGWYRQAPGKRREFVAAIESGRNTVYAESVKGRFTISRDNAKNTVYLQMSSLRAEDTAVYYCGLLKGNRVVSPSVAYWGQGTLVTVKP,na,None;None,None;None,None;None,2023,na,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,
Ensituximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS,QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK,na,na,None,None,None,2010,2011,MUC5AC,Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine,na,Colorectal cancer;Pancreatic cancer,na,,
Enuzovimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLQELGSLDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQEANSFPYTFGQGTKLEIK,na,na,7cjf:AB,None,None,2021,2022,SARS-CoV-2 Spike RBD,ABL Bio;HiFiBiO Therapeutics,na,COVID-19,na,,
Envafolimab,Single Domain Variable Fragment;H,G1,na,Approved,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,na,na,None,None,None,2018,2019,PDL1/CD274,Alphamab;3D Medicines;Sun Yat-Sen University,Solid tumours,Biliary cancer;Breast cancer;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma,na,,Oct '22: Sequence fixed to contain the full DJ/J regions. Genetics: vicpac/homosap
Epacmarstobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWITWVKQAPGQGLEWIGDIYPGSGSTNHIEKFKSKATLTVDTSISTAYMELSRLRSDDTAVYYCATGYGSSYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYTAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHQYGPPFTFGQGTKLEIK,na,na,None,None,None,2022,na,SIRPA,Gilead Sciences,na,Non-Hodgkin's lymphoma,na,,Genetics: musmus/homosap
Epcoritamab,Bispecific mAb,G1;G1,Lambda;Kappa,Approved,Active,EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL,EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,None;None,None;None,None;3giz:HL/6y92:CD:HL,2019,2020,CD3E;MS4A1/CD20,Genmab,Diffuse large B-cell lymphoma,Haematological malignancies;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,na,,Chimeric: Mouse/Human
Epratuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,na,na,None,5vkk:AB:HL/5vl3:EF:AB:HL:CD,None,1999,2000,SIGLEC2/CD22,Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB,na,na,Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia,,
Eptinezumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS,QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK,na,na,None,None,None,2016,2017,CALCA and CALCB,Alder Biopharmaceuticals,Migraine,Cluster headache,na,,
Eramkafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM,4kaq:HL,None,2020,2021,MS4A1/CD20,Spectrum Pharmaceuticals;ImmunGene,na,na,Non-Hodgkin's lymphoma,,Possibly a Rituximab biosimilar. (June '22): Corrected IMGT VH 128 S->A
Erenumab,Whole mAb,G2,Lambda,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,na,na,6umg:HL:hl/6umh:HL:hl/6umi:HL/6umj:HL,None,None,2016,2017,CALCRL,Amgen;Novartis,Migraine,na,Hot flushes,Abgenix XenoMouse,
Erfonrilimab,Bispecific Single Domains (VH-VH'-CH),G1,na;na,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,QVQLVESGGGLVQPGGSLRLSCAASGYIYSAYCMGWFRQAPGKGLEGVAAIYIGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADVIPTETCLGGSWSGPFGYWGQGTLVTVSS,na,None;6rqm:B,None;None,None;None,2020,2021,PDL1/CD274;CTLA4/CD152,Alphamab,na,Non-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma,na,,June '22: Corrected FWH1 sequence. Genetics of Fv1: vicpac/homosap
Erlizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRFMDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIK,na,na,2fgw:HL,None,None,2000,2001,ITGB2/CD18,Genentech;PDL Biopharma; Roche,na,na,Myocardial infarction;Shock ,,
Ersodetug,Whole mAb,G2,Kappa,TBC,Active,EVQLVETGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWYAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHEWGFGMDVWGQGTTVTVSS,DVVMTQSPLSLSVTLGQPASISCRSSLSLVYGDENTYLNWFQQRPGQSPRRLLYKVSDRDSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2023,na,INSR/CD220,TBC,TBC,TBC,TBC,,
Erzotabart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKAFGGTFSSYAISWVRQAPGQGLEWMGRIIRFLGIANYAQKFQGRVTLIADKSTNTAYMELSSLRSEDTAVYYCAGEPGERDPDAVDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPLTFGGGTKVEIK,na,na,8byu:HL,None,None,2023,na,ADPRC1/CD38,TBC,TBC,TBC,TBC,,
Etaracizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,ITGAVB3/CD61/VNR,Applied Molecular Evolution;MedImmune,na,na,Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis,,
Etesevimab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,na,na,7c01:CD:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Eli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences,COVID-19,na,na,,
Etevritamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS,DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,EGFR/ERBB1/HER1;CD3E,Amgen,na,na,Glioblastoma,,Genetics of Fv2: musmus/homosap
Etigilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,TIGIT/WUCAM/VSTM3,OncoMed Pharmaceuticals,na,Solid tumours,na,,
Etokimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,IL13,AnaptysBio,na,na,Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis,,
Etrolizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,na,na,None,None,None,2010,2011,ITGA4B7 and ITGAEB7,Genentech;Roche,na,na,Crohn's disease;Ulcerative colitis,,
Eurestobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYNLKDTFLHWVRQAPGQGLEWMGRIDPAQGNIKYDPKFQGRVTITADTSANTAYMELISLRSEDTAVYYCANSPYYYGSGYRIFDVWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSAFSSVNYMHWYQQKPGQAPRLLIYTTSNLASGIPTRFSGSGSGTSYTLTISSLEPEDFAVYYCQQRSTYPFTFGQGTKLEIK,na,na,None,None,None,2023,na,ENTPD1/CD39,TBC,TBC,TBC,TBC,,
Evalstotug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQYVGSSYLAWYLQKPGQSPQLLIYGAFSRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDGSSPWTFGQGTKVEIK,na,na,None,None,None,2023,na,CTLA4/CD152,TBC,TBC,TBC,TBC,,
Evinacumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK,na,na,None,None,None,2014,2015,ANGPTL3,Regeneron Pharmaceuticals;Sanofi,Hyperlipoproteinaemia type II,Hypertriglyceridaemia,na,,
Evolocumab,Whole mAb,G2,Lambda,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,na,na,None,None,None,2012,2013,PCSK9,Amgen;Amgen Astellas BioPharma;University Hospital Inselspital,Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke,Hyperlipidaemia;Coronary artery disease;Dyslipidaemias,na,Abgenix XenoMouse,
Evunzekibart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFNFGYSYMSWVRQAPGKGLEWVSSIGSTSSHTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVYSSPGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGSTLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYTWVPFTFGQGTKLEIK,na,na,None,None,None,2022,na,TNFRSF9/CD137/4-1BB,Alligator Bioscience,na,Solid tumours,na,,
Exbivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVESGGGVVQPGGSLRLSCAPSGFVFRSYGMHWVRQTPGKGLEWVSLIWHDGSNRFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCARERLIAAPAAFDLWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARISCGGNNIGTKNVHWYQQKPGQAPVLVVYADSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSVSYHVVFGGGTTLTVL,na,na,None,None,None,2004,2005,Hepatitis B Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,,
Exidavnemab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIWRGGSTDYSAAFMSRLTISKDTSKNQVSLKLSSVTAADTAVYYCAKLLRSVGGFADWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGQGTKLEIK,na,na,None,None,None,2021,2022,SNCA,AbbVie,na,SNCA,na,,Genetics: musmus/homosap
Exlinkibart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFAGFEMHWVRQAPGQGLEWMGAIDPKTGGTDYNQKFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDLGYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRSNLNWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQSEKLPRTFGGGTKVEIR,na,na,None,None,None,2022,na,TNFRSF9/CD137/4-1BB,MD Anderson Cancer Center;Lyvgen Biopharma,na,Gastric cancer;Soft-tissue carcinoma;Head and neck cancer;Esophageal cancer;Hepatocellular carcinoma;Metastatic cancer,na,,
Ezabenlimab,Whole mAb,G4,Kappa,Phase-II,Active,EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNVNYYAMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPWTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDCD1/CD279/PD1,Boehringer Ingelheim,na,Solid tumours;Squamous cell cancer;Colorectal caner;Head and neck cancer;Non-small cell lung cancer,na,,June '22: Corrected CDRH3/CDRL3 sequences
Falbikitug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGGGLVKPGGSLRLSCAASGFTFSHAWMHWVRQAPGKGLEWVGQIKAKSDDYATYYAESVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTCWEWDLDFWGQGTMVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLLDSDGHTYLNWLQQRPGQPPRLLIYSVSNLESGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATHAPPYTFGQGTKLEIK,na,na,7n0a:BA,None,None,2023,na,LIF,TBC,TBC,TBC,TBC,,
Fanastomig,Bispecific (L-kappa-H-gamma1_G1(VH-CH1-h)_L-kappa),G1;G1,Kappa;Kappa,TBC,Active,EVQLVQSGAEVKKPGATVKLSCTASGFNIKDDYMHWVKQRPEQGLDWIGWIVPENANTVYASKFQGKATITADTSTNTAYLELSSLRSEDTAVYYCTVYGDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQEISGYLSWLQQKPGGAIKRLIYAASALDSGVPSRFSGSRSGSDYTLTISSLQPEDFADYYCLQYASYPLTFGQGTKLELK,EVQLVESGGGLVQPGGSLRLSCAASGFTSSDYGMHWVRQAPGKGLEWVSYISSGSYTIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAKRGGSSHVNVMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYWSPPYTFGGGTKVEIK,None;None,None;None,None;None,2023,na,LAG3/CD223;PDCD1/CD279/PD1,TBC,TBC,TBC,TBC,,Genetics of both Fvs: musmus/homosap
Faricimab,Bispecific mAb,G1;G1,Kappa;Lambda,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL,1cz8:HL:YX;None,None;None,1bj1:HL:KJ/6bft:AB:HL/7v5n:FE:BA;4iml:AB:HL/4imk:AD:BC,2017,2018,VEGFA;ANGPT2,Chugai Pharmaceutical;Roche,Diabetic macular oedema;Wet age-related macular degeneration,Diabetic retinopathy;Retinal oedema,na,Dual-Affinity Re-Targeting Technology,
Farletuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,na,na,None,None,None,2008,2009,FOLR1,Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd,na,na,Solid tumours;Ovarian cancer;Non-small cell lung cancer,,
Fasinumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,NGFB,Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi,na,na,Back pain;Pain,VelocImmune Mouse,
Favezelimab,Whole mAb,G4,Kappa,Phase-II,Active,QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Merck,na,Non-small cell lung cancer;Haematological malignancies;Solid tumours,na,,Favezelimab is the new name for Mavezelimab (PL123)
Fazpilodemab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASDFSLTTYGVHWVRQAPGKGLEWLGVIWSGGSTDYNAAFISRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARDYGSTYVDAIDYWGQGTLVTVSS,DIVLTQSPDSLAVSLGERATINCRASESVESYGNRYMTWYQQKPGQPPKLLIYRAANLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSNYISWVRQAPGKGLEWVGEIDPYDGDTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCATGTDVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,None;None,None;None,None;None,2022,na,KLB;FGFR1/CD331/BFGFR,Genentech,na,Non-alcoholic steatohepatitis,Type 2 diabetes mellitus,,3sob is 94% similar to FGFR1 binding arm. Genetics of Fv1: musmus/homosap
Feladilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,ICOS/CD278,GlaxoSmithKline,na,Solid tumours;Multiple myeloma;Non-small cell lung cancer;Head and neck cancer,na,,
Felzartamab,Whole mAb,G1,Lambda,Preregistration,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL,na,na,None,None,None,2019,2020,ADPRC1/CD38,MorphoSys,na,Multiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus,Non-small cell lung cancer,,
Fepixnebart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSIVHSTGNTYLEWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFHGTHVPYTFGGGTKVEIK,na,na,5kn5:AB,None,None,2022,na,EREG,Eli Lilly and Company,na,Back pain;Neuropathic pain;Pain;Diabetic nephropathies,na,,
Fezakinumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,na,na,None,None,None,2009,2010,IL22,Pfizer;Wyeth,na,na,Psoriasis;Rheumatoid arthritis,,
Fianlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Regeneron Pharmaceuticals,na,Cancer,na,,
Ficlatuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,HGF/SF,AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco,na,Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer,Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma,,
Fidasimtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2021,2022,PDCD1/CD279/PD1;ERBB2/CD340/HER2,Hanmi Pharmaceutical;Innovent Biologics,na,na,Solid tumours,,June '22: Corrected FWL4 sequence in LC1
Figitumumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,na,na,None,None,None,2008,2009,IGF1R/CD221,Pfizer,na,na,Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours,,
Finotonlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKRLEWVATISGGGRDTYYSDSVKGRFTISRDNAKNNLYLQMNSLRAEDTAVYYCSRQYGTVWFFNWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGNSFMHWYQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAMYFCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Sinocelltech,na,Hepatocellular carcinoma;Heavy and neck squamous cell carcinoma,na,,Genetics: musmus/homosap
Firastotug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIK,na,na,None,None,None,2023,na,CTLA4/CD152,TBC,TBC,TBC,TBC,,
Firivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK,na,na,None,None,None,2014,2015,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,,
Fiztasovimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWGWIRQPPGKGLEWIGEINHSGSANSNPSLKSRVTMSVDTSKNQFSLKVSSVTAADTAVYFCARVTRDLEWIPGDYYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVSISCSGSLSNIGTNYVYWYQQLPGTAPKLLIFKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,na,na,None,None,None,2022,na,Human Herpesvirus Glycoprotein B AD-1,Nobelpharma Co,na,Cytomegalovirus infections,na,,
Flanvotumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK,na,na,None,None,None,2011,2012,TYRP1,ImClone Systems;Eli Lilly,na,na,Malignant melanoma,,
Fletikumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2013,2014,IL20,ZymoGenetics;Novo Nordisk,na,na,Psoriasis;Rheumatoid arthritis,,
Flotetuzumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I/II,Discontinued,EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,IL3RA/CD123;CD3E,MacroGenics;Servier,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,
Fontolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK,na,na,None,1t3f:BA/1t04:DC:BA,None,2002,2003,IFNG,PDL BioPharma,na,na,Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis,,
Foralumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,CD3E,Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences,na,Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus,Transplant rejection;Type 1 diabetes mellitus,,
Foravirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK,na,na,None,None,None,2008,2009,Rabies Virus Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,
Forimtamig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSISGINLMNWYQQKPGQQPKLLIYHASILASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTRESPLTFGQGTRLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFQFSSYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHTTFPSSYVSYYGYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,GPRC5D;CD3E,Roche,na,na,Multiple myeloma,,
Fremanezumab,Whole mAb,G2,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,CALCA and CALCB,Rinat Neuroscience;Teva Pharmaceutical Industries,Migraine,Fibromyalgia;Headache;Interstitial cystitis,Cluster headache,,
Freneslerbart,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRNYNINWVRQAPGKGLEWVSLISGSSSYIYYADSVKGRFTVSRDNAKNSLYLQMNSLRAEDTAVYYCARRTLSYYVMDVWGQGTTVTVSS,DIQVTQSPSPLSASVGDRVTITCRASQGISNYLAWYQQKPGRVPQLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTKLEIK,na,na,None,None,None,2022,na,Fel d 1,Regeneron Pharmaceuticals,na,Cat allergies,na,,Antigen: Felis silvestris catus (domestic cat) allergen 1
Fresolimumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,na,na,None,3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG,None,2009,2010,TGFB,Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme,na,na,Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta,CAT Phage Display,
Frexalimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCTVSGDSITNGFWIWIRKPPGNKLEYMGYISYSGSTYYNPSLKSRISISRDTSKNQFSLKLSSVTAADTGVYYCAYRSYGRTPYYFDYWGQGTTLTVSS,DIVMTQSPSFLSASVGDRVTITCKASSNLGHAVAWYQQKPGKSPKLLIYSASNRYTGVPDRFSGSGSGTDFTLTISSLQPEDFADYFCQQYDDYPYTFGGGTKLEIK,na,na,None,None,None,2022,na,CD40LG/CD154,Sanofi,na,Systemic lupus erythematosus;Multiple sclerosis;Sjogren's syndrome,na,,Genetics: musmus/homosap
Frovocimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK,na,na,None,None,None,2018,2019,PCSK9,Eli Lilly,na,Hypercholesterolaemia,na,,
Frunevetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA,DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Feline osteoarthritis,na,PETization Technology,
Fulranumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,4m6o:HL,None,2010,2011,NGFB,Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen,na,na,Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain,Abgenix XenoMouse,
Futuximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK,na,na,None,None,None,2012,2013,EGFR/ERBB1/HER1,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,,
Galcanezumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK,na,na,None,None,None,2015,2016,CALCA and CALCB,Eli Lilly,Migraine;Cluster headache,na,Musculoskeletal pain,,
Galegenimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK,na,na,7sjm:HL/7sjn:HL:DE:FG/7sjo:HL:EF:IJ/7sjp:HL,None,None,2021,2022,HTRA1,Roche,na,na,Age-related macular degeneration,,
Galiximab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,na,na,None,None,None,2003,2004,B7/CD80/CD28LG,Biogen;Biogen Idec,na,na,Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis,,
Galvokimig1,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv),G1;na,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK,None;None,None;5fuo:HL/5fuz:HL,None;None,2023,na,IL17A and IL17F;ALB,TBC,TBC,TBC,TBC,,G1(VH-CH1-h)-scFv_L-kappa segment. Fv1 identical to Bimekizumab. Fv2 identical to Donzakimig Fv2.
Galvokimig2,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv),na,Kappa,TBC,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYYIHWVRQAPGQCLEWMGRIGPGSGDINYNEKFKGRATFTVDKSTSTAYMELSSLRSEDTAVYYCARFHYDGADWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNINENLDWYQQKPGKAPKLLIYYTDILQTGIPSRFSGSGSGTDYTLTISSLQPEDFATYYCYQYYSGYTFGCGTKLEIK,na,na,None,None,None,2023,na,IL13,TBC,TBC,TBC,TBC,,Final scFv segment. Fv3 identical to Donzakimig Fv3.
Gancotamab,scFv,na,Lambda,Phase-II,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,None,None,None,2018,2019,ERBB2/CD340/HER2,Merrimack Pharmaceuticals;HERMES BioSciences,na,na,Breast cancer,,
Ganitumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,na,na,None,None,None,2010,2011,IGF1R/CD221,Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center,na,na,Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer;Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma,,
Gantenerumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,na,na,5csz:HL:AB,None,None,2012,2008,APP,MorphoSys;Chugai Pharmaceutical;Roche,na,na,Alzheimer's disease,,
Garadacimab,Whole mAb,G4,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL,na,na,None,None,None,2018,2019,F12,CSL Behring,na,Hereditary angioedema;COVID-19,na,,
Garetosmab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,INHBA,Regeneron Pharmaceuticals,na,Fibrodysplasia ossificans progressiva;Osteroporosis,Musculoskeletal disorders,,
Garivulimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK,na,na,None,None,None,2020,2021,PDL1/CD274,BeiGene,na,Solid tumours,na,,
Gatipotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS,DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK,na,na,None,None,None,2016,2017,MUC1/PEM/EMA,NEMOD Biotherapeutics;Glycotope,na,Ovarian cancer;Solid tumours;Fallopian tube cancer,na,GlycoExpress Technology,Gatipotuzumab and PankoMab are the same mAb
Gatralimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK,na,na,6obd:HL:BA,None,None,2019,2020,CD52,Sanofi,na,na,Multiple sclerosis,,
Gedivumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS,EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK,na,na,None,None,4kvn:HL,2016,2017,Influenza A HA,Genentech,na,na,Influenza A virus infections,,
Gefurulimab,Bispecific Single Domains (VH-VH'),,na;na,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS,na,None;None,None;None,None;None,2022,na,C5;ALB,Alexion Pharmaceuticals,na,Myasthenia gravis;Proteinuria,na,,
Gemtuzumab,Whole mAb ADC,G4,Kappa,Approved,NFD,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,na,na,None,None,None,2016,2017,SIGLEC3/CD33/p67,UCB;Celgene Corporation;Pfizer;University of California San Diego,Acute myeloid leukaemia,na,na,,ADC with ozogamicin
Geptanolimab,Whole mAb,G4,Kappa,Preregistration,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Genor Biopharma;Appolomics,na,Peripheral T-cell lymphoma;Primary mediastinal B-cell lymphoma;Hepatocellular carcinoma,Lymphoma;Solid tumours,,Genetics: musmus/homosap
Gevokizumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,na,na,4g6k:HL/4g6m:HL,None,None,2010,2011,IL1B,IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA,na,Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma,Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma,,
Giloralimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF5/CD40,AbbVie,na,Solid tumours,na,,Genetics: musmus/homosap
Gilvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS,DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK,na,na,None,None,None,2016,2017,PDCD1/CD279/PD1 (Canine),Merck,na,Canine Cancers,na,,
Gimsilumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS,EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK,na,na,None,None,None,2017,2018,CSF2,Ludwig Institute for Cancer Research;Morphotek,na,na,Cancer;Rheumatoid arthritis,MORPHODOMA Technology,
Ginisortamab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTRLEIK,na,na,None,None,None,2021,2022,GREM1,UCB,na,Solid tumours,na,,
Girentuximab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,na,na,None,None,None,2009,2010,CA9,Centocor Inc;Heidelberg Pharma AG,na,na,Renal cancer,,
Givastomig,Bispecific (G1-scFv_L-kappa),G1;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYPIEWVRQAPGQRLEWMGNFHPYNDDTKYNEKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARRAYGYPYAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNAGNQKNYLTWYQQKPGQPPKLLIYRASSRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYIYPYTFGGGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKCLEWVSWISYSGGSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAQRNSMREFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVTWYQQLPGTAPKLLIYADSHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDYSLSGYVFGCGTKLTVL,None;None,None;None,None;None,2023,na,CLDN18;TNFRSF9/CD137/4-1BB,I-MAB,na,Solid tumours;Colorectal cancer,na,,Fv2 identical in sequence to Ragistomig Fv2.
Glembatumumab,Whole mAb ADC,G2,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,na,na,None,None,None,2015,2016,GPNMB,CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA),na,na,Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma,,ADC with vedotin
Glenzocimab,Fab,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT,na,na,7r58:HL,None,None,2018,2019,GP6,Acticor Biotech,na,Stroke;COVID-19,na,,June '22: Corrected FWL3 sequence
Glofitamab,Bispecific mAb with Domain Crossover,G1;G1,Lambda;Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,None;3pp3:HL/3pp4:HL,None;6y9a:HL,None;6y97:HL,2019,2020,CD3E;MS4A1/CD20,Roche,Diffuse large B cell lymphoma,Follicular lymphoma;Non-Hodgkin's lymphoma,na,,Genetics of Fv1: musmus/homosap
Golimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,5yoy:RO:IF:QN:GD:HE:PM,None,None,2004,2005,TNF/TNFA,Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex,Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,Hearing disorders;Type 1 diabetes mellitus,Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis,Medarex UltiMAb Mouse,Biosimilars available
Golocdacimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDFKYHTHQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCALVWGTQGKGVRGWDYYYGMDVWGQGTTVTVSS,QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,7r8u:HL,None,None,2022,na,OLR1/LOX1,MedImmune,na,OLR1/LOX1,na,,
Gontivimab,Bispecific Single Domains (VH-VH'-VH'),na;na,na;na,Phase-II,Discontinued,DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,None;None,None;None,None;None,2019,2020,Respiratory Syncytial Virus Glycoprotein F;Respiratory Syncytial Virus Glycoprotein F,Ablynx,na,na,Respiratory syncytial virus infections,,
Gorivitug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSRYAMYWVRQAPGKGLEYVSAISSDGGSTYDADSVKGRFTISRANSKNTLYLQMSSLRAEDTAVYYCVKGLRELLYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPFTFGPGTKVDIK,na,na,None,None,None,2022,na,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,na,COVID-19,na,,
Gosuranemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK,na,na,None,None,None,2018,2019,MAPT,Biogen;Bristol-Myers Squibb;iPierian,na,na,Cardiovascular disorders;Metabolic disorders;Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders,,Genetics: musmus/homosap
Gotistobart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGLSWIRQPPGKGLEWIGYIWYDGNTNFHSPLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKTEGHYYGSNYGYYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKQGKAPKLLLYAATNLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQHLWGTPYTFGQGTKLEIK,na,na,6xy2:HL,None,None,2023,na,CTLA4/CD152,OncoImmune;BioNTech,na,Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,
Gremubamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK,None;None,None;None,6cyf:FE:ML:UT:DC;None,2019,2020,PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas),MedImmune,na,na,Nosocomial pneumonia,,May '22: Added missing Y102 in Fv1 LC.
Gresonitamab,Bispecific scFv-scFv-scFc,G1;G1,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,CLDN18;CD3E,Amgen,na,GE Junction Cancer,na,BiTE Technology,
Grisnilimab,Whole mAb,G2a,Lambda,Phase-I/II,Active,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL,na,na,None,None,None,2020,2021,CD7,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,,
Gruticibart,Whole mAb,G4,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLTGYGIYWVRQPPGKGLEWLGMIWGDGRTDYNSALKSRVTISKDNSKSQVSLKLSSVTAADTARYYCARDYYGSKDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYLTSYRNTGVPDRFSGSGSGTDFTFTISSLQPEDIAVYYCQQHYKTPYSFGGGTKVEIK,na,na,None,None,None,2023,na,F11,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap
Gulgafafusp,Fusion Protein (whole mAb with protein),G2,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTLSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGGSGSYRYYYYGLDVWGQGTTVTVSS,AIQMTQSPSSVSASIGDRVTITCRASQNINNLLAWYQQKPGKAPKLLIYTASSLQSEVPSRFSGSGSGTDFTLTISSLQPEDFAIYCCQQAHRFPPTFGQGTKVEIR,na,na,None,None,None,2023,na,GLP1R,TBC,TBC,TBC,TBC,,
Gumokimab,Whole mAb,G1,Kappa,Phase-III,Active,DVQLQESGPGLVKPSQTLSLTCTVSSYSFTSDYAWSWIRQPPGKGLEWIGYITYSGVTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARADYDSYYTMDYWGQGTSVTVSS,DVVMTQTPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHFWTFGGGTKLEIK,na,na,None,None,None,2021,2022,IL17A,Akeso Biopharma,na,Plaque psoriasis;Ankylosing spondylitis,na,,Genetics: musmus/homosap
Guselkumab,Whole mAb,G1,Lambda,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,na,na,4m6m:HL/4m6n:HL,None,None,2013,2014,IL23A,Janssen Biotech;MorphoSys;Taiho Pharmaceutical,Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis ,Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma,Rheumatoid arthritis,MorphoSys HuCAL Phage Display,
Ianalumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIK,na,na,None,None,None,2017,2018,TNFRSF13C/CD268/BAFFR/BR3,H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis,na,Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus,Chronic lymphocytic leukaemia,POTELLIGENT Technology,Feb '22: Residue 108 changed from Q to D according to amendment in RL83. (June '22) Corrected CDRL1/CDRL3 sequences.
Ibalizumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,na,na,3o2d:HL/7t0r:CB:HL,None,None,2007,2008,CD4,Biogen Idec;TaiMed Biologics;Theratechnologies,HIV-1 infections,na,na,,Biosimilar available
Ibentatug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKRLEWVATISIGGTYTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCARRGYGQYSYYGLDYWGQGTLVTVSS,DIVMTQSALSNPVTLGQSASISCRSSKSLLHSQGITYLYWYLQKPGQSPQLLIYQMSNRASGVPDRFSSSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGQGTKLEIK,na,na,None,None,None,2023,na,CSP1,ZielBio,na,Cholangiocarcinoma;Ovarian cancer;Pancreatic cancer;Solid tumours ,na,,Genetics: musmus/homosap
Ibritumomab,Whole mAb,G1,Kappa,Approved,NFD,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK,na,na,3bky:HL,None,None,1999,2000,MS4A1/CD20,Biogen;Schering;Spectrum Pharmaceuticals,Non-Hodgkin's lymphoma,na,Diffuse large B cell lymphoma;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Multiple myeloma,,Sequence sourced through DrugBank. ADC with tiuxetan
Icrucumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,FLT1,ImClone Systems,na,na,Colorectal cancer;Urogenital cancer;Breast cancer,,
Idactamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK,na,na,None,None,None,2020,2021,SLC1A5,MedImmune,na,Acute myeloid leukemia;Multiple myeloma;Diffuse large B-cell lymphoma,na,,
Idarucizumab,Fab,G1,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK,na,na,4jn2:HL:BA/4jn1:HL,None,None,2013,2014,Dabigatran,Boehringer Ingelheim,Blood coagulation disorders,na,na,,
Ieramilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,LAG3/CD223,Immutep Limited;Novartis,na,Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours,na,,
Ifabotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK,na,na,None,None,None,2015,2017,EPHA3,Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma,na,POTELLIGENT Technology. Humaneering Technology.,Ifabotuzumab is the new name for Fibatuzumab (PL115)
Ifinatamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDDVKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWGYYGSPLYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKPGQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFGQGTKVEIK,na,na,None,None,None,2022,na,B7H3/CD276,Daiichi Sankyo Company,na,Small cell lung cancer;Solid tumours,na,,ADC with deruxtecan
Iladatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2017,2019,AGM6/CD79B,Roche,na,na,Non-Hodgkin's lymphoma,,ADC with vedotin
Iluzanebart,Whole mAb,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDADARYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYFCARRRQGIFGDALDFWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCLQDNNFPPTFGQGTKVDIK,na,na,None,None,None,2023,na,TREM2,TBC,TBC,TBC,TBC,,
Imalumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK,na,na,6foe:HL:AB,None,None,2014,2015,MIF,Cytokine PharmaSciences;Baxalta;Shire;Takeda,na,na,Solid tumours;Lupus nephritis;Colorectal cancer;Malignant ascites,,
Imaprelimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK,na,na,None,None,None,2017,2018,MCAM/CD146/MUC18,Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation,na,na,Cancer;Inflammation;Psoriasis,,
Imgatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,na,na,None,None,None,2012,2013,EGFR/ERBB1/HER1,GLYCART Biotechnology;Roche,na,na,Colorectal cancer;Head and neck cancer;Non-small cell lung cancer,GlycoMAb Technology,
Imsidolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWVRQAPRQGLEWMGMFHPTGDVTRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARTTSMIIGGFAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHRNAITYFYWYLHKPGQPPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL36R,AnaptysBio,na,Generalised pustular psoriasis;Localised pustular psoriasis;Acneiform eruptions;Ichthyosis,Palmoplantas pustulosis;Acne vulgaris;Hidradenitis suppurative,,Genetics: musmus/homosap
Imvotamab,Pentameric IgM with Fused scFv (Bispecific),M,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHPSYGSGSPNFDYWGQGTLVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCVQATQFPLTFGGGTKVEIK,None;None,None;None,None;None,2022,na,CD3E;MS4A1/CD20,IGM Biosciences,na,Non-Hodgkin's lymphoma; Diffuse Large B cell lymphoma; Follicular lymphoma;Mantle cell lymphoma;Splenic marginal zone lymphoma;,na,,Geneticsof Fv1: musmus/homosap
Inclacumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None;None,None;None,None;None,2011,2012,SELP/CD62,Genmab;Roche;Global Blood Therapeutics,na,na,Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders,Medarex UltiMAb Mouse,
Indatuximab,Whole mAb ADC,G4,Kappa,Phase-II,Discontinued,QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS,DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK,na,na,None,None,None,2011,2012,SDC1/CD138,Biotest AG,na,na,Bladder cancer;Breast cancer;Multiple myeloma,,ADC with ravtansine
Indusatumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK,na,na,None,None,None,2014,2015,GUCY2C,Millennium;Takeda Oncology,na,na,Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer,,ADC with vedotin
Inebilizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD19,Cellective Therapeutics;MedImmune,Neuromyelitis optica,Autoimmune disorders;Myasthenia gravis;Renal transplant rejection,B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma,POTELLIGENT Technology,
Inezetamab,Bispecific Mixed mAb and scFv,G1;na,Lambda;Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRNAMSWVRQAPGKGLEWVSATGGSGISTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYSNSWWYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIFEVNQRPSGVSNRFSGSKSGTTASLTISGLQAADEADYFCSSYTTSSTYVIFGGGTKLTVL,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKCLEWISYISSSESIIYYVDAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDVGSHFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLISAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQAKSFPRTFGCGTKVEIK,None;None,None;None,None;None,2022,na,CD40;MSLN,Amgen,na,Solid tumours,na,,
Infliximab,Whole mAb,G1,Kappa,Approved,NFD,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,na,na,5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB,None,None,1997,1998,TNF/TNFA,Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,na,Berylliosis;Hepatitis C;Pyoderma,,Biosimilars available
Inotuzumab,Whole mAb ADC,G4,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2004,2005,SIGLEC2/CD22,Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group,Precursor cell lymphoblastic leukaemia-lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia,Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,,ADC with ozogamicin
Intetumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,None,None,None,2009,2010,ITGAVB3/CD61/VNR,Centocor Inc;Janssen Biotech;Janssen-Cilag,na,na,Malignant melanoma;Prostate cancer,VelocImmune Mouse,
Iparomlimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVRQAPGQGLEWMGEIDPYDSYTNYNQKFKGRVTMTVDKSTSTVYMELSSLRSEDTAVYYCARPGFTYGGMDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLFNSGNQKNYLAWYQQKPGKVPKLLIYGASTRDSGVPYRFSGSGSGTDFTLTISSLQPEDVATYYCQNDHYYPYTFGGGTKVEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Qilu Puget Sound Biotherapeutics,na,Neoplasms,na,,Chimeric: Mouse/Human
Ipilimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL,None,7su0:HL:IM/7su1:HL,2005,2006,CTLA4/CD152,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center,Malignant melanoma;Renal cell carcinoma,Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma,HIV infections;Lymphoma,Medarex UltiMAb Mouse,Biosimilars available
Iratumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS,DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK,na,na,None,None,None,2005,2006,TNFRSF8/CD30,Medarex,na,na,Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma,Medarex UltiMAb Mouse,
Isatuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS,DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK,na,na,4cmh:BC,None,None,2014,2015,ADPRC1/CD38,ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi,Multiple myeloma,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer,Non-small cell lung cancer;Prostrate cancer;T-cell lymphoma,,
Iscalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2017,2018,TNFRSF5/CD40,Novartis;XOMA,na,Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus,Rheumatoid arthritis,,
Isecarosmab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-I,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS,na,EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2019,2020,ADAMTSL5;ALB,Merck,na,Solid tumours,na,,Humanised: Llama/Human
Ispectamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNISAPGIHWVRQAPGKGLEWVGFINPAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDYIRQYWTYVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,na,TNFRSF17/CD269/BCMA/TNFRSF13A,Celgene Corporation,na,Multiple myeloma,na,,
Istiratumab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II,Discontinued,EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK,QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL,None;None,None;None,None;None,2017,2018,IGF1R/CD221;ERBB3/HER3,Adimab;Merrimack Pharmaceuticals,na,na,Ovarian cancer;Pancreatic cancer;Solid tumours,,
Itepekimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK,na,na,None,None,None,2019,2020,IL33,Regeneron Pharmaceuticals;Sanofi,na,Chronic obstructive pulmonary disease,Allergic asthma;Inflammation;Asthma;Atopic dermatitis,,
Itolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK,na,na,None,None,None,2010,2011,CD6,Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium,Plaque psoriasis,Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis,Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis,,ADC with debotansine or tazide
Ivicentamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYNMGWVRQAPGKGLEWVSVIDASGTTYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARELLYFGSSYYDLWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTITCQASQNIDSNLAWYQQKPGKAPKFLIYYASNLPFGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQSADVGSTYVAAFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFSLSYNAMNWVRQAPGKGLEWVSIIFASGRTDYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSTWGDALDPWGQGTLVTVSS,AYDMTQSPSTLSASVGDRVTITCQASQNIIDYLAWYQQKPGKAPKLLIHKASTLASGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQQGYSNSNIDNTFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD37;CD37,Genmab,na,B cell Lymphoma,na,DuoBody,
Ivonescimab,Bispecific (G1-kappa_scFv),G1,Kappa;Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,1bj1:HL:KJ/7v5n:BA:FE;None,None;None,6bft:AB:HL/1cz8:HL:YX;None,2021,2022,VEGFA;PDCD1/CD279/PD1,Akeso Biopharma,na,Non-small cell lung cancer;Solid tumours;Neoplasms;Gynecological Cancer,na,,Bevacizumab and Ivonescimab Fv1 have same sequences. Aug '23: Corrected to be a bispecific. Genetics of Fv2: musmus/homosap
Ivuxolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California,na,Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma,na,,
Ixekizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,na,na,6nov:AB:CD,6nou:AA,None,2011,2012,IL17A,Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis,na,,
Izalontamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II/III,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSS,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,QVQLQESGGGLVKPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVL,5etu:DC:BA/5ff6:DC:BA/5f88:DC:BA/5itf:DC:BA/5ivz:DC:BA/5ir1:DC:BA/5esq:DC:BA/5euk:DC:BA/5hpm:DC:BA/5id1:DC:BA/5icx:DC:BA/5hyq:DC:BA/5icz:DC:BA/5th2:DC:BA/5iop:DC:BA/5i2i:DC:BA/5t1l:DC:BA/5i76:DC:BA/5iv2:DC:BA/5t1k:DC:BA;None,6azk:DC:BA/6azl:BA:DC/6au5:DC:BA/6ayn:BA:DC/6axp:BA:DC/5id0:DC:BA/5t1m:DC:BA/5icy:DC:BA/1yy8:DC:BA/1yy9:DC/4gw5:DC:BA/4kro:DC/4gw1:DC:BA/4krp:DC;None,5gz0:BA:DC/6arp:BA:DC/6aru:CB;None,2022,na,EGFR/ERBB1/HER1;ERBB3/HER3,Systimmune,na,Colorectal cancers;Non-small cell lung cancers;Head and neck cancers;Esophageal squamous cell carcinoma,na,,Arm 1 is highly identical to cetuximab. Also used as ADC with brengitecan. Chimeric: Mouse/Human
Izastobart,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVGRIKSKAQGGTTDYAAHVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCARVSFSTFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSSSNIGSYYVSWYQQLPGTAPKVLIYRNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCDSWDHSSMNVFGGGTKLTVL,na,na,None,None,None,2023,na,C5AR1/CD88,TBC,TBC,TBC,TBC,,
Izeltabart,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWVGEIIPIFGHTNYNEKFKSRFTISLDNSKNTLYLQMGSLRAEDTAVYYCARGGYYYYPRQGFLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWYQQKPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQQSHEDPFTFGQGTKLEIK,na,na,None,None,None,2022,na,ADAM9,ImmunoGen,na,Solid tumours,na,,ADC with tapatansine
Izenivetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRSGYDYYFDVWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCRASENIYSFLAWYQQKPGQAPKLLIYNANTLAEGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQHHFGTPFTFGQGTKLEIK,na,na,None,None,None,2022,na,NGFB (Canine),Zoetis,na,Osteoarthritis,na,,
Izuralimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,None;None,2020,2021,ICOS/CD278;PDCD1/CD279/PD1,Xencor,na,Sarcoma;Malignant melanoma;Solid tumours,na,,Genetics of Fv2: musmus/homosap
Labetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK,na,na,None,None,None,2015,2016,CEACAM5/CD66e,Immunomedics,na,na,Colorectal cancer;Ovarian cancer;Breast cancer,,
Lacnotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS,DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK,na,na,None,None,None,2016,2017,CSF1,Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital,na,Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours,Bone metastases;Prostate cancer,,
Lacutamab,Whole mAb,G1,Kappa,Phase-II,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,KIR3DL2/CD158K,University of Genoa;Innate Pharma,na,Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome,na,,Genetics: musmus/homosap
Ladiratuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK,na,na,None,None,None,2017,2018,SLC39A6/ZIP6,Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics,na,Breast cancer,na,,ADC with vedotin
Lafuvitug,Whole mAb,G1,Kappa,TBC,Active,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,na,na,None,4lsv:HL/4jpv:HL/5v8l:HL:GK:IM:GN/5v8m:HL:RT:SU/7ly9:HL:AM:EI:BC/7mxd:CD:JK:SU/7n28:CD:JK:SU/7pc2:GH:IJ:KL,None,2023,na,HIV-1 gp120,TBC,TBC,TBC,TBC,,
Lampalizumab,Fab,G1,Kappa,Phase-III,Discontinued,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,na,na,4d9q:HL:ED/4d9r:HL:ED,None,None,2012,2013,CFD,Tanox;Genentech,na,na,Dry age-related macular degeneration,,Erroneously dropped during Feb '22 update. Readded August '22.
Lanadelumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK,na,na,4pub:HL/4ogy:HL:MN/4ogx:HL,None,None,2015,2016,KLKB1,Dyax;Shire;Takeda,Hereditary angioedema,na,Diabetic macular oedema,,
Lancastotug,Whole mAb,G1,Kappa,TBC,Active,DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQHVSTALAWYQQKPGKSPKLLIYSASSRYSGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIK,na,na,None,None,None,2023,na,TIGIT/WUCAM/VSTM3,TBC,TBC,TBC,TBC,,
Landogrozumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Eli Lilly,na,na,Cancer;Cachexia;Muscular atrophy;Pancreatic cancer,,
Laprituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK,na,na,None,None,None,2015,2016,EGFR/ERBB1/HER1,ImmunoGen,na,na,Solid tumours,,
Larcaviximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK,na,na,None,5ken:CD:GH:NO,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,
Latikafusp,Whole mAb Fusion,G1,Lambda,Phase-I,Active,EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNAGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,Amgen,na,Solid tumours,na,,
Latozinemab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGTIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQGSIKQGYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSTGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRAEAEDVGVYYCMQQQEAPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,SORT1,Alector,na,Frontotemporal dementia,na,,
Lebrikizumab,Whole mAb,G4,Kappa,Preregistration,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,na,na,4i77:HL,None,None,2009,2010,IL13,Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox,na,Atopic dermatitis,Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease;Idiopathic pulmonary fibrosis,,
Lecanemab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS,DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK,na,na,None,None,None,2019,2020,APP,Biogen;Eisai,Alzheimer's disease,Brain injuries;Down syndrome,na,,June '22: Corrected FWL3 sequence. Genetics: musmus/homosap
Lemalesomab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLQESGPELKKPGETVKISCKASGYTFRNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNVKNEDTATYFCARKGWMDFNGSSLDYWGQGTTVTVSS,DIQLTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2002,2002,NCA90/p95,ND,na,na,Diagnosis of Lesions,,
Lemzoparlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGLTFERAWMNWVRQAPGKGLEWVGRIKRKTDGETTDYAAPVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCAGSNRAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYAGNNRNYLAWYQQKPGQPPKLLINQASTRASGVPDRFSGSGSGTEFTLIISSLQAEDVAIYYCQQYYTPPLAFGGGTKLEIK,na,na,None,None,None,2020,2021,IAP/CD47,I-Mab Biopharma,na,Lymphoma;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes,na,,
Lenvervimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS,DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK,na,na,None,None,None,2017,2018,Hepatitis B Virus,Green Cross;GC Pharma;AbbVie,na,Hepatitis B,na,,
Lenzilumab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,CSF2,Humanigen;KaloBios Pharmaceuticals,na,COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease,Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours,Humaneering Technology,
Lepunafusp,Whole mAb Fusion,G1,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFMNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQLSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2021,2022,TfR1/CD71,JCR Pharmaceuticals,na,Mucopolysaccharidosis I,na,,
Lerdelimumab,Whole mAb,G4,Lambda,Phase-III,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCGRTLESSLWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSSTHRGVFGGGTKLTVL,na,na,None,None,None,2002,2002,TGFB1,Cambridge Antibody Technology,na,na,Cataracts;Proliferative vitreoretinopathy;Scars,,
Leronlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,CCR5/CD195,CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute,Breast cancer,HIV infections;HIV-1 infections;Graft-versus-host disease;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer;COVID-19;Autoimmune disorders;Stroke;Traumatic brain injuries,na,,
Lesabelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYYWGWIRQAPGKGLEWIGIIYPSGGGTNYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARGGGLGFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIPSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHYISWPRQFTFGQGTKVEIK,na,na,None,None,None,2022,na,PDL1/CD274,Dragon Sail Pharmaceutical,na,Cancers,na,,
Lesofavumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,Influenza B Virus,Genentech,na,na,Influenza B virus infections,,
Letaplimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,na,na,None,None,None,2020,2021,IAP/CD47,Innovent Biologics,na,Acute myeloid leukaemia;Lymphoma;Myelodysplastic syndromes;Solid tumours,na,,
Letolizumab,Single Domain Variable Fragment;H,G1,na,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS,na,na,na,None,None,None,2016,2017,CD40LG/CD154,Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute,na,Graft-versus-host disease;Idiopathic thrombocytopenic purpura,na,,
Levilimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS,DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,IL6R/CD126,Biocad,COVID-19;Cytokine release syndrome,Rheumatoid arthritis,na,,Genetics: camdrom/homosap
Lexatumumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,na,na,None,None,4od2:BA,2006,2007,TNFRSF10B/CD262/DR5/TRAILR2,Cambridge Antibody Technology;Human Genome Sciences,na,na,Solid tumours,,
Libivirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVRPGRSLRLSCAASGFAFSDYSINWVRQAPGKGLEWVAIISYDGRITYYRDSVKGRFTISRDDSKNTLYLQMNSLRTEDTAVYYCARQYYDFWSGSSVGRNYDGMDVWGLGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLHRSGNNYLDWYLQKPGHSPQLLIYVGSNRASGVPDRFSGSGSGTEYTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKLEIK,na,na,None,None,None,2004,2005,Hepatitis B Virus Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,,
Licaminlimab,scFv,na,Lambda,Phase-II,Active,EVQLVESGGGSVQPGGSLRLSCTASGFTISRSYWICWVRQAPGKGLEWVGCIYGDNDITPLYANWAKGRFTISRDTSKNTVYLQMNSLRAEDTATYYCARLGYADYAYDLWGQGTTVTVSS,EIVMTQSPSTLSASVGDRVIITCQSSQSVYGNIWMAWYQQKPGRAPKLLIYQASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGNFNTGDRYAFGQGTKLTVL,na,na,None,None,None,2020,2021,TNF/TNFA,Oculis,na,Dry eye syndrome,na,,Jan '22: Added missing FWH1 residue. (Jun '22) Corrected CDRH3 sequence
Lifastuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK,na,na,None,None,None,2013,2014,SLC34A2,Genentech,na,na,Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer,,ADC with vedotin
Ligelizumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK,na,na,6uqr:AA:CC,None,None,2012,2013,IGHE,Novartis;Tanox,na,Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid,Hypersensitivity,,
Ligufalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS,NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,IAP/CD47,Akeso Biopharma,na,Acute myeloid leukaemia;Neoplasms;Myelodysplastic syndromes,na,,Genetics: musmus/homosap
Lilotomab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS,DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK,na,na,None,None,None,2014,2015,CD37,Nordic Nanovector,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,
Linavonkibart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFSMDWVRQAPGKGLEWVSYISPSADTIYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGVLDYGDMLMPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADNHPPWTFGGGTKVEIK,na,na,None,None,None,2022,na,TGFB1,Scholar Rock,na,Solid tumours,na,,
Lintuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,1996,1997,SIGLEC3/CD33/p67,PDL BioPharma;Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,
Linvoseltamab,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2022,na,TNFRSF17/CD269/BCMA/TNFRSF13A,Regeneron Pharmaceuticals,na,Multiple Myeloma,na,,
Lipustobart,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWMGGVNPSNGGTNFNEKFKSRVTITADKSTSTAYMELSSLRSEDTAVYYCARRDYRYDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATISCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSRELPLTFGTGTKVEIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,Livzon Pharmaceutical Group,na,Solid tumours,na,,
Lirentelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIK,na,na,None,7quh:HL,None,2020,2021,SIGLEC8/SAF2,Allakos,na,Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease,Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis,,
Lirilumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,na,na,None,None,None,2012,2013,KIRD2,Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center,na,na,Acute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma;Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer,Medarex UltiMAb Mouse,
Litifilimab,Whole mAb,G1,Kappa,Phase-III,Active,DVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGKGLEWVATISPGDSFGYYYPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRDIYYNYGAWFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANEDPRTFGQGTKVEIK,na,na,None,None,None,2022,na,CLEC4C,Biogen Idec,na,Systemic lupus erythematosus;Cutaneous lupus erythematosus,na,,
Livmoniplimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQPGAEVRKPGASVKVSCKASGYRFTSYYIDWVRQAPGQGLEWMGRIDPEDAGTKYAQKFQGRVTMTADTSTSTVYVELSSLRSEDTAVYYCARYEWETVVVGDLMYEYEYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGQAPKILIYGASRLKTGVPSRFSGSGSGTSFTLTISSLEPEDAATYYCQQYASVPVTFGQGTKVEIK,na,na,None,None,None,2021,2022,LRRC32,AbbVie,na,Solid tumours,na,,
Lixudebart,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYGMNWVRQAPGKGLEWVSSISPSGSYFYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLPGFNPPFDHWGQGTLVTVSS,DIQMTQSPATLSVSPGERATLSCKASQNVGGNVDWYQWKPGQAPRLLIYGASNRYTGIPARFRGSGSGTEFTLTISSLQSEDFAVYYCLQYKNNPWTFGQGTKVEIK,na,na,None,None,None,2023,na,CLDN1,TBC,TBC,TBC,TBC,,
Lodapolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Dana-Farber Cancer Institute;Eli Lilly,na,na,Solid tumours,,
Lodelcizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS,QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Novartis,na,na,Hypercholesterolaemia,,
Lokivetmab,Canine Whole mAb,G2,Kappa,Approved,NFD,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL31,Zoetis,Canine atopic dermatitis,na,na,,
Lomtegovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAATGFTFRRYGMHWVRQAPGKGLEWVAGILFDGSNKYYVDSVKGRFTISRDSSRNTLYLQLNSLRREDTAVYYCAKGGDYEWELLESWGQGTLVTVSS,DIQMTQSPSTVSASVGDRVTITCRASQSIDNWLAWYQEKPGKAPKVLIYKASSLESGVPSRFSGRGSGTEFTLTISSLQPGDFATYYCQHYHSFPLTFGGGTKVDIK,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,Boehringer Ingelheim,na,COVID-19,na,,June '22: Corrected VH sequence
Lomvastomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKTTYMHWVRQAPGKGLEWVGRIDPADDNTKYAPKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCVRDFGYVAWFAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASQSVDNYVAWYLQKPGQSPQLLIYYASNRYIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQHYSSPYTFGQGTKVEIK,None;None,None;None,None;None,2022,na,PDCD1/CD279/PD1;HAVCR2/TIM3,Roche,na,Non-small cell lung cancers;Small cell lung cancers;Squamous cell carcinoma,na,,Fv1 identical in sequence to Tobemstomig and Eciskafusp.
Loncastuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,6ani:HL:IM,None,2017,2018,CD19,ADC Therapeutics,Diffuse large B cell lymphoma,Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma,,ADC with tesirine
Lonigutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPSRFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,IGF1R/CD221,Pierre Fabre,na,Solid tumours,na,,
Lorigerlimab,Bispecific Mixed scFv (scFv-CH2-CH3-scFv),G4;G4,Kappa;Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGSNKHYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7elx:HL:hl,2021,2022,PDCD1/CD279/PD1;CTLA4/CD152,MacroGenics,na,Solid tumours,na,Dual-Affinity Re-Targeting Technology. Chimeric: Mouse/Human,June '22: Corrected VL sequences
Lorukafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL,2018,2019,Ganglioside GD2,Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison,na,Malignant melanoma;Neuroblastoma,na,,
Lorvotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK,na,na,None,None,None,2010,2011,NCAM1/CD56,ImmunoGen,na,na,Multiple myeloma;Solid tumours;Small cell lung cancer;Haematological malignancies,,ADC with mertansine
Losatuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,AbbVie,na,Solid tumours,na,,Losatuxizumab and Serclutamab have identical variable domains. ADC with vedotin
Lucatumumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2007,2008,TNFRSF5/CD40,Novartis;XOMA,na,na,Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma,,
Lulizumab,Single Domain Variable Fragment;L,na,Kappa,Phase-II,Active,na,DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK,na,na,None,None,None,2014,2015,CD28,Bristol-Myers Squibb,na,Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection,na,,
Lumiliximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,na,na,None,3fzu:HL:CD,None,2004,2004,FCER2/CD23,Biogen Idec,na,na,Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia,,Lumiliximab and Gomiliximab are the same mAb
Lumrotatug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGIHWLRQPPGKGLEWIGVIWRGGSTDYNPSLKSRVTISKDTSKSQVSLKLSSVTAADTAVYYCAKGKVTTGFYFDFWGQGTLVTVSS,EIVMTQSPPTLSLSPGERVTLSCRASEDIYNRLVWYQQKPGQAPRLLISGVTSLETSIPARFSGSGSGTDYTLTISSLQPEDFAVYYCQQYWSTPYTFGQGTKVEIK,na,na,None,None,None,2023,na,ADPRC1/CD38,TBC,TBC,TBC,TBC,,
Lumretuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK,na,na,4leo:AB,None,None,2014,2015,ERBB3/HER3,Roche,na,na,Breast cancer;Solid tumours;Non-small cell lung cancer,GlycoMAb Technology,
Lunaxafusp,Fusion Protein,na,Kappa,TBC,Active,QVQLQQSGPELKKPGETVKISCKASGYPFTNYGMNWVKQAPGQGLKWMGWINTSTGESTFADDFKGRFDFSLETSANTAYLQINNLKSEDSATYFCARWEVYHGYVPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVYNAVAWYQQKPGQSPKLLIYSASSRYTGVPSRFTGSGSGPDFTFTISSVQAEDLAVYFCQQHFRTPFTFGSGTKLEIK,na,na,None,None,None,2022,na,ERBB2/CD340/HER2,TBC,TBC,TBC,TBC,,Murine scFv against a human antigen
Lunsekimig1,Trispecific and Pentavalent (sc-5-VH),na;na,na;na,TBC,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREFVAALSGDGYSTYTANSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAKLQYVSGWSYDYPYWGQGTLVTVSS,na,EVQLVESGGGVVQPGGSLRLSCAASGFTFNNYAMKWVRQAPGKGLEWVSSITTGGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCANVPFGYYSEHFSGLSFDYRGQGTLVTVSS,na,None;None,None;None,None;None,2023,na,IL13;IL13,TBC,TBC,TBC,TBC,,"Pentavalent, targets two different epitopes on IL13 and TSLP. Fv1 Chimeric: Alpaca/human."
Lunsekimig2,Trispecific and Pentavalent (sc-5-VH),na;na,na;na,TBC,Active,EVQLVESGGGVVQPGGSLRLSCAASGSGFGVNILYWYRQAAGIERELIASITSGGITNYVDSVKGRFTISRDNSENTMYLQMNSLRAEDTGLYYCASRNIFDGTTEWGQGTLVTVSS,na,EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2023,na,TSLP;ALB,TBC,TBC,TBC,TBC,,"Pentavalent, targets two different epitopes on IL13 and TSLP. Fv3 Chimeric: Llama/Human"
Lunsekimig3,Trispecific and Pentavalent (sc-5-VH),na,na,TBC,Active,EVQLVESGGGVVQPGGSLRLSCAASGFTFADYDYDIGWFRQAPGKEREGVSCISNRDGSTYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAVEIHCDDYGVENFDFDPWGQGTLVTVSS,na,na,na,None,None,None,2023,na,TSLP,TBC,TBC,TBC,TBC,,"Pentavalent, targets two different epitopes on IL13 and TSLP. Fv5 Chimeric: Llama/Human"
Lupartumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS,ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL,na,na,None,None,None,2016,2017,LYPD3,Bayer HealthCare,na,na,Solid tumours,,ADC with amadotin
Lusvertikimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPGKGLEWVSTISASGLRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPLSAHYGFNYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSEDIYQGLAWYQQKPGKAPKLLLYSANTLHIGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYDYPLAFGGGTKVEIK,na,na,None,None,None,2020,2021,IL7R/CD127,OSE Immunotherapeutics,na,Autoimmune diseases,na,,
Lutikizumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,None;None,None;None,None;None,2016,2017,IL1A;IL1B,Abbott Laboratories;AbbVie,na,na,Osteoarthritis,Dual Variable Domain Immunoglobulin Technology,
Luvagrobart,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGFDLSGYDLNWIRQPPGKGLEWIGIVWGDGSSDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCVRGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESISSNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPFTFGQGTKLEIK,na,na,None,None,4edw:HL,2023,na,NGF,TBC,TBC,TBC,TBC,,
Luveltamab,Whole mAb ADC,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIRTQSIHWVRQAPGKGLEWIGDIFPIDGITDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSWSWPSGMDYYLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,na,FOLR1,Sutro Biopharma,na,Ovarian cancers;Fallopian tube cancers;Primary peritoneal cancers;Endometrial cancer;Acute myeloid leukemia;Non-small cell lung cancer,na,,ADC with tazevibulin
Maftivimab,Whole mAb,G1,Kappa,Preregistration,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK,na,na,None,None,None,2018,2019,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,na,na,Ebola virus infections,,
Magrolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK,na,na,None,5iwl:AA:BB,None,2018,2019,IAP/CD47,Forty Seven;Merck KGaA;Stanford University,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer,Lymphoma,,Genetics: musmus/homosap
Manelimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Biocad,na,Solid tumours;Cancer,na,,
Manfidokimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVVKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWIGGINPNNGGTVYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARVRRGMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVTTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSVQPEDLATYYCQQHYSAPWTFGGGTNLEIK,na,na,None,None,None,2021,2022,IL4R/CD124,Akeso Biopharma,na,Atopic dermatitis,na,,
Margetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,ERBB2/CD340/HER2,Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme,Breast cancer,Gastric cancer;Oesophageal cancer,Bladder cancer;Non-small cell lung cancer;Ovarian cancer;Haematological malignancies;Solid tumours,,
Maridebart,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,6dkj:HL:BA,None,None,2023,na,GIPR,TBC,TBC,TBC,TBC,,ADC with cafraglutide
Marstacimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL,na,na,None,None,None,2013,2014,ERBB2/CD340/HER2,Pfizer,na,Haemophilia,na,,
Masavibart,Whole mAb,G1,Lambda,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,na,na,6xdg:CA,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,,Imdevimab is former name for Masavibart
Matuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,na,na,3c08:HL/5vr9:HL:AB,5vsi:HL/3c09:HL:CB,None,2003,2003,EGFR/ERBB1/HER1,ImClone Systems;Merck KGaA;Takeda,na,na,Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer,,
Mavrilimumab,Whole mAb,G4,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,na,na,None,None,None,2009,2010,CSF2RA/CD116,Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune,na,Giant cell arteritis;COVID-19;Inflammation,Rheumatoid arthritis,CAT Phage Display,
Mazorelvimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLILSCAASGFTFSGFAMSWVRQAPGKGLEWVATISSGGTYTYSPDSVMGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRLRRNYYSMDYWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCKSTKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQSNYLPFTFGGGTKVEIK,na,na,None,None,None,2021,2022,Rabies Virus Spike Glycoprotein G,Synermore,na,Rabies post-exposure,na,,Genetics: musmus/homosap
Mecbotamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYSFWGATMNWIRQPPGKGLEWIGLIKPSNGGTSYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGHYESYEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVVSAVAWYQQKPGQAPRLLIYWQDTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEHFSPPLTFGQGTKVEIK,na,na,None,None,None,2022,na,AXL/UFO,BioAtla,na,Non-small cell lung cancer;Ovarian cancer;Soft tissue sarcoma;Solid tumours,na,,ADC with vedotin
Melredableukin,Whole mAb Fusion,G1,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK,na,na,None,6ghg:HL:AB,5i1c:HL,2021,2022,Non-Binding,Roche,na,Ulcerative colitis,na,,Fused to IL2. (June '22: Corrected FWL3 sequence)
Melrilimab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK,na,na,None,None,None,2020,2021,IL1RL1/ST2,GlaxoSmithKline,na,na,Asthma;Atopic dermatitis,,
Metelimumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK,na,na,6amj:HL:BA/6amm:HL,6anp:HL:BA,None,2003,2003,TGFB1,Cambridge Antibody Technology,na,na,Cancer;Fibrosis;Scleroderma,,
Mepolizumab,Whole mAb,G1,Kappa,Approved,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,1999,2000,IL5,GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases,Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome,Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis,Atopic dermatitis,,Biosimilars available
Mevonlerbart,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGRGYNADYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLEYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLRPEDFATYYCQQYNSYPLTFGGGTKVEIK,na,na,5vyf:HL:BA,None,None,2022,na,Fel d 1,Regeneron,na,Cat allergies,na,,Antigen: Felis silvestris catus (domestic cat) allergen 1
Mezagitamab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL,na,na,None,None,None,2019,2020,ADPRC1/CD38,Takeda,na,Multiple myeloma;Systemic lupus erythematosus;Idiopathic thrombocytopenic purpura;Myasthenia gravis,Rheumatoid arthritis,,
Mibavademab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVESGGSVVQPGRSLRLSCAASGFTFSTYAMYWVRQTPGKGLEWVAVLYSDGSNKYYIDSVKGRFTISRDTSTNTLYLQMSSLRADDSALYYCARLNWDYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,na,na,None,None,None,2020,2021,LEPR/CD295/OBR,Regeneron Pharmaceuticals,na,Lipodystrophy,na,,
Milatuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK,na,na,None,None,None,2007,2008,CD74/HLA class II histocompatibility antigen gamma chain,Immunomedics,na,na,Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus,,
Mipasetamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,AXL/UFO,ADC Therapeutics,na,Solid tumours;Advanced or metastatic solid tumours,na,,ADC with uzoptirine
Miptenalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Boehringer Ingelheim,na,Solid tumours;Head and neck cancer;Non-small cell lung cancer,na,,Genetics: musmus/homosap
Mirikizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL23A,Eli Lilly,na,Plaque psoriasis;Ulcerative colitis;Crohn's disease,na,,
Miromavimab,Whole mAb (Mouse),G1,Kappa,Approved,NFD,QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-II,Candila Healthcare,Rabies,na,na,,
Mirvetuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS,DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK,na,na,None,None,None,2015,2016,FOLR1,ImmunoGen;National Comprehensive Cancer Network,Ovarian cancer;Fallopian tube cancer;Peritoneal cancer,Breast cancer;Endometrial cancer,Solid tumours,,
Mirzotamab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,B7H3/CD276,AbbVie,na,na,Haematological malignancies;Solid tumours,,Chimeric: Mouse/Human. ADC with clezutoclax
Mitazalimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL,na,na,None,None,None,2017,2019,TNFRSF5/CD40,Alligator Bioscience;Janssen Biotech,na,Solid tumours,na,,Mitazalimab is the new name for Vanalimab (PL119)
Modakafusp,Whole mAb Fusion,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,ADPRC1/CD38,Takeda,na,Multiple myeloma,na,,
Modotuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK,na,na,None,None,None,2012,2014,EGFR/ERBB1/HER1,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,,Modotuximab is the new name for Zatuximab (PL110)
Mogamulizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CCR4/CD194,Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical,Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides,Spinal cord disorders,Non-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours,POTELLIGENT Technology,
Monalizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK,na,na,None,None,None,2015,2016,KLRC1,Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk,na,Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies,Inflammation;Rheumatoid arthritis,,
Mosunetuzumab,Bispecific mAb,G1,Kappa;Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,None;None,None;None,None;4k7p:YX,2017,2018,CD3E;MS4A1/CD20,Genentech,na,Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma,na,,
Motavizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,na,na,3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC/6ywd:AB,5k8a:BA:FE:VM:HL/4jlr:AB:HL,None,2006,2007,Respiratory Syncytial Virus Glycoprotein F,MedImmune,na,na,Respiratory syncytial virus infections,Affinity Matured from Palivizumab,Biosimilars available
Moxetumomab,Fv Fusion,na,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI,na,na,None,None,None,2009,2010,SIGLEC2/CD22,National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA),Hairy cell leukaemia,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,CAT Phage Display,ADC with pasudotox
Murlentamab,Whole mAb,G1,Kappa,Phase-II,Active,QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,AMHR2,LFB Biotechnologies;GamaMabs Pharma,na,Colorectal cancer;Gynaecological cancer,na,,
Mupadolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVEKPGASVKVSCKASGYTFTSYWITWVRQAPGQGLEWMGDIYPGSGNTNYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCAKEGGLTTEDYALDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASKNVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQHSRELPFTFGQGTKVEIK,na,na,None,None,None,2021,2022,NT5E/CD73,Corvus Pharmaceuticals,na,COVID-19 infections;Oropharyngeal cancer;Cancer,na,,
Muromonab,Whole mAb,G2a,Kappa,Approved,Discontinued,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,na,na,1sy6:HL,None,None,1988,1989,CD3E,Cancer Research UK;Ortho-McNeil;XOMA,na,na,Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis,,LC IMGT 127 is N not K as in Jain paper.
Muzastotug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIK,na,na,None,None,None,2023,na,CTLA4/CD152,TBC,TBC,TBC,TBC,,
Nadecnemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVISGSGGSTYYADAVKGRFTISRDNSKHTLYLQMNSLRAEDTAVYYCTKPSSYSSSNFYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPFPFGPGTKVDIK,na,na,None,None,None,2020,2021,GFRA3,Regeneron Pharmaceuticals,na,Osteoarthritis;Pain chronic,na,,
Nadunolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL1RAP,Lund University;Cantargia,na,Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Triple negative breast cancer,na,,Nadunolimab is the new name for Nidanilimab (PL122)
Namilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK,na,na,None,None,None,2010,2011,CSF2,Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH,na,Ankylosing spondylitis;COVID-19,Plaque psoriasis;Rheumatoid arthritis,Human Phage Display,
Naptumomab,Fab Fusion,G1,Kappa,Phase-III,Discontinued,EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS,SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK,na,na,None,None,None,2006,2007,TPBG/WAIF1,Active Biotech,na,na,Non-small cell lung cancer;Pancreatic cancer;Renal cancer,,
Naratuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS,DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK,na,na,None,None,None,2015,2016,CD37,ImmunoGen;Chronic lymphocytic leukaemia,na,Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,Chronic lymphocytic leukaemia,,ADC with emtansine
Narlumosbart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2022,na,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology,na,Hypercalcemia of malignancy;Glucocorticoid-induced osteoporosis;Bone metastases from solid tumours,na,,"6ghg is technically within 95% ID, but CDRH3 length 7 vs length 15. Same Fv sequence as Denosumab."
Narnatumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,MST1R/CD136,ImClone Systems;Eli Lilly;ImClone Systems,na,na,Solid tumours,,
Narsoplimab,Whole mAb,G4,Lambda,Preregistration,Active,QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS,QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,na,na,None,None,None,2019,2020,MASP2,Omeros,na,Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis,Stroke;Wet age-related macular degeneration,,
Natalizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,na,na,None,4irz:HL/6fg1:HL/6fg2:HL:IM,None,1998,1999,ITGA4/CD49D,Biogen;Biogen Idec;Elan Corporation;Perrigo,Crohn's disease;Multiple sclerosis,Epilepsy;Graft-versus-host disease;Stroke,Multiple myeloma;Rheumatoid arthritis,,Biosimilars available
Navivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS,EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK,na,na,4r8w:HL/4ubd:CD:KL:YX:ST:OP:GH,6fg1:HL/6fg2:HL,None,2015,2016,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,,
Navicixizumab,Bispecific mAb,G2;G2,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,DLL4;VEGFA,OncoMed Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,Colorectal cancer;Solid tumours,,
Naxitamab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,na,na,None,None,None,2018,2019,Ganglioside GD2,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,Neuroblastoma,Osteosarcoma,Breast cancer;Sarcoma;Small cell lung cancer,,Genetics: musmus/homosap
Nebratamig1,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1),na;G1,Kappa;Kappa,TBC,Active,SRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS,DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK,SQSVEESGGGLVQPGGSLRLSCTASGIDLNTYDMIWVRQAPGKGLEWVGIITYSGSRYYANWAKGRFTISKDNTKNTVYLQMNSLRAEDTAVYYCARDYMSGSHLWGQGTLVTVSS,AYDMTQSPSSVSASVGDRVTIKCQASEDIYSFLAWYQQKPGKAPKLLIHSASSLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYGKNNVDNAFGGGTKVEIK,None;None,None;None,None;None,2023,na,TNFRSF9/CD137/4-1BB;PDL1/CD274,TBC,TBC,TBC,TBC,,scFv-IgG1 portion. Joint entry with Nebratamig2 (tetraspecific)
Nebratamig2,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2),na;na,Kappa;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTISRYHMTWVRQAPGKGLEWIGHIYVNNDDTDYASSAKGRFTISRDNSKNTLYLQMNSLRAEDTATYFCARLDVGGGGAYIGDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQSSQSVYNNNDLAWYQQKPGKVPKLLIYYASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCAGGYDTDGLDTFAFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,None;None,None;None,None;None,2023,na,ROR1;CD3D and CD3E,TBC,TBC,TBC,TBC,,scFv-scFv portion. Joint entry with Nebratamig2 (tetraspecific)
Necitumumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,na,na,6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL,None,None,2008,2009,EGFR/ERBB1/HER1,ImClone Systems;Eli Lilly,Non-small cell lung cancer,Solid tumours,Colorectal cancer,,
Negalstobart,Whole mAb,G4,Kappa,TBC,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIYSESYYWGWIRQPPGKGLEWIGSIVYSGYTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVRTWDAAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQVLELPPWTFGGGTKVEIK,na,na,None,None,None,2023,na,LAG3/CD223,TBC,TBC,TBC,TBC,,
Nelmastobart,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTHYNMDWVRQAPGQGLEWIGYIYPSNGGTGYNQKFKSRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGAYHYGSSYAYWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAVKLLISYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQSSKLPFTFGQGTELEIK,na,na,None,None,None,2023,na,BTN1A1,STCube,na,Solid tumours,na,,
Nelistotug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFVEYAISWVRQAPGQGLEWMGGIIPAFGTAQYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGAGYYGDKDPMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVLHTITFGGGTKVEIK,na,na,None,None,None,2023,na,TACTILE/CD96,TBC,TBC,TBC,TBC,,
Nemolizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,IL31RA,Chugai Pharmaceutical;Galderma;Maruho,Atopic dermatitis,Prurigo nodularis;Pruritus;Scleroderma,na,,
Nepuvibart,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,na,na,6xdg:BD,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,,Casirivimab is the former name for Nepuvibart
Nesvacumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK,na,na,None,None,None,2012,2013,ANGPT2,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,,
Netakimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK,na,na,None,None,None,2017,2018,IL17A,CJSC Biocad,Plaque psoriasis,Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis,na,,Chimeric: Llama/Human
Nezastomig,Bispecific mAb,G4;G4,Kappa;Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFMSYDGSNKFYSDSVKGRFTISRDNSRKMLFLQMNNLRAEDTAVYYCARDQYYDFLTDHGVFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGITHYNPSLKSRVTISVDTSKIQFSLKLSSVTAADTAVYYCARWGVRRDYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2023,na,FOLH1/GCPII/PSMA;CD28,TBC,TBC,TBC,TBC,,
Nezutatug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYSITSGYSWHWIRQHPGKGLEWIGSIRYSGGTDYNPSLKSLVTISADTSKNQFSLKLSSVTAADTAVYYCARMTTAPWYPFDYWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQIVGSNVAWYQQKPGKAPEPLIYSASYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSHPLTFGQGTKLEIK,na,na,None,None,None,2023,na,ERBB3/HER3,TBC,TBC,TBC,TBC,,
Nimacimab,Whole mAb,G4,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK,na,na,None,None,None,2018,2019,CNR1/CB1,Bird Rock Bio,na,Diabetic nephropathies;Diabetic gastroparesis;Obesity,Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease,,
Nimotuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,na,na,None,3gkw:HL,None,2005,2006,EGFR/ERBB1/HER1,Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience,Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer,Cervical cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer,Gastric cancer;Polycystic kidney disease;Prostrate cancer;Brain metastases;Squamous cell cancer,,Feb '22: Conflict between our sequence and IMGT-mAb/DB. We take the seminal paper as source of the sequence: https://cancerres.aacrjournals.org/content/69/14/5851.
Nipocalimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL,na,na,None,None,5whk:HL/5whj:HL,2019,2020,FCGRT/FcRn,Momenta,na,Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis,na,,
Nirsevimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK,na,na,5udc:HL:BC:EG/5udd:JP:KQ:LR:MS:OU:NT,None,4jha:HL/4jhw:HL/6s3d:AB:CD:EF:HL,2018,2019,Respiratory Syncytial Virus,AIMM Therapeutics;MedImmune,Respiratory syncytial virus infections,na,na,,
Nisevokitug,Whole mAb,G2,Lambda,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLWEVRALPSVYWGQGTLVTVSS,SYELTQPPSVSVAPGQTARITCGANDIGSKSVHWYQQKAGQAPVLVVSEDIIRPSGIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDRDSDQYVFGTGTKVTVL,na,na,None,None,None,2022,na,TGFB1/TGFB2,Novartis,na,Pancreatic cancers;Colorectal cancers;Myelodysplastic syndromes;Pancreatic ductal adenocarcinoma;Metastatic cancers,na,,
Nivatrotamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKCLEWIGYINPSRGYTNYNQKFKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYSLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGCGTKLQIT,None;None,None;None,None;None,2020,2021,GD2;CD3E,Memorial Sloan-Kettering Cancer Center,na,Neuroblastoma,na,,Genetics of Fv1: musmus/homosap
Nivolumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,na,na,5ggq:HL/5wt9:HL/5ggr:HL:AB,None,None,2012,2013,PDCD1/CD279/PD1,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics,Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer,Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Glioma,Chronic myeloid leukaemia;Hepatitis C;Sepsis,Medarex UltiMAb Mouse,Biosimilars available
Nofazinlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTTYYISWVRQAPGQGLEYLGYINMGSGGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAIIGYFDYWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLDSDGGTYLYWFQQRPGQSPRRLIYLVSTLGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQLTHWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Cstone Pharmaceuticals,na,Solid tumours;Hepatocellular carcinoma,na,,
Nolavetbart,Whole mAb (Canine),G2,Kappa,TBC,Active,EVTLQESGPGLVKPSQTLSLTCVASGFSIKSSFIHWLRQRPGRGLEWIGRIDPAFGATEYNPAFQGRFSITADTAKNQASLQLSSMTTEDSAVYYCARYHYAASHFDAWGQGTLVTVSS,RIVMTQSPGSLAGSVGESVSINCKSSQSVTNDLTWYQQKPGEAPKVLITYASQRYTGVPARFSGSGYGTDFTLTINNLQAEDVGDYFCQQDYASPFTFGQGTKLEIK,na,na,None,None,None,2023,na,IL31RA (Canine),TBC,TBC,TBC,TBC,,
Nurulimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,5xj3:AB:DE:GH:JK/5tru:HL:hl/6jc2:HL/6rp8:HL:hl/7elx:HL:hl,None,2019,2020,CTLA4/CD152,Biocad,na,na,Malignant melanoma,,Likely to be an Ipilimumab Biosimilar
Oberotatug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTYSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVQGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTIFGVVSFDYWGQGTLVTVSS,DVQMTQSPSSLSASVGDRVTITCRASQSISDYLSWYQQRPGKAPNLLIYAASNLKTGVPSRFSGSGSGTDFTLTISTLQPEDFATYYCQQSYRSPWTFGQGTKVEIK,na,na,None,None,None,2023,na,LY75/CD205/DEC205,TBC,TBC,TBC,TBC,,ADC with ravtansine
Obertamig,Bispecific Mixed mAb and scFv,G1;na,Lambda;Kappa,TBC,Active,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQISLQLNSVTPEDTAVYYCAGDRRYGIVGLPFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLHSSNNKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2023,na,CD3E;HLA-G,TBC,TBC,TBC,TBC,,
Obexelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,Xencor,na,Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus,na,XmAb Antibody Engineering Technology,Genetics: musmus/homosap
Obiltoxaximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR,na,na,None,None,None,2015,2016,Anthrax Protective Antigen,Elusys Therapeutics,Anthrax,na,na,,
Obinutuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,na,na,3pp3:HL:IK/3pp4:HL,6y9a:HL,6y97:HL,2008,2011,MS4A1/CD20,GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds,Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia,Primary biliary cirrhosis,GlycoMAb Technology,Obinutuzumab is the new name for Afutuzumab (PL101)
Obrindatamab,Bispecific scFv with Domain Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,B7H3/CD276;CD3E,MacroGenics,na,na,Advanced or Metastatic solid tumours,,Genetics of both Fvs: musmus/homosap
Ocaratuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,MS4A1/CD20,Applied Molecular Evolution;MENTRIK Biotech,na,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis,,
Ociperlimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,TIGIT/WUCAM/VSTM3,BeiGene,na,Non-small cell lung cancer; Cervical cancer; Small-cell lung cancer; Squamous cell cancer; Solid tumours,na,,June '22: Corrected CDRH1 sequence
Ocrelizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,na,na,None,None,4k7p:YX,2005,2006,MS4A1/CD20,Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche,Multiple sclerosis,na,Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus,,Biosimilars available
Odesivimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,Ebola virus infections ,na,na,,
Odronextamab,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,None;None,None;None,None;None,2019,2020,MS4A1/CD20;CD3E,Regeneron Pharmaceuticals,na,Follicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,,
Ofatumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,na,na,3giz:HL/6y92:HL:CD,None,None,2005,2006,MS4A1/CD20,Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network,Chronic lymphocytic leukaemia,B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia,Medarex HuMAb Mouse,Biosimilars available
Ogalvibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,na,na,7k8r:HL/7k8z:HL:MN,None,None,2022,na,SARS-CoV-2 Spike RBD,National Institute of Allergy and Infectious Diseases;Rockefeller University;Xencor,na,COVID-19,na,,
Olaratumab,Whole mAb,G1,Kappa,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,na,na,None,None,None,2010,2011,PDGFRA/CD140A,ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research,Soft tissue sarcoma,Pancreatic cancer;Solid tumours,Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer,Medarex UltiMAb Mouse,
Oleclumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL,na,na,None,None,None,2016,2017,NT5E/CD73,MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute,na,Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours,Prostate cancer,,
Olendalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK,na,na,None,None,None,2015,2017,C5,Alexion Pharmaceuticals,na,na,Antiphospholipid syndrome;Graft-versus-host disease;Inflammation,,Olendalizumab is the new name for Lendalizumab (PL116)
Olinvacimab,Whole mAb,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS,NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL,na,na,None,None,None,2018,2019,KDR/CD309/VEGFR2,PharmAbcine;3SBio,na,Glioblastoma;Breast cancer,Cancer;Choroidal neovascularisation;Solid tumours,,Olinvacimab is the new name for Tanibirumab
Oloctinebart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYMHWVRQAPGQRLEWMGWIYPGSGNTNYNEKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCSTAPGGFDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSKSLLHSDGITYLYWYLQKPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQMLEFPLTFGQGTKLEIK,na,na,None,None,None,2023,na,LGALS3/GAL3,TBC,TBC,TBC,TBC,,
Olokizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,na,na,4cni:HL:AB,None,None,2010,2011,IL6,R-Pharm;UCB,Rheumatoid arthritis;SARS-CoV-2 acute respiratory disease,Inflammation,na,,
Omalizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,na,na,4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL/7shy:EF:IJ:KL:CD,5g64:IM:HL/6tcq:HL/6tcr:HL/6tcs:AA/,7shu:CD:EF/7shz:CD:EF:IJ:KL/7si0:CD:IJ:EF:KL,2000,2001,IGHE,Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis,Allergic asthma;Urticaria,Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis,Hypersensitivity;Peanut hypersensitivity,,Biosimilars available
Omburtamab,Whole mAb Radiolabelled,G1,Kappa,Preregistration,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK,na,na,5cma:BA,None,None,2018,2019,B7H3/CD276,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,na,Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer,Solid tumours,,
Omoprubart,Whole mAb,G2/G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFTDFYMQWVRQAPGQGLEWMGEILPGTGHTEYAQKFQGRVTMTRDTSISTVYMEVRRLRSDDTAVYYCARYFFGSTPNWYFDVWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCGATENIYGALNWYQHEPGKAPKLLIYGASNRYTGVTSRFSGSGSGTDFTLTISTLQPEDFATYYCQQVLNTPVSFGGGTKVDIK,na,na,None,None,None,2023,na,C5,TBC,TBC,TBC,TBC,,
Omodenbamab,Whole mAb,G3,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK,na,na,None,None,None,2020,2021,Staphylococcus aureus Protein A,XBiotech Inc.,na,Staphylococcal infections,na,,
Onartuzumab,Fab + di-Fc,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,na,na,4k3j:HL,None,None,2010,2011,MET/HGFR,Chugai Pharmaceutical;Genentech,na,na,Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours,,
Onfekafusp,Whole mAb Fusion,na,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,Malignant melanoma;Basal cell cancer;Squamous cell cancer;Solid tumours,na,,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Ongericimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Shanghai Junshi Biosciences,na,Hypercholesterolemia,na,,
Ontamalimab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK,na,na,4hcr:MN:HL,None,None,2018,2019,MADCAM1,Pfizer;Takeda,na,na,Crohn's disease;Ulcerative colitis,,
Ontuxizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK,na,na,None,None,None,2013,2014,CD248/CD164L1,Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA),na,Colorectal cancer;Malignant melanoma;Soft tissue sarcoma,Lymphoma;Solid tumours,,
Onvatilimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK,na,na,None,None,None,2017,2018,VSIR/VISTA,Janssen Research & Development,na,na,Solid tumours,,
Opelkibart,Whole mAb ADC,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMAIINPRDSDTRYRPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARHGRGYEGYEGAFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQGIRSDLGWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANGFPLTFGGGTKVEIK,na,na,None,None,None,2023,na,KIT/CD117,TBC,TBC,TBC,TBC,,
Opicinumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS,DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK,na,na,4oqt:HL,None,None,2015,2016,LINGO1,Biogen Idec;Dyax;Biogen,na,na,Multiple sclerosis;Optic neuritis,Dyax Human Phage Display,
Oportuzumab,scFv,na,Kappa,Preregistration,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM/CD326,University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies,na,na,Bladder cancer;Head and neck cancer;Liver cancer;Ovarian cancer,,ADC with monatox
Opucolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS,QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Shanghai Henlius Biotech,na,na,Solid tumours,,
Ordesekimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKVSGYFFTTYWIGWVRQMPGKGLEYMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGNWNCFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYGSSHTFGQGTKLEIS,na,na,None,None,None,2020,2021,IL15,Genmab;Immunex Corporation;Amgen;Cellimmune,na,Psoriasis;Inflammatory arthritis diseases;Celiac disease,na,,
Orilanolimab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK,na,na,6nha:HL,None,None,2018,2019,FCGRT/FcRn,Syntimmune,na,na,Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus,,Genetics: musmus/homosap
Ormutivimab,Whole mAb,G1,Lambda,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,None,None,2021,2022,Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1,North China Pharmaceutical Company,Rabies,na,na,,
Orticumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL,na,na,None,None,None,2012,2013,OxLDL,Abcentra;BioInvent International;Genentech,na,Psoriasis,Atherosclerosis;Aortic valve stenosis,Human Phage Display,
Osemitamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGQGLEWMGNIDPYYGGTSYNQKFKGRVTMTIDKSTSTVYMELSSLRSEDTAVYYCARMYHGNAFDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNLKNYLTWYQQKPGQPPKLLIYWASTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGGGTKVEIK,na,na,None,None,None,2022,na,CLDN18,Transcenta,na,Solid tumours,na,,
Osocimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK,na,na,None,6hhc:HL,None,2018,2019,F11,Bayer HealthCare,na,na,Arterial thrombosis;Venous thrombosis;Venous thromboembolism,,
Otelixizumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,na,na,None,None,None,2007,2008,CD3E,BTG;GlaxoSmithKline;Tolerx,na,Type 1 diabetes mellitus,Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis,,
Otilimab,Whole mAb,G1,Lambda,Phase-III,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL,na,na,None,5c7x:MN:HL/5d7s:HL,5d72:MN:HL/5d71:HL,2018,2019,CSF2,GlaxoSmithKline;MorphoSys,na,na,Inflammation;Multiple sclerosis;Osteoarthritis;Rheumatoid arthritis,MorphoSys HuCAL Phage Display,
Otlertuzumab,di-scFv+Fc,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD37,Trubion Pharmaceuticals;Aptevo Therapeutics,na,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma,ADAPTIR Monospecific Platform,
Oxelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2010,2011,TNFSF4/CD134/CD252/OX40L,Genentech;Genmab;Roche,na,na,Allergic asthma;Allergic rhinitis,,
Ozanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,na,na,None,None,None,2012,2013,RTN4/Nogo,GlaxoSmithKline,na,na,Amyotrophic lateral sclerosis;Multiple sclerosis,,
Ozekibart,VH-IgG,G1,na,TBC,Active,EVQLLESGGGEVQPGGSLRLSCAASGLTFPNYGMGWFRQAPGKEREFVSAIYWSGGTVYYAESVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCAVTIRGAATQTWKYDYWGQGTLVTVKPG,na,na,na,None,None,None,2023,na,TNFRSF10B/CD262/DR5/TRAILR2,TBC,TBC,TBC,TBC,,
Ozoralizumab,Bispecific Single Domains (VH-VH'-VH),na;na,na;na,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,5m2j:D;None,2011,2012,TNF/TNFA;ALB,Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical,na,Rheumatoid arthritis,Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis,Nanobody Technology,
Ozuriftamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,na,ROR2,BioAtla,na,Malignant Melanoma;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,Genetics: musmus/homosap
Pabinafusp,Whole mAb Fusion,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,TFRC/CD71,JCR Pharmaceuticals,Mucopolysaccharidosis II,na,na,,
Pacanalotamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Amgen,na,Multiple myeloma,na,BiTE Technology,Genetics of Fv2: musmus/homosap
Pacmilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDL1/CD274,CytomX Therapeutics,na,Solid tumours;Lymphoma,na,,
Palivizumab,Whole mAb,G1,Kappa,Approved,NFD,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,na,na,None,2hwz:HL,None,1998,1999,Respiratory Syncytial Virus Glycoprotein F,MedImmune,Respiratory syncytial virus infections,na,na,GS Gene Expression System,Biosimilars available
Pamrevlumab,Whole mAb,G1,Kappa,Phase-III,Active,EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK,na,na,None,None,None,2015,2016,CTGF/CCN2,FibroGen,na,Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer,Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis,,
Pamvatamig,Bispecific mAb,G1;G1,Kappa;Kappa,TBC,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYSMNWVRQAPGQGLEWMGWINTYTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARETYFYDRGGYPFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNANTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAKDRHWHWWLDAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2023,-,MET/HGFR;EGFR/ERBB1/HER1,TBC,TBC,TBC,TBC,,
Panitumumab,Whole mAb,G2,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,5sx5:HL:JK/5sx4:HL:JI,None,None,2004,2005,EGFR/ERBB1/HER1,Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma,Colorectal cancer,Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer,Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours,Abgenix XenoMouse,
Panobacumab,Whole mAb,M,Kappa,Phase-II,Active,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,Serotype IATS O11,Berna Biotech;Aridis Pharmaceuticals,na,Nosocomial pneumonia,na,,
Paridiprubart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIK,na,na,4r7d:AB:CD:EF:GH:IJ:MN:OP,None,4r7n:AB:CD:EF:GH:IJ:MN:OP:QR:ST,2022,na,TLR4/CD284,Edesa Biotech,na,COVID-19,na,,
Parsatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,EGFL7,Chugai Pharmaceutical;Genentech,na,na,Colorectal cancer;Non-small cell lung cancer;Solid tumours,,
Pasotuxizumab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2014,2015,FOLH1/GCPII/PSMA;CD3E,Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc,na,na,Prostate cancer,,
Patecibart,Whole mAb,G4,Kappa,TBC,Active,QVTLKESGPTLVKPTQTLTLTCTFSGFSLTTSGLGVAWIRQPPGKALEWLAHIWSDGDTRYYPALKNRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHMKDDSLYFDNWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQNIGTSIHWYQQKPDQYPKLLIKYASKSISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQHSYSFPWTFGQGTKVEIK,na,na,None,None,None,2023,na,EDNRA,TBC,TBC,TBC,TBC,,
Pateclizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK,na,na,4mxv:HL:YX:FE/4mxw:HL:WV,None,None,2011,2012,LTA,Genentech,na,na,Rheumatoid arthritis,,
Patritumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,ERBB3/HER3,Amgen;U3 Pharma;Daiichi Sankyo Company,na,Non-small cell lung cancer;Head and neck cancer;Breast cancer,Solid tumours,,
Pavurutamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Amgen,na,na,Multiple myeloma,BiTE Technology,Genetics of Fv2: musmus/homosap
Pelgifatamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFAFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCARGGDFLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKTGKVPKFLIYEASTLQSGVPSRFSGGGSGTDFTLTISSLQPEDVATYYCQNYNSAPFTFGPGTKVDIK,na,na,None,None,None,2020,2021,FOLH1/GCPII/PSMA,Bayer,na,Prostate cancer;Metastatic cancers,na,,ADC with corixetan
Pembrolizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,na,na,5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC,None,None,2013,2014,PDCD1/CD279/PD1,Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society,Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma,Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections,na,,Pembrolizumab is the new name for Lambrolizumab (PL110)
Pemivibart,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFGSYEMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFGGDTAWAGTGFTYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL,na,na,None,None,7u2d:HL,2023,na,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,,
Penpulimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Akeso Biopharma;Chia Tai Tianqing Pharmaceutical,Hodgkin's disease,Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Solid tumours,,,Genetics: musmus/homosap
Pepinemab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK,na,na,None,None,None,2018,2019,SEMA4D/CD100,Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex,na,Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer,Multiple sclerosis,,Genetics: musmus/homosap
Perakizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,IL17A,Roche,na,na,Psoriatic arthritis,,
Perenostobart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSEGISWVRQAPGQGLEWMGSILPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAGYYRYRYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHALWPLTFGGGTKVEIK,na,na,None,None,None,2022,na,ENTPD1/CD39,Surface Oncology;Arcus Biosciences,na,Prostate cancers,na,,
Peresolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYSLSKYDMSWVRQAPGKGLEWMGIIYTSGYTDYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGNPYYTNGFNSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSPNNLLAWYQQKPGKAPKLLIYGASDLPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNNYYVGPVSYAFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,Eli Lilly,na,Rheumatoid arthritis;Plaque Psoriasis,na,,June '22: Corrected CDRH3 sequence
Pertuzumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,na,na,1l7i:HL/4llu:AB:CD/1s78:FE:DC/6oge:CB,None,4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL,2003,2004,ERBB2/CD340/HER2,Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group,Breast cancer,Ovarian cancer;Brain metastases;Colorectal cancer,Gastric cancer;Non-small cell lung cancer;Prostate cancer,,Biosimilars available
Petosemtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,EGFR/ERBB1/HER1;LGR5,Merus,na,na,Colorectal cancer;Solid tumours,,
Pexelizumab,scFv,na,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2002,2002,C5,Stanford University,na,na,Myocardial infarction;Reperfusion injury,,Same VH as eculizumab
Picankibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYLMHWVRQAPGQGLEWMGYINPYNEGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARNWDLPYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISDYLHWYQQKPGKAPKLLIKYASQSMSGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQGHSFPFTFGQGTKLEIK,na,na,None,None,None,2023,na,IL23A,Innovent Biologics,na,Plaque psoriasis;Ulcerative colitis;Autoimmune disorders;Gastrointestinal disorders,na,,
Pidilizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK,na,na,None,None,None,2012,2013,PDCD1/CD279/PD1,American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center,na,Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer,na,,
Pimivalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Jounce Therapeutics,na,Solid tumours;Non-small cell lung cancer,na,,
Pimurutamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLEWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK,na,na,None,None,None,2019,2020,EGFR/ERBB1/HER1,Shanghai Henlius Biotech,na,Solid tumours,na,,June '22: Corrected FWH2 sequence. Biobetter available
Pinatuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,na,na,None,6and:HL,None,2012,2013,SIGLEC2/CD22,Genentech,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,,ADC with vedotin
Pivekimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKYNEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVSS,EIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPSRFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIK,na,na,None,None,None,2021,2022,IL3RA/CD123,ImmunoGen,na,Acute myeloid leukaemia;Blastic plasmacytoid dendritic cell neoplasm,na,,ADC with sunirine. Genetics: musmus/homosap
Placulumab,Single Domain Variable Fragment (VL) + Fc,G1,Kappa,Phase-II,Discontinued,na,DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNF/TNFA,Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries,na,na,Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica,,
Plamotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS,QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,MS4A1/CD20;CD3E,Xencor,na,B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma,na,,Genetics of Fv2: musmus/homosap
Plonmarlimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYLHWVRQAPGQGLEWMGWIFPGDDKTKYNEKFKGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTKYLNWNFDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKANQNVGTTLAWYQQKPGKSPKALIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCHQYTTYPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,CSF2,I-Mab Biopharma,na,Rheumatoid arthritis;COVID-19;Osteoarthritis,na,,June '22: Corrected FWL4 sequence
Plozalizumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK,na,na,None,None,None,2015,2016,CCR2/CD192,Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology,na,Atherosclerosis;Diabetic nephropathies;Malignant melanoma,Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours,,
Polatuzumab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,AGM6/CD79B,Chugai Pharmaceutical;Genentech;Roche,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma;Follicular lymphoma,Chronic lymphocytic leukaemia,,ADC with vedotin
Polzastobart,Whole mAb,G4,Kappa,Phase-I/II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLNTYAMGVSWIRQPPGKALEWLASIWWNGNKYNNPSLKSRLTVTKDTSKNQVVLTMTNMDPVDTATYYCAHSRIIRFTDYVMDAWGQGTLVTVSS,DIQMTQSPSSLSTSVGDRVTITCRASEDIYNDLAWYQQKPGKAPKLLIYNANSLHTGVASRFSGSGSGTDFTFTISSLQPEDVATYFCQQYYDYPLTFGQGTKLEIK,na,na,None,None,None,2022,na,LILRB2,Jounce Therapeutics,na,Cancers,na,,
Ponezumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,na,na,3u0t:BA:DC,None,None,2010,2011,APP,Rinat Neuroscience;Pfizer,na,na,Alzheimer's disease;Cerebral amyloid angiopathy,,
Ponsegromab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYNIDWVRQAPGQGLEWMGGINPIFGTAFYNQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQSVHNYLAWYQQKPGQAPRLLIYDASTRADGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFWSWPWTFGQGTKVEIK,na,na,None,None,None,2020,na,GDF15/MIC1,Pfizer,na,na,Cachexia,,
Porustobart,VH-CH2-CH3,G1,na,Phase-II,Active,EVQLVESGGGLIQPGGSLRLSCAVSGFTVSKNYMSWVRQAPGKGLEWVSVVYSGGSKTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPHSPSSFDIWGQGTMVTVSS,na,na,na,7dv4:H:B:D:F,None,None,2022,na,CTLA4/CD152,Harbour Biomed,na,Solid tumours,na,,
Posdinemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISKGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWGDYGWFAYWGQVTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDINRYLNWFQQKPGKAPKSLIYRANRLLDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYDEFPLTFGQGTKLEIK,na,na,None,None,None,2022,na,MAPT,Janssen Research & Development,na,Alzheimer's disease;Dementia,na,,
Pozelimab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSSYWTWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCAREGNVDTTMIFDYWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFAGRGSGTDFTLTISSLQPEDFATYYCLQDFNYPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,C5,Alnylam Pharmaceuticals;Regeneron Pharmaceuticals,na,Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria;Gastrointestinal disorders,na,,
Plutavimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTEYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARELGYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISTWLVWYQQKPGKAPNLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANAYPYTFGQGTKLEIK,na,na,None,None,None,2022,na,SARS-CoV-2 Spike RBD,Sorrento Therapeutics,na,COVID-19,na,,
Porgaviximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS,DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK,na,na,None,5kel:HL:PT:QU,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,na,Ebola virus infections ,Zmapp Technology,
Pradusinstobart,Whole mAb,G4,Kappa,Phase-I,Active,QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGTCVSWIRQPPGKALEWLATICWEDSKGYNPSLKSRLTISKDTSKNQAVLTMTNMDPVDTATYYCARREDSGYFWFPYWGQGTLVTVSS,NIQMTQSPSSLSASVGDRVTITCKAGQNVNNYLAWYQQKPGKAPKVLIFNANSLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSWTTFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,MD Anderson Cancer Center;Lyvgen Biopharma,na,Gastric cancers;Head and neck cancers;Esophageal cancers;Hepatocellular cancers;Metastatic cancers,na,,
Prafnosbart,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGSTFSNYGMKWIRQAPGKGLEWVSSISRSSTYIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAAISTPFYWYFDFWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCLASSSVSYMTWYQQKPGQSPRLWIYGTSNLASGVPDRFSGSGSGTDFLTLTIRLEPEDFAVYYCLHLTSYPPYTFGQGTKVEIK,na,na,None,None,None,2022,na,ACVR1,Daiichi Sankyo,na,Fibrodysplasia ossificans prograssiva,na,,
Praluzatamab,Whole mAb,G1,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,ALCAM/CD166,CytomX Therapeutics;Immunogen,na,Solid tumours,na,,ADC with ravtansine
Prasinezumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK,na,na,None,None,None,2017,2018,SNCA,Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche,na,Parkinson's disease,na,,
Prezalumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2015,2016,ICOSLG,Amgen;MedImmune,na,na,Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus,,May have had a former name of Prezalizumab
Pritoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS,DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 1,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,,
Pritumumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGDLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAITPSGGSTNYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYICGRVPYRSTWYPLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYAASSLHSKVPTQFSGSGSGTDFTLTISSLQPEDFATYYCLQYSTYPITFGGGTKVEIK,na,na,None,None,None,2003,2004,VIM,UCSD;Nascent Biotech,na,Glioma;Breast cancer;COVID-19,Pancreatic cancer,,
Prolgolimab,Whole mAb,G1,Lambda,Approved,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS,QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Biocad,Malignant melanoma,Cervical cancer;Non-small cell lung cancer;Hodgkin's disease,Solid tumours,,Genetics: vicpac/homosap
Pucotenlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVQSGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQAPGKGLDWVATISGGGRDTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCARQKGEAWFAYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNKGTGVPARFSGSGSGTDFTLNINPMEENDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Taizhou Hanzhong Pharmaceuticals,Solid tumours,Gastrointestinal cancer;Malignant Melanoma;Non-small cell lung cancer;Bladder cancer;Breast cancer;Liver cancer,na,,Genetics: musmus/homosap
Pulocimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGLDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,None,3s34:HL/3s37:HL/3s36:HL,None,2021,2022,KDR/CD309/VEGFR2,Akeso Biopharma,na,Solid tumours,na,,
Puxitatug,Whole mAb,G1,Kappa,TBC,Active,QVQLQQWGAGLLKPSETLSLACTVYGGSFSGYYWNWIRQPPGKGLEWIGEINHSGSTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVLYNWNVDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNDVGWYQQKPGKAPKRLIYAASRLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK,na,na,None,None,None,2023,na,VTCN1/B7H4,TBC,TBC,TBC,TBC,,ADC with samrotecan
Quavonlimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK,na,na,None,None,None,2019,2020,CTLA4/CD152,Merck,na,Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Solid tumours,na,,
Quetmolimab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK,na,na,None,None,None,2018,2019,CX3CL1,KAN Research Institute;EA Pharma;Eisai Co Ltd,na,Crohn's disease;Rheumatoid arthritis,Primary biliary cirrhosis,,Genetics: musmus/homosap
Quilizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK,na,na,3hr5:HL:JQ:BA:IP,None,None,2011,2012,IGHE,Genentech,na,na,Allergic asthma;Allergic rhinitis;Urticaria,,
Quisovalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYNWHWIRQPPGKGLEWIGEITHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVREIAVAGTGYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGINSAFAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFSF14/CD258,Avalo Therapeutics,na,Crohn's disease;COVID-19,na,,
Racotumomab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2008,2009,Idiotope of anti-NeuGc-ganliosides,Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio,Non-small cell lung cancer,Neuroblastoma,Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours,,
Rademikibart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRNAMFWVRQAPGKGLEWVSGIGTGGATSYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDHSAGWTFGQGTKVEIK,na,na,None,None,None,2023,na,IL4R/CD124,TBC,TBC,TBC,TBC,,
Radretumab,di-scFv + CH4,E,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,na,Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease,,Radretumab+Bifikafusp+Onfekafusp have identical V domains
Rafivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,None,None,2008,2009,Rabies Virus Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,
Ragifilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF18/CD357/GITR,Incyte,na,Non-small cell lung cancer;Hepatocellular carcinoma;Cutaneous squamous cell cancers,Glioblastoma;Solid tumours,,
Ragistomig,Bispecific (G1-scFv_L-kappa),G1;na,Kappa;Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKSLEWVATISDAGGYIYYRDSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYICARELPWRYALDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTPAVAWYQQKPGKAPKLLIYSTSSRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYTTPLTFGQGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKCLEWVSWISYSGGSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAQRNSMREFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVTWYQQLPGTAPKLLIYADSHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDYSLSGYVFGCGTKLTVL,None;None,None;None,None;None,2023,na,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,Fv2 identical in sequence to Givastomig Fv2.
Ralpancizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,None,None,3sqo:HL,2013,2014,PCSK9,Pfizer,na,na,Hypercholesterolaemia,,
Raludotatug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIK,na,na,None,None,None,2022,na,CDH6,Daiichi Sankyo,na,Ovarian cancers;Renal cell carcinoma,na,,ADC with deruxtecan
Ralzapastotug,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSGTLSLTCAVSGYSITSGYSWHWVRQPPGKGLEWIGYVHYSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARMDYGNYGGAMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVRTAVAWYQQKPGQAPRLLIYSASYRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYSTQWTFGGGTKVEIK,na,na,None,None,None,2022,na,TIGIT/WUCAM/VSTM3,Arcus Biosciences,na,Multiple myeloma;non-Hodgkin's lymphoma;Non-small cell lung cancer;Melanoma;Solid tumours,na,,
Ramucirumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,3s34:HL/3s37:HL/3s36:HL,None,None,2008,2009,KDR/CD309/VEGFR2,Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine,Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer,Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer,Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma,Dyax Human Phage Display,
Ranevetmab,Canine Whole mAb,G1,Kappa,Unknown,Active,EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS,DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Osterarthritis,na,PETization Technology,
Ranibizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB/7v5n:BA:FE,2004,2004,VEGFA,Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn,Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy,Retinopathy of prematurity;Polypoidal choroidal vasculopathy,Retinal telangiectasis,,Biosimilars available
Ravagalimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,na,na,6pe7:HL/6pe8:HL:AB,None,6pe9:AB:CD:EF:HL:KM,2017,2018,TNFRSF5/CD40,AbbVie,na,Ulcerative colitis;Sjogren's syndrome,Crohn's disease,,
Ravulizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2017,2018,C5,Alexion Pharmaceuticals,Paroxysmal nocturnal haemoglobinuria,Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy,na,,
Recaticimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS,DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK,na,na,None,None,None,2020,2021,PCSK9,Shanghai Hengrui Pharmaceuticals,na,Hypercholesterolemia,na,,Genetics: musmus/homosap
Refanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK,na,na,None,None,None,2015,2016,SIGLEC4/MAG,GlaxoSmithKline,na,na,CNS trauma;Stroke,,
Reflocibart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGFWIHWVRQAPGQGLEWMGHINPGNGGTNYNEKFKRRVTMTRDKSISTAYMELSRLRSDDTAVYYCARSYSNYVRAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGKTLPPTFGGGTKVEIK,na,na,None,None,None,2023,na,VEGFB,TBC,TBC,TBC,TBC,,
Regdanvimab,Whole mAb,G1,Lambda,Approved,Active,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,na,na,7cm4:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Celltrion,na,COVID-19,na,,
Relatlimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK,na,na,None,7um3:HL:IM,None,2018,2019,LAG3/CD223,Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Malignant melanoma,Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,,
Relfovetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS,EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,NGFB,TBC,TBC,TBC,TBC,,
Remternetug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGGSGSYYNGFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSLGNWLAWYQQKPGKAPKLLIYQASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYKGSFWTFGQGTKVEIK,na,na,None,None,None,2023,na,APP,Eli Lilly,na,Alzheimer's disease,na,,Jul '23: Corrected antigen label
Remtolumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK,4nyl:EF:AB:HL:CD/6cr1:HL;None,3wd5:HL;None,None;None,2016,2017,IL17A;TNF/TNFA,Abbott Laboratories;Abbvie,na,na,Psoriatic arthritis;Rheumatoid arthritis,Dual Variable Domain Immunoglobulin Technology,
Renvistobart,Whole mAb,G1,Kappa,TBC,Active,QVHLQESGPGLVKPSETLSLTCTVSGGSVSSGIYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYYVSGNYYNVDYYFFGVDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLFTFGPGTKVDIK,na,na,None,None,None,2023,na,TIGIT/WUCAM/VSTM3,TBC,TBC,TBC,TBC,,
Reozalimab,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPSFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,None;None,None;None,None;None,2022,na,PDCD1/CD279/PD1;PDL1/CD274,Innovent Biologics,na,na,Solid tumours,,
Reslizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,na,na,None,None,None,2001,2002,IL5,Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries,Asthma,Sinusitis;Churg-Strauss syndrome,Oesophagitis,,
Resugosbart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNLDWLRQAPGEGLEWIGDIDPNDGDILYNQKFRDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRWAYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKSPKLLIYYTSNRFTGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCQQDYSSPVTFGGGTKVEIK,na,na,None,None,None,2022,na,SOST,Jiangsu Hengrui Medicine,na,"Osteoporosis,Postmenopausal women",na,,Genetics: musmus/homosap
Retifanlimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDCD1/CD279/PD1,MacroGenics;Incyte Corporation;ZAI Lab,Merkel cell carcinoma,Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma,Haematological malignancies,,Chimeric: Mouse/Human
Retlirafusp,Whole mAb Fusion,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2020,2021,PDL1/CD274,Jiangsu Hengrui Medicine,na,Pancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma,na,,
Revdofilimab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,AbbVie,na,Solid tumours,na,,Genetics: musmus/homosap
Rezetamig,Bispecific (half G4-kappa_G4(VH-h-CH2-CH3)),G4;G4,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFHNYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSRGYGDYSLGGAYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,QLQLQESGPGLVKPSETLSLTCTVSGDSISSGDYYWGWIRQPPGKGLEWIGHIYYSGATYYNPSLENRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRDDSSNWRSRGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,None;None,None;None,None;None,2023,na,CD3;SIGLEC2/CD22,TBC,TBC,TBC,TBC,,
Rezorstobart,Whole mAb,G1,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYAMSWVRQAPGKGLEWVSAISASGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPLDSSFWADFDLWGRGTLVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHSVLPITFGGGTKVEIK,na,na,None,None,None,2023,na,KLRB1,TBC,TBC,TBC,TBC,,
Riliprubart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKLSCTASGFNIKDDYIHWVKQAPGQGLEWIGRIDPADGHTKYAPKFQVKVTITADTSTSTAYLELSSLRSEDTAVYYCARYGYGREVFDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCKASQSVDYDGDSYMNWYQQKPGQPPKILIYDASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAIYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2023,na,C1S,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap
Rilotumumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,na,na,None,None,None,2009,2010,HGF/SF,Amgen;Astellas Pharma,na,na,Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours,Abgenix XenoMouse,
Riltovetbart,Whole mAb,G2,Kappa,TBC,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2022,na,IL31 (Canine),TBC,TBC,TBC,TBC,,
Rilvegostomig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYAGEVKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRRPVNWYQQLPGTAPKLLIYSQNQRPSGVPDRFSGSQSGTSASLAISGLQSEDEADYFCAVWDDIGRVLQLGGGTQLTVL,None;None,None;None,None;None,2022,na,PDCD1/CD279/PD1;TIGIT/WUCAM/VSTM3,AstraZeneca,na,Non-small cell lung cancers,na,,
Rimteravimab,Mixed Nanobody (VHH-CH2-CH3 dimer),G1,na,Phase-I/II,Active,DVQLVESGGGLVQPGGSLRLSCAASGRTFSEYAMGWFRQAPGKEREFVATISWSGGATYYTDSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCAAAGLGTVVSEWDYDYDYWGQGTLVTVSS,na,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,ExeVir,na,COVID-19,na,,Also complementary vs. SARS-CoV Spike RBD and WIV-CoV Spike RBD. Genetics: vicpac/homosap
Rinucumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS,EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR,na,na,None,None,None,2015,2016,PDGFRB/CD140B,Regeneron Pharmaceuticals,na,na,Wet age-related macular degeneration,,
Ripertamab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM,4kaq:HL,None,2019,2020,MS4A1/CD20,Sinocelltech,na,Non-Hodgkin's lymphoma,na,,Likely to be a Rituximab biosimilar
Risankizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK,na,na,None,None,None,2015,2016,IL23A,AbbVie;Boehringer Ingelheim,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Crohn's disease;Ulcerative colitis;Atopic dermatitis,Psoriasis;Ankylosing spondylitis;Asthma,,
Rituximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM,4kaq:HL,None,1997,1998,MS4A1/CD20,Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis,Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection,Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus,,Biosimilars available
Rivabazumab,Fab,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS,DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,PcrV type III secretion system,KaloBios Pharmaceuticals Inc,na,na,Infectiology;Inflammation;Inherited diseases,Humaneering Technology,
Robatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,na,na,None,None,None,2008,2009,IGF1R/CD221,Merck & Co;Schering-Plough,na,na,Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours,,
Rocatinlimab,Whole mAb,G1,Kappa,Phase-III,Active,QITLKESGPTLVKPKQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAVIYWDDHQLYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRGAFQHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFRSF4/CD134/OX40,Kyowa Hakko Kirin,na,Ulcerative colitis;Atopic dermatitis,na,,
Roconkibart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTNYGMNWMRQAPGQGLEWMGWINDHTGEPTYADKFQGRVTFTLDTSISTAYMELSRLRSDDTAVYYCANYGFGYFDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNSYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKLEIK,na,na,None,None,None,2023,na,IL17A,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap
Roledumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS,AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT,na,na,None,None,None,2010,2011,RhD/CD240D/RhPI,LFB Biotechnologies,na,Haemolytic disease of newborn,na,EMABling Platform,
Rolinsatamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,PRLR,AbbVie,na,Solid tumours,na,,ADC with talirine. Genetics: musmus/homosap
Rolistobart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGQSFMHWYQQKPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNNEDPYTFGQGTKLEIK,na,na,None,None,None,2023,na,LILRB4/CD85K,TBC,TBC,TBC,TBC,,
Romilkimab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK,QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS,DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK,None;None,None;None,None;None,2017,2018,IL13;IL4,Sanofi,na,na,Idiopathic pulmonary fibrosis;Systemic scleroderma,,Chimeric: Mouse/Human
Romlusevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSSEITTLGGMDVWGQGTTVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVL,na,na,None,8gx9:PM:ON,None,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,COVID-19,na,,
Romosozumab,Whole mAb,G2,Kappa,Approved,NFD,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,ChiroscienceGroup plc;Amgen;UCB,Male osteoporosis;Postmenopausal osteoporosis,na,Fracture,,
Rontalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK,na,na,4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY,None,None,2009,2010,IFNA1,Chugai Pharmaceutical;Genentech,na,na,Systemic lupus erythematosus,,
Rosmantuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK,na,na,None,None,None,2016,2017,RSPO3,OncoMed Pharmaceuticals,na,na,Colorectal cancer;Solid tumours,,
Rosnilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIK,na,na,None,None,None,2022,na,PDCD1/CD279/PD1,AnaptysBio,na,Alopecia areata;Autoimmune disorders,na,,
Rosopatamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS,DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK,na,na,None,None,None,2019,2020,FOLH1/GCPII/PSMA,Weill Cornell Medical,na,Prostate cancer;Cancers,na,,Genetics: musmus/homosap
Rovalpituzumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK,na,na,None,None,None,2015,2016,DLL3,Bristol-Myers Squibb;Stemcentrx,na,na,Small cell lung cancer;Solid tumours,,ADC with tesirine
Rovelizumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNNWMQWVRQAPGQGLEWMGAIFPGDDETRYTQKFRGKATITADTSTSTAYMELSSLRSEDTAVYYCGRGGKLRPFALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVESYGNNFMYWYQQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDNEDPPTFGQGTKLEIK,na,na,None,None,None,1999,2000,ITGAL/CD11A/LFA1A and ITGB2/CD18,ICOS Corporation,na,na,Adult respiratory distress syndrome;Cerebral vasospasm;CNS trauma;Multiple sclerosis;Myocardial infarction;Peripheral arterial occlusive disorders;Shock;Stroke;Vascular restenosis ,,
Rozanolixizumab,Whole mAb,G4,Kappa,Approved,Active,EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK,na,na,6fgb:HL,None,None,2016,2017,FCGRT/FcRn,UCB,Myasthenia gravis,Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;CNS disorders;Encephalitis;Fibromyalgia,Immunological disorders,,
Rozibafusp,Whole mAb Fusion,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2018,2019,ICOS/CD278,Amgen,na,Systemic lupus erythematosus,Rheumatoid arthritis,,
Rulonilimab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQTPEKRLEWVATISGGGRDTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARQKDTSWFVHWGQGTLVTVSS,EIVLTQSPATLAVSPGERATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYVASNQGSGVPARFSGSGSGTDFTLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Shandong New Time Pharmaceutical,na,na,Lymphoma;Solid tumours;Liver cancer,,Genetics: musmus/homosap
Runimotamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF;None,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL;None,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None,2020,2021,ERBB2/CD340/HER2;CD3E,Genentech,na,Solid tumours,na,,Genetics of Fv2: musmus/homosap
Ruplizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY/6w4w:HL,None,None,2000,2001,CD40LG/CD154,Biogen,na,na,Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus,,
Sabatolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,HAVCR2/TIM3,Novartis,na,Chronic myelomonocytic leukaemia;Myelodysplastic syndromes;Acute myeloid leukaemia;Myelofibrosis;Solid tumours;Glioblastoma,na,,
Sabestomig,Bispecific mAb,G1;G1,Kappa;Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSYGTYYGNYFEYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGDNIGGKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVLDRRSDHFLFGGGTKLTVL,None,None,None,2023,na,PDCD1/CD279/PD1;HAVCR2/TIM3,TBC,TBC,TBC,TBC,,
Sabirnetug,Whole mAb,G2,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISRGSSTIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGITTALDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKASNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSRLGPSFGQGTKLEIK,na,na,None,None,None,2023,na,APP,TBC,TBC,TBC,TBC,,
Sacituzumab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK,na,na,None,None,None,2016,2017,TACSTD2/TROP2/EGP1,IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University,Breast cancer,Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma,na,,ADC with tirumotecan
Samalizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK,na,na,None,None,None,2010,2011,MOX2/CD200,Alexion Pharmaceuticals;The Leukemia & Lymphoma Society,na,na,Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours,,
Samrotamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK,na,na,None,None,None,2017,2018,LRRC15,AbbVie,na,na,Solid tumours,,Chimeric: Mouse/Human
Sarilumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,IL6R/CD126,Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi,Rheumatoid arthritis,Juvenile rheumatoid arthritis,Ankylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis,VelocImmune Mouse,
Sasanlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK,na,na,6xkr:HL,None,None,2019,2020,PDCD1/CD279/PD1,Pfizer,na,Bladder cancer;Non-small cell lung cancer;Solid tumours,na,,
Satralizumab,Whole mAb,G2,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS,DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE,na,na,None,None,None,2015,2017,IL6R/CD126,Chugai Pharmaceutical;Roche,Neuromyelitis optica,na,Rheumatoid arthritis,,Satralizumab is the new name for Sapelizumab (PL116)
Satumomab,Whole mAb Radiolabelled,G1,Kappa,Approved,NFD,QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIK,na,na,None,1bbj:HL:BA,None,1999,2000,TAG72,Cytogen Corporation,Radionuclide imaging enhancers,na,na,,
Secukinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,na,na,6wio:AB/6wir:AB,None,None,2009,2010,IL17A,Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon,Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries,Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis,Abgenix XenoMouse,Biosimilars available
Selicrelumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,TNFRSF5/CD40,Abramson Cancer Center of the University of Pennsylvania;Roche,na,na,Pancreatic cancer;Solid tumours;Non-Hodgkin's Lymphoma,,
Semorinemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS,DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,MAPT,AC Immune;Genentech,na,Alzheimer's disease,na,,Genetics: musmus/homosap
Semzuvolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGPELKKPGASVKVSCKASGYTFTDYVIHWVKQATGQGLEWIGEIYPGSGSAYSNAKFKDRVTMTADKSSNTAYMELSSLTSDDTAVYFCARRGNGTGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATITCKAGQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEENDAATYYCQQSYKDPLTFGQGTKLEIK,na,na,None,None,None,2022,na,CD4,United Biopharma;Kaohsiung Medical University Chung-Ho Memorial Hospital;Kaohsiung Veterans General Hospital;United Biomedical,na,HIV1 infections,na,,Genetics: musmus/homosap
Seniprutug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGSELKKPGESVKVSCKASGYTFTDYLVHWVRQAPGQGLEWMGWINTYTGTPTYADDFEGRFVFSLDTSVSTANLQISSLKAEDTAVYFCARSWRRGLRGIGFDYWGQGTLVTVSS,DIQMTQSPYSLSASVGDRVTITCKASKSINKYLAWFQQKPGKPNKLLIYDGSTLQSGVPSRFSGSGSGTDFTLTISSLEPEDFATYYCQQHNEYPPTFGQGTKLEIK,na,na,None,None,None,2023,na,TRBV9,TBC,TBC,TBC,TBC,,
Serclutamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,AbbVie,na,na,Solid tumours,,Losatuxizumab and Serclutamab have identical variable domains. Genetics: musmus/homosap
Seribantumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,na,na,None,None,None,2012,2013,ERBB3/HER3,Merrimack Pharmaceuticals;Sanofi,na,na,Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,Dyax Human Phage Display,
Serplulimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK,na,na,7e9b:HL,None,None,2019,2020,PDCD1/CD279/PD1,Henlix Biotech;Shanghai Henlius Biotech,Solid tumours,Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B;Gastric cancer;Cervical cancer;Hepatitis B;Liver cancer,na,,
Setoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA,DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 2,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,,
Setrusumab,Whole mAb,G2,Lambda,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL,na,na,None,None,None,2017,2018,SOST,MorphoSys;Novartis;Mereo BioPharma,na,Osteogenesis imperfecta,Hypophosphatasia;Postmenopausal osteoporosis,MorphoSys HuCAL Phage Display,
Sibeprenlimab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYTIHWVRQATGQGLEWMGWIYPLRGSINYAQKFQGRVTMTADKSISTVYMELSSLRSEDTAVYFCARHGAYYSNAFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASESVDNDGIRFLHWYQQKPGQAPRLLIYRASTRATGIPARFSGSGSRTEFTLTISSLQSEDFAVYYCQQSNKDPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,TNFSF13/CD256/APRIL,Visterra,na,IgA Nephropathy,na,,
Sifalimumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,na,na,4ypg:HL:BA,None,None,2009,2010,IFNA1,Medarex;MedImmune,na,na,Myositis;Psoriasis;Systemic lupus erythematosus,,
Siltuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,na,na,None,None,None,2008,2009,IL6,Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center,Giant lymph node hyperplasia,Multiple myeloma,Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma,,
Simaravibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILDRVMYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAIDSDTYVEQSHFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPSLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQPLTFGGGTKVEIK,na,na,7s6j:HL:CD:FG/7s6k:HL:CD:FG/7s6l:HL/7sbu:HL,None,None,2022,na,SARS-CoV-2 Spike RBD,Toscana Life Sciences,na,COVID-19,na,,
Simlukafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,FAP,Roche,na,na,Malignant melanoma;Renal cell carcinoma;Solid tumours,,
Simridarlimab,Bispecific Mixed mAb/VH-VH-CH2-CH3,G1;G1,Kappa;na,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSIEHYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,QVQLQESGGGLVQPGGSLRLSCAASAYTISRNSMGWFRQAPGKGLEGVAAIESDGSTSYSDSVKGRFTISLDNSKNTLYLEMNSLRAEDTAVYYCAAPKVGLGPRTALGHLAFMTLPALNYWGQGTLVTVSS,na,None;None,None;None,None;None,2021,2022,IAP/CD47;PDL1/CD274,Innovent Biologics,na,Solid tumours,na,,
Simtuzumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,na,na,None,None,None,2012,2013,LOXL2,Arresto Biosciences;Gilead Sciences,na,na,Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis,,
Sintilimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University,Hodgkin's disease,Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours,na,,
Sirexatamab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGGGFGTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPGYNNYYFDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSESWPLHFGGGTKVEIK,na,na,None,None,None,2021,2022,DKK1,Leap Therapeutics,na,DKK1,na,,June '22: Corrected VH/VL sequences
Sirtratumab,Whole mAb ADC,G2,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,SLITRK6,Astellas/Agensys;Seattle Genetics,na,Bladder Cancer,na,,ADC with vedotin
Sirukumab,Whole mAb,G1,Kappa,Preregistration (w),Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL6,Centocor Inc;GlaxoSmithKline;Janssen Biotech,na,COVID-19,Rheumatoid arthritis;Atherosclerosis;Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder,,
Sigvotatug,Whole mAb,G1,Kappa,TBC,Active,QFQLVQSGAEVKKPGASVKVSCKASGYSFTDYNVNWVRQAPGQGLEWIGVINPKYGTTRYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCTRGLNAWDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLEDGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCQNVLTTPYTFGQGTKLEIK,na,na,None,None,None,2023,na,ITGB6,TBC,TBC,TBC,TBC,,Also found as an ADC with vedotin
Silevimig,Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3)),G1;G1,Kappa;Lambda,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFGSYGMHWVRQAPGKGLEWVATISYDGSIKDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDRTGNLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIRNALNWYQQKPGKAPKLLIYDASTRQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNSEFPPTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTYSGYTINWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDLGGYDFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,None;None,None;None,None;None,2023,na,Rabies Lyssavirus Glycoprotein G epitope III;Rabies Lyssavirus Glycoprotein G epitope I,TBC,TBC,TBC,TBC,,
Sipavibart,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLVQPGRSLRLSCAASGFPFDDYAIHWVRLAPGKGLEWVSSISWDSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGAFPGYSSGWYYGLEVWGQGTTVTVSS,QSVVTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIFEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGNKGVFGGGTKLTVL,na,na,None,None,7zff:HL,2023,na,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,,
Socazolimab,Whole mAb,G1,Lambda,Preregistration,Active,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPYYYYYMDVWGQGTTVTVSS,QSALTQPASVSGSLGQSVTISCTGSSSDVGSYNLVSWYQQHPGKAPNLMIYDVSKRSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGISTVVFGGGTKLTVL,na,na,None,None,None,2021,2022,PDL1/CD274,Sorrento Therapeutics;China Oncology Focus Ltd;Lee's Pharmaceutical,na,Small cell lung cancer;Oesophageal cancer;Osteosarcoma;Urogenital cancer;Cervical cancer;Malignant melanoma,Cancer,,
Sofituzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,MUC16/CA125,Genentech,na,na,Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer,,ADC with vedotin
Solanezumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,4xxd:ED:BA,None,2008,2009,APP,Eli Lilly,na,Alzheimer's disease,na,,
Solitomab,Bispecific scFv,na;na,Kappa;Kappa,Phase-I,Discontinued,EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS,ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK,DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK,None;None,None;None,None;None,2011,2012,EPCAM/CD326;CD3E,Micromet Inc;Amgen,na,na,Solid tumours,,
Solrikitug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYAMHWVRQAPGQGLEWMGTFIPLLDTSDYAQKFQGRVTMTADTSTSTAYMELRSLRSDDTAVYYCARMGVTHSYVMDAWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQPISISVHWYQQKPGQAPRLLIYFASQSISGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTFSLPYTFGQGTKVEIK,na,na,None,None,None,2023,na,CRLF2,TBC,TBC,TBC,TBC,,
Sonelokimab1,Trispecific Single Domains (VH-VH'-VH''); Bispecific Entry 1,na;na,na;na,Phase-II,Active,DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYVVGWFRQAPGKEREFIGAISGSGESIYYAVSEKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTADQEFGYLRFGRSEYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;None,2019,2020,IL17A;ALB,Ablynx;Avillion; MoonLake Immunotherapeutics;Merck Serono,na,Hidradenitis suppurativa;Psoriasis;Psoriatic arthritis;Ankylosing spondylitis,na,,VH-VH' portion. Joint entry with Sonelokimab2 (trispecific). Humanised: Llama/Human
Sonelokimab2,Trispecific Single Domains (VH-VH'-VH''); Entry 2,na,na,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGRTYDAMGWLRQAPGKEREFVAAISGSGDDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCATRRGLYYVWDANDYENWGQGTLVTVSS,na,na,na,None,None,None,2019,2020,IL17F,Ablynx;Avillion; MoonLake Immunotherapeutics;Merck Serono,na,Hidradenitis suppurativa;Psoriasis;Psoriatic arthritis;Ankylosing spondylitis,na,,VH'' portion. Joint entry with Sonelokimab1 (trispecific). Humanised: Llama/Human
Sotiburafusp,Fusion Protein (whole mAb with protein),G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYAFTGYTIHWVRQAPGQRLEWMGWFYPGSGTLKYSEKFQGRVTITRDKSLSTAYMELSSLRSEDTAVYYCARHGTGTLMAMDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLANSYGNTYLSWYLHKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPPTFGQGTKLEIK,na,na,None,None,None,2023,na,VEGFR-1,TBC,TBC,TBC,TBC,,
Sotigalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK,na,na,None,None,None,2020,2021,TNFRSF5/CD40,Apexigen,na,Pancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma,Brain cancer;Glioma;Solid tumours,,
Sotevtamab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGATVKISCKVSGFNIKDIYMHWVQQAPGKGLEWMGRIDPAYGNTKYDPKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARRYDTAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLWTFGQGTKLEQL,na,na,None,None,None,2021,2022,CLU,Alethia Biotherapeutics,na,Solid tumours,na,,
Sotrovimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB;7tm0:JK:LM:NO/7tn0:BA:CD/7xck:AB/7x1m:AB/7xsw:AB:HL/7yad:AB:CD/7yr0:CB/7yqy:HF:IG:JE/7yqx:HF:IG/7yxz:IG:JH/8df5:AB:CD/8dw2:DC/8dw3:DC,None,2020,2021,SARS-CoV-2 Spike RBD,GlaxoSmithKline;Vir Biotechnology,COVID-19,na,na,,
Sovipostobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl,None,None,2023,na,CTLA4/CD152,TBC,TBC,TBC,TBC,,Cleavable prodomain.
Spartalizumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1/CD279/PD1,Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital,na,Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer,Neuroendocrine tumours,,
Spesolimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS,QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK,na,na,6u6u:HL,None,None,2018,2019,IL36RN,Boehringer Ingelheim,Pustular psoriasis,Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis,na,,
Stamulumab,Whole mAb,G1,Lambda,Phase-I/II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDENWGFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGHALGDKFVSWYQQKPGQSPVLVIYDDTQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSFVFGGGTKVTVL,na,na,None,None,None,2006,2006,MSTN/GDF8,Cambridge Antibody Technology;Wyeth,na,na,Muscular dystrophies;Sarcopenia,,
Stapokibart,Whole mAb,G4,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVSTISSGGSYTNYADSVKGRFTISRDNVKNTLYLQMNSLRAEDTAVYYCARATARATEFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2023,na,IL4R/CD124,TBC,TBC,TBC,TBC,,
Suciraslimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVSS,DIQLTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,SIGLEC2/CD22,Lonn Ryonn Pharma; SinoMab Bioscience Ltd,na,Rheumatoid arthritis;Non-Hodgkin's lymphoma;Systemic lupus erythematosus;Sjogren's syndrome,na,,
Sudubrilimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSETWLHWVRQAPGKGLEWVAWVSPFGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFLYHPATFGQGTKVEIK,na,na,None,None,5x8l:GL:FK:SN:HM:JO/5xxy:HL,2020,2021,PDL1/CD274,Zhejiang Hisun Pharmaceutical,na,TBC,TBC,,
Sugemalimab,Whole mAb,G4,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Cstone Pharmaceuticals,Non-small cell lung cancer,Cancers;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer,na,,
Suptavumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,Respiratory Syncytial Virus Glycoprotein F,Regeneron Pharmaceuticals,na,na,Respiratory syncytial virus infections,VelocImmune Mouse. VelociGene,
Surzebiclimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVAAISSGGSLYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGREADGGYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASESVEYYGTSLMQWYQQKPGQAPRLLIYAASNVESGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSLKVPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,HAVCR2/TIM3,BeiGene,na,Solid tumours,na,,
Sutimlimab,Whole mAb,G4,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS,QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK,na,na,None,None,None,2017,2018,C1S,Bioverativ;True North Therapeutics,Autoimmune haemolytic anaemia,na,Idiopathic thrombocytopenic purpura;Bullous pemphigoid;Renal transplant rejection,,Chimeric: Mouse/Human
Suvemcitug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVKPGGSLRLSCAASGFSFSNNDVMCWVRQAPGKGLEWIGCIMTTDVVTEYANWAKSRFTVSRDSAKNSVYLQMNSLRAEDTAVYFCARDSVGSPLMSFDLWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCQASQSIYNNNELSWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCGGYKSYSNDGNGFGGGTKVEIK,na,na,None,None,None,2023,na,VEGFA,TBC,TBC,TBC,TBC,,
Suvizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS,DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK,na,na,3ntc:HL,None,None,2009,2010,HIV-1 gp120,Kaketsuken;Kumamoto University;University of Missouri-Columbia,na,na,HIV-1 infections,,
Suvratoxumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK,na,na,4u6v:HL:KM,None,None,2016,2017,Staphylococcus aureus Toxin A,Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune,na,Nosocomial pneumonia,na,,
Tabalumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,TNFSF13B/CD257/BAFF,Eli Lilly,na,na,Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus,,
Tabituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK,na,na,None,None,None,2018,2019,FZD10/CD350,OncoTherapy Science;Centre Leon Berard,na,na,Synovial sarcoma,,
Tacatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYAFTSYVIHWVRQAPGQGLYWIGYIHPYNGGTKYNEKFKGKATITADESTNTAYMELSSLRSEDTAFYFCARSGGGDPFAYWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDINKYIGWYQQKPGKAPKLLMHYTSALLPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGGGTKLQIK,na,na,None,None,None,2005,2006,Alpha Ferroprotein,Immunomedics,na,na,Liver cancer,,
Tadocizumab,Fab,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS,DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK,na,na,None,None,None,2005,2006,ITGA2B and ITGB3,PDL BioPharma;Yamanouchi,na,na,Coronary artery restenosis;Stroke;Thrombosis,,
Tafasitamab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor,Diffuse large B cell lymphoma,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma,na,MorphoSys HuCAL Phage Display. XmAb Engineering Technology.,Genetics: musmus/homosap
Tafolecimab,Whole mAb,G2,Kappa,Preregistration,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Innovent Biologics,na,Hypercholesterolaemia,na,,
Tagitanlimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLSNYDISWIRQPPGKGLEWLGVIWTGGATNYNPALKSRLTISRDNSKNQVSLKMSSVTAADTAVYYCVRDSNYRYDEPFTYWGQGTLVTVSS,EIVLTQSPDTLSVTPKEKVTLTCRASQSIGTNIHWFQQKPGQSPKLLIKYASESISGVPSRFSGSGSGTDFTLTINSVEAEDAATYYCQQSNSWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,PDL1/CD274,Sichuan Kelun-Biotech Biopharmaceutical,na,Hodgkin Lymphoma;Nasopharyngeal Carcinoma,na,,June '22: Corrected FWL4 sequence
Talacotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,na,na,4jzj:HL:AB,None,None,2017,2018,IL3RA/CD123,CSL;Janssen Biotech,na,Myelodysplastic syndromes,Acute myeloid leukaemia;Systemic lupus erythematosus,,
Talizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSMYWLEWVRQAPGHGLEWVGEISPGTFTTNYNEKFKARATFTADTSTNTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,DILLTQSPGTLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPSRFSGSGSGTDFTLTISRLEPEDFAMYYCQQSDSWPTTFGQGTKVEIK,na,na,None,None,None,2002,2004,IgE,Tanox,na,na,Peanut hypersensitivity,,
Talquetamab,Bispecific mAb,G4;G4,Kappa;Lambda,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2019,2020,GPRC5D;CD3E,Genmab;Janssen Research & Development,na,Multiple myeloma,na,,Chimeric: Mouse/Human
Tamgiblimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYYMHWVRQAPGQGLEWMGIISPSAGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDHDIRLAGRLADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAVILPITFGGGTKVEIK,na,na,None,None,None,2021,2022,TIGIT/WUCAM/VSTM3,Innovent Biologics,na,Cancer,na,,
Tamrintamab,Whole mAb ADC,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK,na,na,6vgr:HL:CD,None,None,2018,2019,DPEP3,Stemcentrx,na,Ovarian cancer;Solid tumours,na,,ADC with pamozirine
Tamtuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS,DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL,na,na,None,None,1bfo:HG:FE:BA:DC,2015,2016,CD52,Aratana Pharmaceuticals,na,Canine T-cell lymphoma,na,,Chimeric: Rat/Dog
Tanezumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,na,na,4edw:HL,None,None,2008,2009,NGFB,Rinat Neuroscience;Pfizer,na,Back pain;Musculoskeletal pain,Diabetic neuropathies;Postherpetic neuralgia;Cancer pain,,
Tarcocimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB/7v5n:BA:FE,2021,2022,VEGFA,Kodiak Biosciences,na,Age-related macular degeneration;Retinal diseases;Diabetic macular edema,na,,Name corrected from tarcolimab in previous version. ADC with tedromer
Tarextumab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK,na,na,None,None,None,2013,2014,NOTCH2 and NOTCH3,OncoMed Pharmaceuticals,na,Pancreatic cancer;Small cell lung cancer,Solid tumours,MorphoSys HuCAL Phage Display. XmAb Engineering Technology,
Tarlatamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,DLL3;CD3E,Amgen,na,Small cell lung cancer,na,BiTE Technology,Genetics of Fv2: musmus/homosap
Tarperprumig,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-II,Active,QVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS,na,None;None,None;None,None;None,2022,na,CFP;ALB,Alexion Pharmaceuticals,na,Sickle cell disease,na,,
Tavolimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK,na,na,None,None,None,2016,2018,TNFSF4/CD134/CD252/OX40L,European Network of Gynaecological Oncological Trial Groups;MedImmune,na,na,Ovarian cancer;Solid tumours,,Tavolimab is the new name for Tavolixizumab (PL118)
Tebentafusp,scFv Fusion,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,CD3E,Immunocore;MedImmune,Uveal melanoma,Malignant melanoma,na,,T-Beta section specific for PMEL peptide 280-288 presented by MH1. 6kr0:DD has an identical heavy chain. Identical sequence to Brenetafusp.
Tebotelimab,Bispecific scFv with Crossover,G4;G4,Kappa;Kappa,Phase-II/III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK,None;None,None;None,None;None,2019,2020,PDCD1/CD279/PD1;LAG3/CD223,MacroGenics,na,na,Biliary cancer;Cholangiocarcinoma;Endometrial cancer;Gastric cancer;Haematological malignancies;Head and neck cancer;Liver cancer;Malignant melanoma;Oesophageal cancer;Solid tumours;Triple negative breast cancer,,
Tecaginlimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYIMHWVRQAPGQGLEWMGGIIPNNGGTSYNQKFQGRVTMTVDKSTSTGYMELSSLRSEDTAVYYCTRREVYGRNYYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQGINNYLNWYQQKPGKAVKLLIYYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYSNLPYTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD40;TNFRSF9/CD137/4-1BB,Genmab,na,Solid tumours,na,,
Teclistamab,Bispecific mAb,G4;G4,Lambda;Lambda,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Genmab;Janssen Research & Development,Multiple myeloma,na,na,,Genetics of Fv2: musmus/homosap
Tegoprubart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY/6w4w:HL,None,None,2023,na,CD40LG/CD154,ALS Therapy Development Institute;Eledon Pharmaceuticals,na,Allotransplant rejection;Amyotrophic lateral sclerosis;IgA nephropathy;Renal transplant rejection;Autoimmune disorders,na,,Same Fv sequence as Ruplizumab
Telazorlimab,Whole mAb,G1,Kappa,Phase-II,Active,QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Glenmark Pharmaceuticals,na,Atopic dermatitis;Systemic lupus erythematosus;Ulcerative colitis;Rheumatoid arthritis,na,,
Telisotuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,MET/HGFR,Pierre Fabre;AbbVie,na,na,Solid tumours,,
Temelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS,QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,MS-associated Retrovirus Envelope Protein,GeNeuro,na,Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy,na,,
Temtokibart,Whole mAb,G1,Lambda,TBC,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMNWVRQAPGKGLEWVSSIYNDASNTAYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGFSGTYYSESWGQGTLVTVSS,SQELTQPSSVSVALGQTARITCQGGYYAHWYQQKPGQAPVLVIYGQNNRPSGIPERFSGSGAGNTATLTISRAQAEDEADYYCQSGSSSSNAVFGGGTKLTVL,na,na,None,None,None,2023,na,IL22RA1,TBC,TBC,TBC,TBC,,
Tenatumomab,Whole mAb Radiolabelled,G2b,Kappa,Phase-I,Discontinued,EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK,na,na,None,None,None,2007,2008,TNC,sigma-tau SpA,na,na,Cancer,,
Teneliximab,Whole mAb,G1,Kappa,Phase-II,ND,QIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTHSGVPKYVEDFKGRFAFSLETSANTAYLQISNLKNEDTATYFCVRSGNGNYDLAYFAYWGQGTLVTVSA,DIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGGGTKLEIK,na,na,5dmi:HL,None,None,2002,2003,TNFRSF5/CD40,Bristol-Myers Squibb,na,Cancer,na,,
Teplizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,na,na,None,None,None,2007,2008,CD3E,Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics,na,Type 1 diabetes mellitus,Multiple sclerosis;Psoriasis;Psoriatic arthritis,,
Tepoditamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2017,2018,CLEC12A;CD3E,Genmab;Janssen Research & Development,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,
Teprotumumab,Whole mAb,G1,Kappa,Approved,Active,QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK,na,na,None,None,None,2009,2010,IGF1R/CD221,Genmab;Roche;Horizon Therapeutics plc,Graves ophthalmopathy,Diffuse scleroderma,Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours,Medarex UltiMAb Mouse,
Teropavimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,na,na,None,4lsv:HL/4jpv:HL/5v8l:HL:GK:IM:GN/5v8m:HL:RT:SU/7ly9:HL:AM:EI:BC/7mxd:CD:JK:SU/7n28:CD:JK:SU/7pc2:GH:IJ:KL,None,2021,2022,HIV-1 gp120 CD4bs,Gilead,na,HIV-1,na,,
Tesidolumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL,na,na,None,None,None,2014,2015,C5,MorphoSys;Novartis,na,Paroxysmal nocturnal haemoglobinuria,Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration,MorphoSys HuCAL Phage Display. XmAb Engineering Technology,
Tesnatilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,KLRK1,Janssen Research & Development,na,Crohn's disease,na,,
Tezepelumab,Whole mAb,G2,Lambda,Approved,Active,QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,5j13:CB,None,None,2015,2016,TSLP,Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia,Asthma,Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease,na,,
Tibulizumab,Bispecific Mixed mAb and scFv,G4;G4,Kappa;Kappa,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK,None;None,None;None,None;6nou:AA/6nov:AB,2017,2018,TNFSF13B/CD257/BAFF;IL17A,Eli Lilly,na,na,Rheumatoid arthritis;Sjogren's syndrome,,
Tidutamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,SSTR2;CD3E,ICON;Xencor,na,na,Gastrointestinal stromal tumours;Neuroendocrine tumours,,Genetics of Fv2: musmus/homosap
Tifcemalimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,BTLA/CD272,Shanghai Junshi Biosciences,na,Solid tumours,na,,Chimeric. Tifcemalimab is the new name for Icatolimab (PL124). Genetics: musmus/homosap
Tigatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,na,na,None,None,None,2007,2008,TNFRSF10B/CD262/DR5/TRAILR2,Daiichi Sankyo Company;University of Alabama at Birmingham,na,na,Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer,,
Tilavonemab,Whole mAb,G4,Kappa,Phase-II,Active,EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFSGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK,na,na,None,None,None,2018,2019,MAPT,AbbVie;C2N Diagnostics,na,Alzheimer's disease;Progressive supranuclear palsy,na,,Fixed missing FWL3 residue from Jan '22 release onwards. Genetics: musmus/homosap
Tildrakizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,IL23A,Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries,Plaque psoriasis,Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis,Autoimmune disorders,,
Tilogotamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTKVEIK,na,na,None,6t3j:CD:HI,None,2019,2020,TNFRSF10B/CD262/DR5/TRAILR2,Genmab,na,Solid tumours,na,,June '22: Corrected FWL4 sequence
Tilvestamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,AXL/UFO,BerGenBio,na,Cancer,na,,Feb '22: Removed erroneous W insertion from CDRH1.
Timigutuzumab,Whole mAb,G1,Kappa,Phase-I,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2/CD340/HER2,Roche,Breast cancer,na,na,,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains.
Timolumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS,VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,AOC3/VAP1,Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation,na,na,Inflammation;Plaque psoriasis;Rheumatoid arthritis;Primary sclerosing cholangitis,,
Timcevibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVADAFDIWGQGTMVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPFTFGPGTKVDIK,na,na,7b3o:HL,None,None,2023,na,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,,8elo:HL is 94.6% identical
Tinurilimab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,CEACAM6/CD66c,Bayer;German Cancer Research Center,na,na,Solid tumours,,
Tiragolumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK,na,na,None,None,None,2017,2018,TIGIT/WUCAM/VSTM3,Genentech,na,Non-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma,na,,
Tirnovetmab,Whole mAb (Canine),G2,Kappa,Unknown,Active,EVQLVESGPSLVKPGGSLRLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGITDYNPSLKSRITISRDTSKNQYYLQLNSVTTEDTATYYCARYGNYGYAMDYWGQGTSVTVSS,DIVMTQSPASLSVSLGQRATISCRASESVDTYGNSFMHWYQQKPGQSPKLLIYRASNLESGIPARFGGSGSGTDFTLTIDPVQADDVATYYCQQSYEDPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL31 (Canine),Kindred Biosciences,na,Canine atopic dermatitis,na,,
Tislelizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK,na,na,7bxa:BC:HL/7cgw:HL:AB,None,None,2017,2018,PDCD1/CD279/PD1,BeiGene;Celgene Corporation,Hodgkin's disease;Urogenital cancer,Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer,na,,
Tisotumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS,DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,F3,Genmab;Seattle Genetics,Cervical cancer,Bladder cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours,na,,ADC with vedotin
Tixagevimab,Whole mAb,G1,Kappa,Approved,NFD,QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK,na,na,7l7d:HL/8d8r:HL/8d8q:CB,7l7e:AB:HL:IJ:TU,7b0b:HL/7e3k:DE:HL:FG/7mm0:HL/7mlz:HL/7tbf:HL/7tb8:HL/7tcc:FG:JK:OP/7u0d:OP,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,,
Tobemstomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFIFDDYTMNWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRFTISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTDTTLYGSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSSPLTFGGGTKVEIK,None;None,None;None,None;None,2022,na,PDCD1/CD279/PD1;LAG3/CD223,Roche,na,Melanoma;Liver cancers;Esophageal squamous cell carcinoma,na,,Fv1 identical in sequence to Eciskafusp and Lomvastomig Fv1.
Tobevibart,Whole mAb,G1,Lambda,TBC,Active,ELQLVESGGGWVQPGGSQRLSCAASGRIFRSFYMSWVRQAPGKGLEWVATINQDGSEKLYVDSVKGRFTISRDNAKNSLFLQMNNLRVEDTAVYYCAAWSGNSGGMDVWGQGTTVSVSS,SYELTQPPSVSVSPGQTVSIPCSGDKLGNKNVAWFQHKPGQSPVLVIYEVKYRPSGIPERFSGSNSGNTATLTISGTQAMDEAAYFCQTFDSTTVVFGGGTRLTVL,na,na,None,None,None,2022,na,Human Papillomavirus Envelope Protein,TBC,TBC,TBC,TBC,,
Tocilizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,na,na,None,None,None,2004,2004,IL6R/CD126,Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh,Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis,Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer,Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus,,Biosimilars available
Tomaralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,TLR2/CD282,Opsona Therapeutics,na,Delayed graft function;Myelodysplastic syndromes;Cancer,Autoimmune disorders;Inflammation,,Genetics: musmus/homosap
Tomuzotuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,None,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,2016,2017,EGFR/ERBB1/HER1,Glycotope,na,Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours,na,GlycoExpress Technology,Cetuximab biobetter
Toripalimab,Whole mAb,G4,Kappa,Approved,Active,QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK,na,na,6jbt:HL,None,None,2018,2019,PDCD1/CD279/PD1,Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University,Malignant melanoma,Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer,na,,Genetics: musmus/homosap
Torudokimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVETGGGLIQPGGSLRLSCAASGFTFSFYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTIHGIRAAYDAFIIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGINLSWYQQKPGQAPRLLIYGASHRLTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYSQPPPFTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL33,Eli Lilly,na,Atopic dermatitis,na,,
Tosatoxumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS,QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL,na,na,None,None,None,2013,2014,Staphylococcus aureus Toxin A,Aridis Pharmaceuticals;Kenta Biotech,na,Nosocomial pneumonia,Sepsis,,
Tovetumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,na,na,None,None,None,2013,2014,PDGFRA/CD140A,Cambridge Antibody Technology;MedImmune,na,na,Glioblastoma;Non-small cell lung cancer;Solid tumours,,
Tozorakimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISAIDQSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQKFMQLWGGGLRYPFGYWGQGTMVTVSS,SYVLTQPPSVSVSPGQTASITCSGEGMGDKYAAWYQQKPGQSPVLVIYRDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCGVIQDNTGVFGGGTKLTVL,na,na,None,None,None,2020,2021,IL33,AstraZeneca,na,Chronic Obstructive Pulmonary Disease;Diabetic nephropathy,na,,
Trabikibart,Whole mAb,G4,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFPWYRVHWVRQAPGKGLEWVSSIRSSGGFPYYNYKVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFYDSFFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,na,na,5dwu:HL,None,None,2023,na,CSF2RB/CD131,TBC,TBC,TBC,TBC,,
Tralokinumab,Whole mAb,G4,Lambda,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,na,na,5l6y:HL,None,None,2009,2010,IL13,Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune,na,Atopic dermatitis;Alopecia areata,Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis,,
Trastuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,1fvc:DC:BA/4hkz:BA/4ub0:HL/5xhf:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF,1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2/CD340/HER2,Roche,Breast cancer,na,na,,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains. Also found as an ADC with brengitacan.
Traxivitug,Whole mAb,G1,Lambda,TBC,Active,QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGRFTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS,QSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWYQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVL,na,na,None,None,None,2023,na,BK Polyomavirus Major Capsid Protein VP1,TBC,TBC,TBC,TBC,,
Tregalizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CD4,Biotest AG,na,na,Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis,,
Tremelimumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,na,na,5ggu:HL:AB/5ggv:HL,None,None,2005,2008,CTLA4/CD152,AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine,Non-small cell lung cancer;Liver cancer,Head and neck cancer;Mesothelioma;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer,Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes,Abgenix XenoMouse,Tremelimumab is the new name for Ticilimumab (PL97)
Trevogrumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS,DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN,Regeneron Pharmaceuticals;Sanofi,na,Muscular atrophy;Osteoporosis,na,VelocImmune Mouse,
Trinbelimab,Whole mAb,G1,Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIPMFGTVNYAQKFQGRVTISADKSTSTAYMELSRLRSEDTAVYYCARPPSGGCGGDCSRRGYYYAMDVWGQGTTITVSS,QSALTQPASVSGSPGQSITISCSGSSSDVGGYKYVSWYQQHPGKAPQLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGGGTKLTVL,na,na,None,None,None,2021,2022,RhD/CD240D/RhPI,Bharat Serums and Vaccines,TBC,TBC,TBC,,June '22: Corrected CDRH3 sequence
Trontinemab,Bispecific Mixed Format with Domain Crossover,G1;G1,Kappa;Kappa,Phase-I/II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,QSMQESGPGLVKPSQTLSLTCTVSGFSLSSYAMSWIRQHPGKGLEWIGYIWSGGSTDYASWAKSRVTISKTSTTVSLKLSSVTAADTAVYYCARRYGTSYPDYGDASGFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNYASSNVDNTFGGGTKVEIK,5csz:AB:HL;None,None;None,None;None,2022,na,APP Abeta 1-40/42;TFRC/CD71,Roche,na,Dementia,na,,Arm 1 has same Fv as Gantenerumab
Tucotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EIQLVQSGAEVKKPGETVKISCKASGYTFTNYGMNWVKQTPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSTSTAFLQINNLRSEDTATYFCVRFISKGDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERVTLTCSASSSVSYMLWYQQKPGSSPKPWIFDTSNLASGFPARFSGSGSGTSYSLIISSMEAEDAATYYCHQRSGYPYTFGGGTKLEIK,na,na,None,None,None,2005,2006,EPCAM/CD326,EMD Lexigen;Merck KGaA,na,na,Ovarian cancer;Small cell lung cancer,,ADC with celmoleukin
Tulisokibart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFDIQDTYMHWVKQRPGQGLEWMGRIDPASGHTKYDPKFQVRVTITRDTSTSTVYLELSSLRSEDTAVYYCARSGGLPDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSYMYWYQQKPGQAPRPLIYATSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWEGNPRTFGGGTKLEIK,na,na,None,None,None,2022,na,TNFSF15/TL1A/VEGI,Prometheus Biosciences,na,Crohn's disease;Ulcerative colitis;Diffuse cutaneous systemic sclerosis;Interstitial lung disease,na,,
Tuparstobart,Whole mAb,G1,Kappa,Phase-II,Active,QVQMVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWMGEIDPANDNTKYDPKFQGRVTITADTSTSTVYMELSSLRSEDTAVYYCATYYYKYDVGGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCSVSSSISSSNLHWYQQKPGQAPRLLIYGTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,na,LAG3/CD223,Incyte Biosciences,na,Head and neck cancers;Melanoma;Endometrial cancers;Urothelial cancers,na,,
Tusamitamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS,DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK,na,na,None,None,None,2020,2021,CEACAM5/CD66e,Sanofi-Aventis,na,Non-small cell lung cancer;Breast cancer;Pancreatic cancer;Solid tumours,na,,ADC with ravtansine. Genetics: musmus/homosap
Tuvonralimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVESGGGVVEPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYKPSEKDYADSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLGYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSINSYLAWYQQKPGQAPRPLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRYPFTFGPGTKVDIK,na,na,None,None,None,2021,2022,CTLA4/CD152,Qilu Puget Sound Biotherapeutics,na,Neoplasms,na,,
Ubamatamab,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-II,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYYMSWVRQAPGKGLEWISYISGRGSTIFYADSVKGRITISRDNAKNSLFLQMNSLRAEDTAVYFCVKDRGGYSPYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2021,2022,MUC16/CA125;CD3E,Regeneron Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,na,,
Ublituximab,Whole mAb,G1,Kappa,Approved,Active,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK,na,na,None,None,None,2010,2011,MS4A1/CD20,LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc,Multiple sclerosis,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Neuromyelitis optica,EMABling Platform,Rituximab biobetter
Ucenprubart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGFSFSSGYYMAWVRQAPGQGLEWMGLIGVGSGSLWYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARHFALSDPFNLWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCQASESIDSYLLWYQQKPDQSPKLLIKQASTLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQNYYDISSNDFGGGTKVEIK,na,na,None,None,None,2023,na,MOX2R/CD200R1,TBC,TBC,TBC,TBC,,
Ulenistamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGNTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRAITTATAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLYTFGQGTKVEIK,na,na,None,None,None,2021,2022,PAUF,Prestige Biopharma,na,Pancreatic cancer;Ovarian cancer,na,,
Uliledlimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCAVSGYSITSGYYWNWIRQPPGKKLEWMGYINYGGSNGYNPSLKSRITISRDTSKNQFSLKLSSVTAADTAVYYCARDYDAYYEALDDWGQGTTVTVSS,EIVLSQSPATLSLSPGERATLSCRASSRVNYMHWYQQKPGQSPRPWISATSNLASGVPARFSGSGSGTSYTLTISSLEPEDFAVYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,NT5E/CD73,TRACON Pharmaceuticals;I-Mab Biopharma,na,Breast cancer;Gastrointestinal cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,Genetics: musmus/homosap
Ulocuplumab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK,na,na,None,None,None,2013,2014,CXCR4/CD184,Bristol-Myers Squibb;Medarex;University of Bari,na,Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours,B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma,,
Ulviprubart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDHNMHWVKQATGQGLEWFGFINPNTGVTRYNQKFQGRVTLTINKAISTAYLELSSLRSEDTAVYYCARDYYGSAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTLLYSSDQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNYPTFGGGTKVEIK,na,na,None,None,None,2022,na,KLRG1,Abcuro,na,T-cell large granular lymphocytic leukemia;Inclusion body myositis,na,,
Umesolerbart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSFISDSSSNIYYADSVKGRFTISRDNAKKSLYLQMTSLRAEDTAVYYCAREAIGSTSFDNWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRRLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCHQYNNWPLTFGGGTKVEIK,na,na,7mxl:HL,None,None,2022,na,Bet v 1,Regeneron,na,Allergic rhinitis;Birch pollen allergy,na,,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5714.
Umizortamig1,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1),na;G1,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,DVQLQESGPSLVKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYISYSGNTRYNPSLKSRISITRDTSKNQFFLQLNSVTIEDTATYYCVTAGRGFPYWGQGTLVTVSA,DILMTQSPSSMSVSLGDTVSITCHSSQDINSNIGWLQQRPGKSFKGLIYHGTNLDDEVPSRFSGSGSGADYSLTISSLESEDFADYYCVQYAQFPWTFGGGTKLEIK,None;None,None;3g5x:DC:BA,None;3g5v:BA/3g5z:BA,2022,na,EGFRvIII;CD3E,TBC,TBC,TBC,TBC,,scFv-IgG1 portion. Joint entry with Umizortamig2 (tetraspecific)
Umizortamig2,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2),na;na,Kappa;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK,SQSLVESGGGLVQPGGSLRLSCAASGFSFSSNYWICWVRQAPGKGLEWIACIYVGSSGDTYYASSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSSYYMFNLWGQGTLVTVSS,ALVMTQSPSTLSASVGDRVTINCQASEDIDTYLAWYQQKPGKAPKLLIFYASDLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGGYYTSSADTRGAFGGGTKVEIK,None;None,None;None,None;None,2022,na,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,scFv-scFv portion. Joint entry with Umizortamig2 (tetraspecific)
Unasnemab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME,na,na,None,None,None,2020,2021,RGMA,Mitsubishi Tanabe Pharma Corporation,na,Acute spinal cord injury,na,,Genetics: musmus/homosap
Upanovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVKLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYDGGGGTVDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGVPARFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRTFGQGTKVEIK,na,na,None,None,7cyh:ED/7cyp:GF:IH:ED/7cwt:IJ:GF:ED/7e5s:RO,2021,2022,SARS-CoV-2 Spike RBD,Sinocelltech,na,COVID-19,na,,Genetics: musmus/homosap
Uprevstobart,Whole mAb,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGESLKISCKGSGYTFTSYGLSWVRQMPGKGLEWMGEIYPGSGNTYYNEKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDYLGSSYGFDYWGAGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQDVSTAVAWYQQKPGQPPKLLIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYNTPYTFGGGTKLEIK,na,na,None,None,None,2023,na,NT5E/CD73,TBC,TBC,TBC,TBC,,
Upinitatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK,na,na,None,None,None,2019,2020,SLC34A2,Mersana Therapeutics,na,Non-small cell lung cancer;Ovarian cancer,na,,Upinitatug is the new name for Upifitamab (PL128). Genetics: musmus/homosap
Urabrelimab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,IAP/CD47,Surface Oncology,na,na,Haematological malignancies;Solid tumours,,
Urelumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,na,na,6mhr:AB:DE,None,None,2010,2011,TNFRSF9/CD137/4-1BB,Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex,na,Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma,Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer,Medarex UltiMAb Mouse,"Jain paper: ""VL sequence modified at one position to match patent document (US7659384) and JK germline"""
Urtoxazumab,scFv,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISTGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDAWGNLDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQTISNNLHWYQQKPGQAPRLLIKSASQSISGIPARFSGSGSGTDFTLTISSLESEDFAVYYCQQSYSWPLTFGQGTKVEIK,na,na,None,None,None,2004,2005,Shiga-like Toxin II,Teijin Pharma,na,na,Haemolytic uraemic syndrome,,Anti-e coli mAb
Usilnetug,Whole mAb,G1,Kappa,TBC,Active,EVQLQESGPGLVKPSQTLSLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPYMKRRLTISKDTSKNQVSLKISSVTAADTAVYYCARRADDYDVGFAYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCLASQTIGTWLAWYQQKPGKSPKLLIYAATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLYSSPFTFGQGTKLEIK,na,na,None,None,None,2023,na,APP Abeta N3pGlu,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap
Ustekinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,na,na,3hmw:HL/3hmx:HL,None,None,2008,2009,IL12B/CLMFp40,Centocor Inc;Janssen Biotech;Medarex,Crohn's disease;Plaque psoriasis;Psoriatic arthritis,Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis,Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis,Medarex UltiMAb Mouse,Biosimilars available
Utomilumab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL,na,na,6a3w:GH:DE:AB:JK/6mi2:DE:AB,None,None,2016,2017,TNFRSF9/CD137/4-1BB,Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer,na,Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer,Non-Hodgkin's lymphoma;Colorectal cancer,MorphoSys HuCAL Phage Display,
Vadastuximab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,SIGLEC3/CD33/p67,Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,ADC with talirine
Valanafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK,na,na,None,5kqv:PQ:CD/4zxb:CD,3loh:CD/2dtg:CD/3w14:CD:PQ,2017,2018,INSR/CD220,ArmaGen Technologies,na,Mucopolysaccharidosis I,na,,
Vamikibart,Whole mAb,G2,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYVLPNYLIEWVRQAPGQGLEWMGVTTPGGGTINYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRWDPLYYYALEYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASESVDNYGIPFMNWYQQKPGQPPKLLIYAASNRGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSEEVPLTFGQGTKLEIK,na,na,None,None,None,2023,na,IL6,TBC,TBC,TBC,TBC,,
Vandortuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,STEAP1,Roche;Genentech,na,na,Cancers;Prostate Cancer,,ADC with vedotin
Vantictumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL,na,na,None,None,None,2013,2014,FZD,Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals,na,na,Breast cancer;Non-small cell lung cancer;Pancreatic cancer,MorphoSys HuCAL Phage Display,Targets the FZD Family
Vanucizumab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ/7v5n:BA:FE,None;None,None;6bft:AB:HL/1cz8:HL:YX,2014,2015,ANGPT2;VEGFA,Roche,na,na,Solid tumours;Colorectal cancer,,
Varisacumab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS,DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,VEGFA,Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS,na,na,Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer,,
Varlilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,TNFRSF7/CD27,Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia,na,Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma,Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma,,
Varokibart,Whole mAb,G4,Lambda,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASLGNWFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKNVYWYQQKPGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISRVEVGDEADYSCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2022,na,IL5,Teva Pharmaceutical,na,Asthma,na,,
Vatelizumab,Whole mAb,G4,Kappa,Phase-II/III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS,DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK,na,na,None,None,None,2011,2012,ITGA2/CD49B,Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi,na,na,Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis,,
Vedolizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,ITGA4B7,Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology,Crohn's disease;Ulcerative colitis,Graft-versus-host disease;Coeliac disease,Malignant melanoma,,
Veligrotug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS,DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2023,na,IGF1R/CD221,TBC,TBC,TBC,TBC,,
Veltuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,na,na,None,None,None,2007,2008,MS4A1/CD20,Immunomedics;Weill Cornell Medical College,na,na,Chronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma,,
Venanprubart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFSLSSYGVSWVRQAPGQGLEWMGAISYDGITYYASWAKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGDYYDDYVYVYALDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCQASQSISTALAWYQQKPGQAPRLLIYAASTLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGYSSSNLDNVFGGGTKVEIK,na,na,8f6o:AB,None,None,2023,na,BTLA/CD272,Eli Lilly,na,Systemic lupus erythematosus,na,,
Vensobafusp,Fusion Protein (whole mAb with protein),G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTITDYHFDWVRQAPGQGLEWMGDISMNYGYHIYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRDIRYSGNSYKWYFDEWGQGTMVTVSS,DIQLTQSPSFLSASVGDRVTITCRTSKSISKHLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNEYPYTFGQGTKLEIK,na,na,None,None,None,2023,na,C5,TBC,TBC,TBC,TBC,,
Vepsitamab,Bispecific (scFv-scFv-scFc),na;na,Lambda;Lambda,Phase-I,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKNQFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQGTLVTVSS,SYELTQPSSVSVPPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGVPERFSGSNSGNTATLTISGTQAMDEADYYCQAWGSSTAVFGCGTKLTVL,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,MUC17;CD3E,Amgen,na,GE Junction Cancer;Gastric Adenocarcinoma,na,BiTE Technology,Fv3 has the same sequence as Fv1. Genetics of Fv2: musmus/homosap
Vesencumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK,na,na,2qqn:HL,None,None,2010,2011,NRP1,Genentech;Roche,na,na,Solid tumours,,
Verekitug,Whole mAb,G1,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFRSSAMHWVRQAPGKGLKWVSSVSGSGAGTYYADSVKGRFTISRDNPKNTLYLQMNSLRAEDTAVYYCVKEGGSRGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYTASSLQSGVPSKFSGSGSGTDFTLTISSLQPEDFATYYCQQYNLYPPTFGQGTKVEIK,na,na,None,None,None,2023,na,CRLF2,TBC,TBC,TBC,TBC,,
Verzistobart,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFRQNAWSWVRRAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGDYGGNYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPASFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2023,na,HAVCR2/TIM3,TBC,TBC,TBC,TBC,,
Vibecotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,IL3RA/CD123;CD3E,Xencor,na,na,Haematological malignancies,,Genetics of both Fvs: musmus/homosap
Vibostolimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK,na,na,None,None,None,2019,2020,TIGIT/WUCAM/VSTM3,Merck,na,Solid tumours;Non-small cell lung cancer;Malignant melanoma,na,,
Vilamakitug,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGRFTNYAILWVRQAPGQGLQWLGGIIPIFDETDHAQDFQDRLTITVDESMTTAYMELSSLRPEDTAIYYCATGSNSYYGLYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPSTFGQGTKVEIK,na,na,None,None,None,2022,na,IL1A,"XBiotech USA, Inc",na,Pancreatic cancer;Arthritis;Colorectal cancer,na,,
Vilastobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYFMNWVRQAPGQGLEWMGRVDPEQGRADYAEKFKKRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAMDNYGFAYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSANSALSYMYWYQQKPDQSPKLWVHGTSNLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCHHWSNTQWTFGGGTKVEIK,na,na,None,None,None,2023,na,CTLA4/CD152,TBC,TBC,TBC,TBC,,Prodomain Kappa
Vilobelimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2019,2020,C5,InflaRX,COVID-19 pneumonia,Hidradenitis suppurativa;Inflammation;Microscopic polyangiitis;Pyoderma gangrenosum;Sepsis;Systemic inflammatory response syndrome;Squamous cell cancer,Inflammation,,
Vipalanebart,Whole mAb,G4,Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISLSGGSTYYAASHKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVREVGASTHNYYGMDVWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIWRWLAWYQQKPGKAPKLLIHDASQLFEGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFDLLPLTFGGGTKVEIK,na,na,None,None,None,2023,na,ADCYAP1/PACAP,TBC,TBC,TBC,TBC,,
Visilizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2000,2001,CD3E,PDL BioPharma,na,na,Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis,,
Visugromab,Whole mAb,G4,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPTLKSRLTITKDPSKNQVVLTMTNMDPVDTATYYCARSSYGAMDYWGQGTLVTVSS,DIVLTQSPSFLSASVGDRVTITCKASQNVGTNVAWFQQKPGKSPKALIYSASYRYSGVPDRFTGSGSGTEFTLTISSLQPEDFAAYFCQQYNNFPYTFGGGTKLEIK,na,na,None,None,None,2022,na,GDF15/MIC1,CatalYm,na,Solid tumours,na,,Genetics: musmus/homosap
Vixarelimab,Whole mAb,G4-G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL,na,na,None,None,None,2020,2021,OSMR,Kiniksa Pharmaceuticals,na,Prurigo nodularis;Pruritus;Atopic dermatitis,na,,
Vixtimotamab,"Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)",na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGNTGFAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRANTDYSLGMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYANWVQQKPGKAPKALIGGTNKRAPGVPSRFSGSLIGDKATLTISSLQPEDFATYYCALWYSNLWVFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSYFAYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSRSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLIGWVFGGGTKVTVL,None;None,None;None,None;None,2020,2021,CD3E;SIGLEC3/CD33/p67,Amphivena Therapeutics,na,na,Acute myeloid leukemia;Myelodysplastic syndromes;Solid tumours,,Genetics of Fv2: musmus/homosap
Vobarilizumab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,7xl0:B:A;None,None;None,None;None,2015,2016,IL6R/CD126;ALB,Ablynx,na,na,Rheumatoid arthritis;Systemic lupus erythematosus,Nanobody Technology,
Vobramitamab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATINSGGSNTYYPDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHDGGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPGKAPKLLVYNTKTLPEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPPWTFGQGTRLEIK,na,na,None,None,None,2022,na,B7H3/CD276,TBC,TBC,TBC,TBC,,ADC with Duocarmazine
Vofatamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK,na,na,None,None,4wv1:BA:ED/3grw:HL,2018,2019,FGFR3/CD333,BioClin Therapeutics;Rainier Therapeutics,na,Urogenital cancer,Multiple myeloma;Solid tumours;Achondroplasia,,
Volagidemab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,na,na,None,4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL,None,2018,2019,GCCR/NR3C1,Amgen;REMD Biotherapeutics,na,Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders;Glucose intolerance,na,,
Volociximab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLKESGPGLVAPSQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSRMTIRKDNSKSQVFLIMNSLQTDDSAMYYCARHGTYYGMTTTGDALDYWGQGTSVTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYLRSPPTFGGGTKLEIK,na,na,None,None,None,2005,2006,ITGA5B1,Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma,na,na,Age-related macular degeneration;Intestinal cancer;Non-small cell lung cancer;Peritoneal cancer;Malignant melanoma;Pancreatic cancer;Renal cell carcinoma,,
Volrustomig,Bispecific mAb,G1,Kappa;Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,5ggu:HL:AB/5ggv:HL;None,None;None,None;None,2022,na,CTLA4/CD152;PDCD1/CD279/PD1,AstraZeneca,na,Solid tumours;Renal cell carcinoma,na,,
Vonlerolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,na,na,6okn:AB:CD/6ogx:CD/7yk4:HL:IM,None,None,2015,2017,TNFRSF4/CD134/OX40,Genentech,na,na,Solid tumours;Urogenital cancer,,Vonlerolizumab is the new name for Pogalizumab (PL116)
Vonsetamig,Bispecific mAb,G4,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2023,na,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,TBC,TBC,TBC,TBC,,
Vopikitug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSLAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGSVSGTLVDFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNIYPITFGGGTKVEIK,na,na,6yio:HL,None,None,2023,na,IL2RA/CD25,TBC,TBC,TBC,TBC,,
Vopratelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK,na,na,None,None,None,2017,2018,ICOS/CD278,Jounce Therapeutics,na,Solid tumours;Urogenital cancer;Non-small cell lung cancer,na,,
Vorsetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNFSF7/CD70/CD27LG,Seattle Genetics,na,na,Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis,,
Voxalatamab,Bispecific mAb,G4;G4,Kappa;Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFKSDAMHWVRQAPGKGLEWVSEISGSGGYTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSYDSSLYVGDYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2021,na,FOLH1/GCPII/PSMA;CD3E,Janssen Research & Development,na,Solid tumours,na,,Fv2 Chimeric: Mouse/Human
Vudalimab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl;None,2020,2021,CTLA4/CD152;PDCD1/CD279/PD1,Xencor,na,Solid tumours,na,,Genetics of Fv2: musmus/homosap
Vulinacimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,KDR/CD309/VEGFR2,Henlix,na,na,Solid tumours,,
Vunakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK,na,na,None,None,None,2016,2017,IL17A,Atridia;Jiangsu Hengrui Medicine Co.,na,Plaque psoriasis;Psoriasis;Spondylarthritis,Autoimmune disorders,,
Xaluritamig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEWMGEILPGSGQTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2022,na,STEAP1;CD3,Amgen;Xencor;BeiGene,na,Prostate cancer;Ewing's sarcoma,na,,
Xeligekimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGMSMSDYWMNWVRQAPGKGLEWVAAINQDGDEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDLISDYYIHYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVHNRLTWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNGSPTTFGQGTKVEIK,na,na,None,None,None,2021,na,IL17A,Genrix Biopharmaceutical,na,Psoriasis,na,,
Xentuzumab,Whole mAb,G1,Lambda,Phase-II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS,DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL,na,na,None,None,None,2015,2016,IGF1 and IGF2,Boehringer Ingelheim;Eli Lilly,na,Breast cancer;Prostate cancer,Non-small cell lung cancer;Solid tumours,MorphoSys HuCAL Phage Display,
Xirestomig,Bispecific (G1-scFv_L2 dimer),G1;na,Lambda;Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASRGPFSTYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARTMEGYGFGNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTVSEVGGYNEVSWYQQHPGKAPKLMIYGNSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYDSSLSGTVFGGGTKLTVL,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTNWGPSDAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQRVTISCSGSTSDIGSYSVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,None;None,None;None,None;None,2023,na,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,
Zagotenemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,MAPT,Eli Lilly,na,na,Alzheimer's disease,,
Zalifrelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,CTLA4/CD152,4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma,na,Non-small cell lung cancer;Cervical cancer;Cancer;Haemangiosarcoma;Soft tissue sarcoma;Sold tumours,na,,
Zalutumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2005,2006,EGFR/ERBB1/HER1,Danish Head and Neck Cancer Group;Genmab,na,na,Head and neck cancer;Colorectal cancer;Non-small cell lung cancer,,
Zamerovimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYIMLWVRQAPGQRLEWIGDIYPYYGSTSYNLKFKGKATLTVDTSASTAYMELSSLRSEDTAVYYCARQGGDGNYVLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTTVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGQGTKLEIK,na,na,None,None,None,2021,na,Rabies Virus Spike Glycoprotein G,Synermore,na,Rabies Exposure,na,,
Zampilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS,DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK,na,na,None,None,None,2018,2019,TGM2,UCB,na,Autoimmune disorders,na,,Chimeric: Mouse/Human
Zanidatamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2/CD340/HER2;ERBB2/CD340/HER2,Zymeworks,na,Gastric cancer;Oesophageal cancer;Breast cancer;Solid tumours,Ovarian cancer,,Biparatopic Bispecific. Humanised
Zanolimumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,CD4,Emergent BioSolutions;Genmab,na,na,Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis,Medarex HuMAb Mouse,
Zansecimab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIK,na,na,None,None,None,2020,na,ANGPT2,Eli Lilly,na,na,Solid tumours;COVID-19,,
Zeleciment,Fab,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSQTLSLTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGQPVKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPYTFGQGTKLEIK,na,na,None,None,None,2023,na,TFRC/CD71,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap
Zelminemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK,na,na,None,None,None,2019,2020,ADCYAP1R1/PAC1,Amgen,na,Migraine,na,,
Zeluvalimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK,na,na,None,None,None,2020,na,PDCD1/CD279/PD1,Amgen,na,Solid tumours,na,,June '22: Corrected CDRH1 sequence
Zenocutuzumab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,5o4o:BA/5o7p:BA;5o4g:BA,None;None,None;None,2017,2018,ERBB3/HER3;ERBB2/CD340/HER2,Merus,na,Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer,Endometrial cancer;Ovarian cancer,GlymaxX Technology,
Zeripatamig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQMHPRAPKTFGQKTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIEDKYVQWYQQRPGSSPTIVIYYDNERPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDQSLYGWVFGGGTKVTVL,None;None,None;None,None;None,2022,na,IAP/CD47;CD19,TG Therapeutics,na,Chronic lymphocytic lymphoma;Follicular lymphoma;B cell lymphoma,na,,
Zifibancimig,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS,AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK,SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS,AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK,None;None,None;None,None;None,2022,na,ANPT2;VEGFA,Roche,na,Age-related macular degeneration,na,,Biparatopic Bispecific with same V region
Zigakibart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDAPKYNEKFKGKATMTSDTSASTAYMELSSLRSDDTAVYYCARGLGYALYYAMDYWGQGTTVTVSS,DIVMTQSPSTLSASVGDRVTITCKASQNVGNNVAWYQQKPGKAPKLLISSASNRDSGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNIYPFTFGQGTKLEIK,na,na,None,None,None,2022,na,TNFSF13/CD256/APRIL,Chinook Therapeutics,na,IgA Nephropathy,Multiple myeloma,,
Ziltivekimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK,na,na,None,None,None,2019,2020,IL6,AstraZeneca;Corvidia,na,Cardiovascular disorders,na,,
Zilovertamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGWYYFDYWGHGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK,na,na,None,None,None,2020,na,ROR1,University of California;Oncternal Therapeutics;Merck,na,Chronia lymphocytic leukemia;Mantle-cell Lymphoma;Prostate cancer;Endometrial cancer;Ovarian cancer,HER2 negative breast cancer,,June '22: Corrected FWL2 sequence
Zimberelimab,Whole mAb,G4,Lambda,Approved,Active,QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL,na,na,None,None,None,2020,na,PDCD1/CD279/PD1,Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology,Hodgkin's disease,Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours,na,,
Zinlirvimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,na,na,6orn:AB:FI:OP/6udk:AB:FI:OP/6udj:AR:KL:QB/6v8z:DE:PQ:JK/6ccb:DE:HL/6okp:KL/7ucf:HL/7ucg:HL:JK:QR/7ugn:MP:NQ:OR/7ugo:MP:NQ:OR/7ugp:MP:NQ:OR/7ugq:MP:NQ:OR,5t3x:HL/5t3z:HL,4fq2:HL,2022,na,HIV-1 gp120 V3,Gilead,na,HIV-1 infections;AIDS,na,,VL sequence truncation prevents 3D modelling with ABodyBuilder2
Zolbetuximab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,na,na,None,None,None,2017,2018,CLDN18,Ganymed Pharmaceuticals,na,Gastric cancer;Oesophageal cancer;Pancreatic cancer,Solid tumours,,Zolbetuximab and Claudiximab are the same mAb
Zovostotug,Whole mAb,G1,Kappa,TBC,Active,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARENVRPYYDFWSGYYSEYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRGTFGQGTKVEIK,na,na,None,None,None,2023,na,CD163,TBC,TBC,TBC,TBC,,
Zuberitamab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS,DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK,na,na,None,None,3bky:HL,2019,2020,MS4A1/CD20,Zhejiang Hisun Pharmaceutical,na,na,Diffuse large B-cell lymphoma,,Rituximab biosimilar
